Substituted 4-(indazol-3-yl)phenols

ABSTRACT

This invention provides compound of formulae I or II having the structure  
                 
 
     wherein  
     R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10  are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

[0001] This application claims priority from copending provisional application Serial No. 60/413,931, filed Sep. 25, 2002, the entire disclosure of which is hereby incorporated by reference.

BACKGROUND

[0002] This invention relates to ligands for the estrogen receptor (ER), and specifically relates to substituted 4-(indazol-3-yl)phenols useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

[0003] The ability of ligands for the estrogen receptor to inhibit inflammatory gene expression causing a reduction of cytokines, chemokines, adhesion molecules and inflammatory enzymes provides a means to treat the inflammatory component of diseases such as atherosclerosis, myocardial infarction (MI), congestive heart failure (CHF), inflammatory bowel disease and arthritis. Other potential therapeutic indications for these type of molecules include type II diabetes (Cefalu, J Womens Health & Gender-based Med. 2001, 10, 241 & Yuan et al., Science, 2001, 293, 1673), osteoarthritis (Pelletier et al., Arthr. & Rheum., 2001, 44:1237 and Felson et al., Curr Opinion Rheum, 1998, 10, 269) asthma (Chin-Chi Lin et. al., Immunol. Lett., 2000, 73, 57), Alzheiemer's disease (Roth, A. et. al.,; J. Neurosci. Res., 1999, 57, 399) and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

[0004] A common component of these chronic inflammatory conditions is polymorphonuclear leukocyte and monocyte infiltration into the site of damage through increased expression of cytokines and adhesion molecules responsible for their recruitment. Overproduction of the cytokine interleukin (IL-6) has been associated with states of chronic inflammation (Bauer M. A., Herrmann F., Ann. Hematol., 1991, 62, 203). Synthesis of the IL-6 gene is induced by the transcription factor nuclear factor κB (NF-κB). Interference at this step in the inflammatory process can effectively regulate the uncontrolled proliferative process that occurs in these chronic conditions.

[0005] In endothelial cells, 17β-estradiol (E2) inhibits IL-1β induced NF-κB reporter activity and IL-6 expression in an ER dependent fashion (Kurebayashi S. et. al., J. Steroid Biochem. Molec. Biol., 1997, 60, 11). This correlates with anti-inflammatory action of E2 in vivo as confirmed in different animal models of inflammation. In models of atherosclerosis, E2 was shown to protect endothelial cell integrity and function and to reduce leukocyte adhesion and intimal accumulation (Adams, M. R. et al., Arterio., 1990, 1051, Sullivan, T. R. et al. J. Clin. Invst. 1995, 96, 2482, Nathan, L. et. al., Circ. Res., 1999, 85, 377). Similar effects of estrogen on the vascular wall have also been demonstrated in animal models of myocardial infarction (Delyani, J. A. et al., J. Molec. Cell. Cardiol., 1996, 28, 1001) and congestive heart failure . Clinically, estrogen replacement therapy (ERT) has been demonstrated to reduce the risk of mortality in patients with both CHF (Reis et. al., J. Am. Coll. Cardio., 2000, 36, 529) and MI (Grodstein, F. et. al., Ann. Int. Med., 2000, 133, 933, Alexander et. al., J. Am. Coll. Cardio., 2001, 38, 1 and Grodstein F. et. al., Ann. Int. Med, 2001, 135,1). In ERT, clinical studies demonstrated an influence of E2 on the decrease in the production of β-amyloid 1-42 (Aβ42), a peptide central for the formation of senile plaques in Alzheimer's disease (Schonknecht, P. et. al., Neurosci. Lett., 2001, 307, 122).

[0006] However, 17-β-estradiol also strongly stimulates creatine kinase expression. Thus, in ERT some potential unwanted side effects, such as an increase risk of cardiovascular events in the first year of use, have been demonstrated (Hulley, S. et. al., J. Am. Med. Assoc., 1998, 280, 605) as well as proliferative effects on uterine and breast tissue.

DESCRIPTION OF THE INVENTION

[0007] The invention provides substituted 4-(1H-indazol-3-yl)phenols represented by the general formula I and substituted 4-(2H-indazol-3-yl)phenols represented by formula II that are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

[0008] wherein

[0009] R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

[0010] R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁;

[0011] R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

[0012] R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁;

[0013] R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

[0014] R₁₂ is hydrogen or —CO₂R₁₁;

[0015] n=0-3,

[0016] or a pharmaceutically acceptable salt thereof.

[0017] As used herein, the term “alkyl” includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e.g. methyl (Me), ethyl (Et), propyl (Pr), isopropyl (i-Pr), isobutyl (i-Bu), secbutyl (s-Bu), tertbutyl (t-Bu), isopentyl, isohexyl and the like. The term “alkyl” further includes both unsubstituted and mono-, di- and tri-substituted hydrocarbon groups, with halogen substitution particularly preferred.

[0018] The term “alkenyl” refers to an unsaturated or partially unsaturated aliphatic hydrocarbon group having the specified number of carbon atoms, for example ethenyl, 1-propenyl, 2, butenyl, etc. The term “alkenyl” further includes both unsubstituted and mono-, di- and tri-substituted hydrocarbon groups, with halogen substitution particularly preferred.

[0019] The term “cycloalkyl” includes cyclized alkyl chains having the specified number of carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term “cycloalkenyl” includes cyclized alkyl chains containing an alkenyl group having the specified number of carbon atoms, e.g., cyclopentenyl, cyclohexenyl, etc. The term “halogen” includes fluorine, chlorine, iodine and bromine.

[0020] The term “aryl” means an aromatic carbocyclic moiety of up to 20 carbon atoms, e.g., 6-20, which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings of which at least one ring is aromatic) fused together or linked covalently. Any suitable ring position of the aryl moiety may be covalently linked to the defined chemical structure. Examples of aryl moieties include, but are not limited to, chemical groups such as phenyl, 1-naphthyl, 2-naphthyl, dihydronaphthyl, tetrahydronaphthyl, biphenyl, anthryl, phenanthryl, fluorenyl, indanyl, biphenylenyl, acenaphthenyl, acenaphthylenyl, and the like.

[0021] The term “arylalkyl” means aryl, as herein before defined, suitably substituted on any open ring position with an alkyl moiety wherein the alkyl chain is either a (C₁-C₆) straight or (C₂-C₇) branched-chain saturated hydrocarbon moiety. Examples of arylalkyl moieties include, but are not limited to, chemical groups such as benzyl, 1-phenylethyl, 2-phenylethyl, diphenylmethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl, and homologs, isomers, and the like.

[0022] The term “heterocyclic ring or ring system”, employed alone or in combination with other terms, is defined herein as an unsaturated, partially unsaturated or saturated ring or ring system, which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently. The rings may contain from one to four hetero atoms selected from nitrogen (N), oxygen (O), or sulfur (S), wherein the nitrogen or sulfur atom(s) are optionally oxidized, or the nitrogen atom(s) are optionally quarternized. Any suitable ring position of the heterocyclic moiety may be covalently linked to the defined chemical structure. Examples of unsaturated heterocyclic rings or ring systems include, but are not limited to, heterocycles such as furan, thiophene, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, imidazole, N-methylimidazole, oxazole, isoxazole, thiazole, isothiazole, 1 H-tetrazole, 1-methyltetrazole, 1,3,4-oxadiazole, 1H-1,2,4-triazole, 1-methyl-1,2,4-triazole 1,3,4-triazole, 1-methyl-1,3,4-triazole, pyridine, pyrimidine, pyrazine, pyridazine, benzoxazole, benzisoxazole, benzothiazole, benzofuran, benzothiophene, thianthrene, dibenzo[b,d]furan, dibenzo[b,d]thiophene, benzimidazole, N-methylbenzimidazole, indole, indazole, quinoline, isoquinoline, quinazoline, quinoxaline, purine, pteridine, 9H-carbazole, β-carboline, and the like. Examples of saturated or partially unsaturated heterocyclic rings or ring systems include, but are not limited to, chemical groups such as azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, dihydro-1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0023] As used herein the terms “aryl” and “heterocyclic” as a group or part of a group (e.g., arylalkyl, aryloxy) include such groups optionally mono-, di- or tri-substituted with one or more substituents, the same or different, such as those selected from the following:

[0024] halogen, hydroxy, alkyl of 1-6 carbon atoms; alkenyl of 2-6 carbon atoms; cycloalkyl of 3-6 carbon atoms, alkoxy of 1-6 carbon atoms; alkylthio of 1-6 carbon atoms;

[0025] hydroxyalkyl of 1 to 6 carbon atoms, CN, perfluoroalkyl of 1-4 carbon atoms, —O-per-fluoroalkyl of 1-4 carbon atoms, NO₂, amino, alkylsulfonyl of 1-6 carbon atoms; carboxy, and alkoxycarbonyl of 2-7 carbon atoms.

[0026] As used herein the terms “alkyl” and “alkenyl” include such groups optionally mono- or poly-substituted with one or more substituents, the same or different, such as those selected from the following: halogen, hydroxy, cycloalkyl of 3-8 carbon atoms and cycloalkenyl of 4-8 carbon atoms.

[0027] The compounds of formula I and formula II can be converted to salts, in particular pharmaceutically acceptable salts using art recognized procedures. The compounds of formulas I and II that have a basic center can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic, or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or such as benzoic acid, or with organic sulfonic acids, such as alkane- (of 1 to 4 carbon atoms) or arylsulfonic acids, for example methane- or p-toluenesulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group can form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine, or a mono-, di-, or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included.

[0028] As used in accordance with this invention, the term “providing,” with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or substance, or administering a prodrug, derivative, or analog which will form the effective amount of the compound or substance within the body. This invention also covers providing the compounds of this invention to treat the disease states disclosed herein that the compounds are useful for treating.

[0029] Examples of R₁ include alkyl of 1-6 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl), alkenyl of 2-7 carbon atoms (e.g., allyl), cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms (e.g. cyclohexyl, cyclopentyl, cyclobutyl), or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S (e.g., thienyl). Preferably R₁ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkenyl of 4-8 carbon atoms. Most preferably R₁ is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms. When substituted examples of alkyl are cyclohexylmethyl, 2,2,2-trifluoroethyl and 2-hydroxyethyl. Other examples of R₁ include phenyl and substituted phenyl.

[0030] Examples of R₂ include hydrogen, alkyl of 1-6 carbon atoms (e.g., methyl), alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms or halogen. Preferably R₂ is hydrogen, alkyl of 1-6 carbon atoms, halogen or hydroxy.

[0031] Examples of R₇ and R₉ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, hydroxy, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S.

[0032] Examples of R₉ include alkyl of 1-6 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S. Preferably R₉ is alkyl of 1-6 carbon atoms, halogen, or trifluoromethyl.

[0033] R₁₀ may be for example hydrogen.

[0034] Preferred compounds of this invention include those in which:

[0035] (A). R₁ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

[0036] R₂ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, or halogen;

[0037] R₇ and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, hydroxy, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S,

[0038] where the remaining substituents are as defined above.

[0039] Preferred compounds of this invention include those of (A) in which:

[0040] (B). R₁ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkenyl of 4-8 carbon atoms;

[0041] R₂ is hydrogen, alkyl of 1-6 carbon atoms, halogen, or hydroxy;

[0042] R₉ is alkyl of 1-6 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

[0043] R₁₀ is hydrogen,

[0044] where the remaining substituents are as defined above.

[0045] Preferred compounds of this invention include those of (B) in which:

[0046] (C). R₁ is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

[0047] R₉ is alkyl of 1-6 carbon atoms, halogen, or trifluoromethyl, where the remaining substituents are as defined above.

[0048] This invention also provides a process for preparing a compound of formula I or II or a pharmaceutically acceptable salt thereof which comprises one of the following:

[0049] a) deprotecting a compound of formula IV or V:

[0050] wherein R₁₋₉ are as defined herein and P is a hydroxy protecting group, e.g., methyl, benzyl or t-butyldiphenylsilyl; to give a corresponding compound of formula I or II wherein R₁₀ is hydrogen; or

[0051] b) acylating a compound of formula XI or XII

[0052] wherein R₁₋₉ are as defined herein, with a compound of formula HalCOR₁₁ wherein R₁₁ is as defined herein to give a compound of formula I or II where R₁₀ is —COR₁₁; or

[0053] c) reacting a compound of formula XI or XII as defined above with a compound of formula

HOCO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁

[0054] wherein n, R₁₁ and R₁₂ are as defined herein in the presence of a coupling or activating agent to give a compound of formula I or II where R₁₀ is —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; or

[0055] d) reacting a compound of formula XI or XII as defined above with a compound of formula

R₁₁NCO

[0056] wherein R₁₁ is as defined herein, to give a compound of formula I or II where R₁₀ is —CONHR₁₁; or

[0057] e) reacting a compound of formula XI or XII as defined above with a dichlorophosphate of formula

R₁₁O—P(═O)Cl₂

[0058] wherein R₁₁ is as defined herein, to give a compound of formula I or II where R₁₀ is —P(═O)(OH)OR₁₁; or

[0059] f) reacting a compound of formula

[0060] with a hydrazine salt of formula R₁NHNH₂ wherein R₁ is as defined herein to give a corresponding compound of formula I wherein R₂ and R8 are OH, and R₃, R4, R₅, R₆, R₇, and R₉ are hydrogen; or

[0061] g) converting a basic compound of formula (I) or (II) to a pharmaceutically acceptable salt or vice versa; or

[0062] h) converting an acidic compound of formula (I) or (II) to a pharmaceutically acceptable salt or vice versa.

[0063] The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. Compounds of formula I and formula II wherein R₁₀=H can be prepared from a common precursor of formula III as outlined in scheme 1.

[0064] where

[0065] R₁=alkyl, cycloalkyl, alkenyl, cycloalkenyl, arylalkyl;

[0066] R₂, R₃, R₄, R₅, R₆, R₇, R8, R₉ are as previously defined.

[0067] P is a phenol protecting group, preferably but not limited to methyl, benzyl or t-butyldiphenylsilyl.

[0068] Thus, compounds of formula III are treated with sodium hydride in a suitable solvent such as 4-dimethylaminopyridine (DMAP). When the gas evolution ceases, the alkyl halide is added and the solution is heated at 50° C. overnight. The reaction is partitioned with ethyl acetate and water. The organic phase is dried with a suitable drying agent such as sodium sulfate (Na₂SO₄). The crude products IV and V are isolated as a single residue after filtration and concentration of the organic layer in vacuo. Separation is easily carried out by chromatography known to one skilled in the art, to provide the separated intermediates IV and V.

[0069] Compounds of formula I and formula II are prepared from IV or V respectively by a deprotection step.

[0070] When P=benzyl, deprotection to the phenol is accomplished by hydrogenation over 10% palladium on carbon using either hydrogen gas, or catalytic hydride transfer with cyclohexene or ammonium formate.

[0071] When P=methyl, deprotection is carried out using BBr₃ with cyclohexene as a scavenger for HBr.

[0072] When P=t-butyldiphenylsilyl, deprotection can be accomplished with tetrabutylammonium fluoride.

[0073] Compounds of formula IV can also be prepared as outlined in scheme 2 from compounds of formula VI.

[0074] Reaction of 2-fluorobenzophenones of compound VI can be reacted directly with optimally substituted hydrazines where R₁=alkyl or aryl which are either commercially available or readily prepared by common procedures known to those skilled in the art. Thus, a mixture of the benzophenones of compound VI are combined with the hydrazines in a suitable solvent such as methanol in the presence of ethyl acetate. The intermediate hydrazone either spontaneously cyclizes to the compounds of formula IV or can be isolated by concentration of the reaction mixture. The isolated hydrazone is heated neat to temperatures of up to 190° C. The residues are purified by chromatography to provide compounds of formula IV.

[0075] Compounds of formula I, wherein R₂ and R₈ are OH and R₃, R₄, R₅, R₆, R₇, and R₉ are hydrogen, can also be prepared by a similar process from commercially available 2-2′-4-4′-tetrahydrobenzophenone according to the literature preparation of R. Krishnan, S. A. Lang, Y. I. Lin, R. G. Wilkinson J. Heterocycl. Chem, 1988, 25, 447 and outlined in Scheme 3.

[0076] Thus, a solution of the substituted hydrazine salt (1 to 2 equivalents), sodium acetate (1 to 4 equivalents) and 2,2′,4,4′-tetrahydroxybenzophenone (1 equivalent) in an appropriate solvent such as methanol (0.2 molar solution) is stirred at ambient temperature overnight. The reaction mixture is concentrated in vacuo and the residues partitioned with EtOAc and H₂O. The organic phase is dried (Na₂SO₄) and concentrated in vacuo to give the intermediate hydrazone. The residues are heated at 190° C. overnight. Product residues are purified by chromatography.

[0077] Compounds of formula III are readily prepared from compounds of formula VI as shown in Scheme 4.

[0078] Thus, an appropriately substituted compound of formula VI is reacted with an excess of hydrazine hydrate in pyridine containing DMAP. The reaction is heated at 100° C. for at least 24 hours. The reaction is concentrated in vacuo and the residue is partitioned with ethyl acetate and 1 N HCl. The organic phase is washed with brine and dried with a drying agent such as Na₂SO₄. The solvent is evaporated to provide the compounds of formula III.

[0079] Compounds of formula VI are readily prepared as outlined in scheme 5 from the reaction of an appropriately substituted 2-fluoro-N-methoxy-N-methyl-benzamide of formula VII.

[0080] where X is preferably but not limited to Br.

[0081] Thus, reaction of compounds of formula VII with compounds of formula VIII, which are either commercially available or readily prepared by one skilled in the art, in a suitable solvent such as tetrahydrofuran (THF).

[0082] The Weinreb amides of formula VII are generated by the reaction of an appropiately substituted 2-fluorobenzoic acid with N,O-dimethylhydroxylamine and N,N-carbonyldiimidazole in a suitable solvent such as DMF (Robertson et. al., J. Med. Chem., 1990, 33, 3167) or from the acid chloride prepared from reaction of the benzoic acid with oxalyl chloride in a suitable solvent such as THF in the presence of a base such as N,N-diisopropylethylamine.

[0083] Compounds of formula IV can also be prepared as outlined in Scheme 6

[0084] where

[0085] R₁, R₂, R₃, and R₄ are as defined above;

[0086] and halo=Cl or Br

[0087] Thus, when halo=Br, compounds of formula IV where R₉=aryl, heteroaryl, heterocycle, and alkenyl, can be prepared by the Suzuki coupling of IX with an appropriately substituted boronic acid in a suitable solvent such as dioxane, in the presence of an aqueous base such as potassium carbonate, in the presence of 1 to 5 mol % of palladium catalyst such as tetrakis(triphenylphoshine)palladium (0). The mixture is typically heated at 80° C. for a period of 1 to 24 hours (see Miyaura, N. Suzuki, A., Chem Rev., 1995, 95, 2457). The compounds are obtained in pure forms by chromatography known to those skilled in the art.

[0088] When halo=Cl, compounds of formula IV where R₉=aryl, hetroaryl, heterocyclic can be prepared as described by Huang J. and Nolan S. P., et al, J. Am. Chem Soc., 1999, 121, 9889. Thus, reaction of IX with a suitably substituted aryl magnesium bromide in a suitable solvent such as dioxane in the presence of an N-heterocyclic carbene ligand and a palladium catalyst such as but not limited to palladium(II)acetate.

[0089] Compounds of formula V can be prepared as outlined in Scheme 7.

[0090] where

[0091] R₁, R₂, R₃, and R₄ are as defined above;

[0092] and halo=Cl or Br.

[0093] Thus, compounds of formula V where R₉=aryl, heteroaryl, heterocyclic, and alkenyl, can be prepared in an analogous fashion to the regioisomer described above in Scheme 6.

[0094] Prodrugs of formula I and formula II can readily be prepared as described below.

[0095] Thus when R₁₀=COR₁₁, compounds can be prepared by methods commonly known to those skilled in the art. The reaction of an acid chloride with compounds of formula I and formula II wherein R₁=H in a suitable solvent such as methylene chloride in the presence of a suitable base such as N,N-diisopropylethylamine affords the ester prodrugs.

[0096] For amino acid esters, standard coupling techniques known to those skilled in the art can be used, including activation of the carboxylic acid in the presence of DMAP (Boden E. P., Keck, G. E., J. Org. Chem, 1985, 50, 2394). A solution of compounds of formulas I and II dicyclohexylcarbodiimide and DMAP in a suitable solvent such as CH₂Cl₂ is stirred overnight at ambient temperature. The reaction mixture is purified typically by column chromatography known to those skilled in the art to provide the ester.

[0097] When R₁₀=CONHR₁₁, compounds of formula I and II are reacted with substituted isocyanates in a suitable solvent such as dioxane and heated at 80° C. for up to 48 hours. (March's Adv. Org. Chem, 5^(th) ed, 16: 1183, Wiley lnterscience, 2001).

[0098] When R₁₀=P(═O)(OH)OR₁₁, the substituted hydrogen phosphates of compounds of formulas I and II can be prepared as described by Rodriguez, M. J. et al., Bioorg. Med. Chem. Lett., 1999, 9, 1863. Thus, a solution of compounds of formulas I or II, wherein R₁₀=H substituted dichlorophosphate and lithium hexamethyldisilazide in a suitable solvent such as THF is stirred for 1 hour at ambient temperature. The reaction mixture is quenched with H₂O and purified by reversed phase HPLC, known by one skilled in the art.

[0099] The compounds of this invention are useful in the treatment of the inflammatory component of diseases and are therefore particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, arthritis, inflammatory bowel disease, type II diabetes, osteoarthritis, asthma and any other autoimmune disease in humans or other mammals which comprises administering to a human or other mammal an antiinflammatory effective amount of a compound of the present invention.

[0100] Representative compounds of this invention were evaluated in the following standard pharmacological test procedures which demonstrated the antiinflammatory activity for the compounds of this invention. The test procedures used and the results obtained are briefly described below.

[0101] Test Procedures:

[0102] Cells

[0103] T-175 flasks of 100% confluent HAECT-1 cells (immortalized human aortic endothelial cells) were washed with 8 ml of HBSS (HEPES buffered saline solution) and infected for four hours with 6 ml of a 1:10 dilution of Ad5-wt-hERα virus (an adenovirus transfection vector that mediates CMV promoter driven expression of human ERα) in phenol red free Endothelial Cell Basal medium (Clonetics, San Diego Calif., Catalog # CC-3129) containing 0.25% bovine serum albumin (EBM-BSA). After four hours, cells were washed with EBM-BSA and incubated overnight in the same medium. Following overnight incubation, cells were washed with EBM-BSA and infected for 2 hours with 6 ml of a 1:10 dilution of Ad5-3×(NFκB).Luc virus (Adenovirus luciferase expression vector driven by 3 repeats of the MHC NFκb site 5′ to the thymidine kinase promoter) in EBM-BSA. After two hours, cells were washed and incubated at 34° C. for 1 hour. Cells were then washed, trypsinized, counted and resuspended in 95% FBS/5% dimethylsulfoxide at a concentration of 4×10⁶ cells/ml, frozen as 1 or 5 ml aliquots in cryo-vials and stored at −150° C. Control (no ER infection) cells were processed as above without Ad5-wt-hERα virus infection.

[0104] IL-6 and Creatine Kinase Assays

[0105] ERα infected HAECT-1 cells or control cells were thawed, diluted 42× in warm EBM-BSA, plated into 96-well plates at 0.1 ml/well and incubated for 4 h at 34° C. Test compounds were added to the cells as 2× stocks in EBM-BSA containing 2 ng/ml IL-1β (R&D Systems) and plates were returned to the incubator (34° C.). After 15-20 h, 100 μl aliquots of media were removed from the cells and assayed for IL-6 content using a BioSource human IL-6 ELISA Kit. Cells were subsequently washed with 300 μl of Dulbecco's phosphate buffered saline and lysed in 50 μl of Cell Culture Lysis Reagent (Promega). Luciferase was determined on a Wallac Victor² Luminometer (Gaithersburg, Md.) using 10 μl of lysate and mixing with 100 μl of Promega Luciferase Assay reagent. Creatine kinase was determined from the rate of increase in A₃₄₀ following addition of 100 μl of CK assay reagent (Sigma, cat. No 47-10) to the remainder of the cell lysate.

[0106] Data Analyses

[0107] For IC₅₀ and EC₅₀ calculations, mean IL-6, luciferase or CK values versus log₁₀ of the compound concentration were fitted to a four parameter logistic equation. The IC50/EC₅₀ value, ‘Hill slope’, upper and lower limits of the curve were iteratively estimated.

[0108] Mice

[0109] Ovariectomized C57BL/6 mice (16-20 g) (Taconic) were separated into groups of 8. After 5-7 days of recuperation, the mice were fed a chow diet or an atherogenic diet (15.75% fat, 1.25% cholesterol and 0.5% sodium cholate) (Purina diet #21539). EE or test compound was administered once daily by gavage in a methylcellulose/tween vehicle (0.1 ml per mouse) for 5 weeks. At the end of the experimental period, the liver was collected and uterine wet weight was recorded.

[0110] RNA Analysis

[0111] Liver total RNA was prepared by using Trizol reagent (BRL). Estrogen and compound regulation of NF-κB target genes were verified by real time RT-PCR using an ABI PRISM 7700 Sequence Detection System according to the manufacturer's protocol (Applied Biosystems). The data was analyzed using the Sequence Detector v1.7 software (Applied Biosystems) and normalized to GAPDH using the Applied Biosystems primer set.

[0112] The following table summarizes the results obtained in the standard pharmacological test procedures described above. TABLE 1 Effects of 17-β-estradiol on NE-κB, IL-6 and CK expression in Ad5-wt-ER infected HAECT-1 cells ER/NF-KB-luc ER/IL-6 ER/CK Example # IC₅₀ (nM) % E2 IC₅₀ (nM) % E2 EC₅₀ (nM) % E2 1 62 74 3318 101 1217 33 2 112 49 1137 67 549 29 4 443 63 15775 58 5 165 71 4790 66 6 86 85 478 43 7 90 92 246 77 1827 54 11 60 54 2317 91 114 26 12 208 61 7606 73 1199 58 13 133 97 601 83 828 47 14 53 73 761 67 15 164 94 8127 110 16 95 79 81 58 438 45 17 305 71 701 114 3070 97 20 149 69 21 140 73 22 50 73 23 239 76 72 55 24 63 83 25 274 112 26 356 101 27 1027 96 28 551 86 30 37 105 31 636 120 32 65 91 33 37 92 51 34 34 66 115 137 87 37 40 95 303 61 38 89 25 70 39 9 89 57 46 40 108 22 79 41 95 85 415 39 42 190 102 43 51 79 138 34 44 43 90 309 48 45 31 86 121 43 46 102 67 47 97 94 13 26 48 42 107 79 49 49 3 91 10 44 50 106 84 327 43 51 18 94 46 37 52 17 76 111 27 53 58 84 184 31 54 393 77 55 26 90 401 49 56 14 96 477 47 57 45 89 205 45 58 20 100 97 38 59 5 90 133 36 60 20 76 13 90 331 34 61 50 62 76 33 62 47 82 253 30 63 1883 158 64 100 81 114 94 198 18 65 41 86 218 42 66 29 56 17 32 67 48 65 68 56 74 69 235 68 704 32 70 14 76 72 7 85 140 46 73 94 76 103 19 74 59 86 26 75 63 83 982 48 76 22 86 57 20 77 41 87 302 29 78 590 90 2197 32 79 92 93 734 52 80 18 48 81 33 92 308 62 82 191 68 83 20 82 84 36 75 85 235 46 86 255 83 413 27 87 347 77 188 24 88 419 74 89 435 97 91 80 82 787 24 92 228 87 93 128 60 94 332 86 96 88 78 101 505 61 103 138 79 104 250 81 105 918 66 110 2 89 12 82 111 214 78 112 667 48 114 268 67 115 246 71 115 27 82 166 91 116 140 63 229 25 117 150 52 169 22 118 418 66 122 350 78 123 328 71 125 479 128 126 134 85 122 52 387 52 130 62 97 205 54 131 195 82 380 72 815 65 134 897 76 1927 36 139 183 67 329 40 722 36 142 114 69 65 60 390 47 143 310 65 145 125 66 97 60 439 48 147 166 65 431 29 149 319 67 115 49 527 30 151 1061 81 158 515 106 1124 59 162 113 84 107 34 167 311 83 588 29 168 347 95 1374 86 169 65 69 65 65 364 38 170 276 77 827 28 171 582 95 2382 42 172 349 95 1325 92 176 587 111 1041 70 180 28 88 156 50 182 443 121 2935 71 183 431 135 2935 48 188 751 90 2453 31 192 371 87 608 51 198 303 100 1000 30 199 487 100 1260 42 200 435 86 1478 58 202 539 160 1839 68 203 196 117 1068 48 206 473 84 902 27 219 369 104 220 112 84 2341 48 226 32 87 309 20 227 56 70 279 21 228 75 83 230 367 82 231 382 78 3254 32 232 143 75 233 87 81 234 34 72 235 16 74 223 35 236 47 83 112 36 237 480 79 238 11 74 240 158 54 974 32 241 32 60 243 142 83 244 33 48 208 33 245 16 70 246 11 82 136 28 247 12 70 17 42 248 481 73 249 59 59 250 47 80 251 24 57 252 56 59 253 21 62 254 27 56 255 4 89 256 13 94 292 32 257 43 76 490 27 258 644 77 259 18 73 143 38 260 28 53 261 98 42 262 8 75 263 30 84 165 17 264 15 74 15 21 265 6 82 138 28 266 68 77 213 35 267 53 64 250 35

[0113] Efficacy values are relative to the maximal inhibition (NF-κB or IL-6 test procedure) or stimulation (CK test procedure) observed with E2

[0114] E2 inhibits NF-κB and IL-6 expression in Ad5-wt-ER infected HAECT-1 cells with an IC₅₀ value around 1 nM and induces expression of creatine kinase in the same cells with similar potency (5.8 nM) (Table 1). In contrast, compounds of the present invention potently and efficaciously inhibit NF-κB and IL-6 expression in Ad5-wt-ER infected HAECT-1 cells but do not induce CK expression (Table 1) in an ER-dependent manner. The ability of compounds of the present invention to inhibit NF-κB and IL-6 expression without inducing CK activity (Table 1) is demonstrates anti-inflammatory activity in the absence of classic estrogenic activity.

[0115] Based on the results obtained in the standard pharmacological test procedures, the compounds of this invention are selective antiinflammatory compounds described herein useful for the treatment and prevention of chronic inflammatory diseases without stimulating uterine and breast cell proliferation as found with classic estrogens.

[0116] Accordingly, the compounds of this invention are useful in treating or inhibiting osteoporosis and in the inhibition of bone demineralization, which may result from an imbalance in an individual's formation of new bone tissues and the resorption of older tissues, leading to a net loss of bone. Such bone depletion results in a range of individuals, particularly in post-menopausal women, women who have undergone bilateral oophorectomy, those receiving or who have received extended corticosteroid therapies, those experiencing gonadal dysgenesis, and those suffering from Cushing's syndrome. Special needs for bone, including teeth and oral bone, replacement can also be addressed using these compounds in individuals with bone fractures, defective bone structures, and those receiving bone-related surgeries and/or the implantation of prosthesis. In addition to those problems described above, these compounds can be used in treatment or inhibition for osteoarthritis, hypocalcemia, hypercalcemia, Paget's disease, osteomalacia, osteohalisteresis, multiple myeloma and other forms of cancer having deleterious effects on bone tissues.

[0117] The compounds of this invention are also active in the brain and are therefore useful for inhibiting or treating Alzheimer's disease, cognitive decline, decreased libido, senile dementia, neurodegenerative disorders, stroke, depression, anxiety, insomnia, schizophrenia, and infertility. The compounds of this invention are also useful in treating or inhibiting benign or malignant abnormal tissue growth including, glomerulosclerosis, prostatic hypertrophy, uterine leiomyomas, breast cancer, scleroderma, fibromatosis, endometriosis, endometrial cancer, polycystic ovary syndrome, endometrial polyps, benign breast disease, adenomyosis, ovarian cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, such as glioma or astioblastomia.

[0118] The compounds of this invention are cardioprotective and are antioxidants, and are useful in lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, and vasospasm, and inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage.

[0119] The compounds of this invention are also useful in treating disorders associated with inflammation or autoimmune diseases, including inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis), arthritis (rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis), pleurisy, ischemia/reperfusion injury (e.g. stroke, transplant rejection, myocardial infarction, etc.), asthma, chronic obstructive pulmonary disease, giant cell arteritis, prostatitis, uveitis, psoriasis, multiple sclerosis, systemic lupus erythematosus and sepsis.

[0120] The compounds of this invention are also useful in treating or inhibiting ocular disorders including cataracts, uveitis, and macular degeneration and in treating skin conditions such as aging, alopecia, and acne.

[0121] The compounds of this invention are also useful in treating or inhibiting metabolic disorders such as type-II diabetes, of lipid metabolism, appetite (e.g. anorexia nervosa and bulimia).

[0122] Compounds in this invention are also useful in treating or inhibiting bleeding disorders such as hereditary hemorrhagic telangiectasia, dysfunctional uterine bleeding, and combating hemorrhagic shock. The compounds of this invention are useful in disease states where amenorrhea is advantageous, such as leukemia, endometrial ablations, chronic renal or hepatic disease or coagulation diseases or disorders.

[0123] The following describes the preparation of representative compounds of this invention.

GENERAL METHODS Intermediates 1-15

[0124] Method A: Substituted (2-Fluoro-phenyl)-(4-methoxyphenyl)-methanone

[0125] Step A Substituted-N-Methoxy-N-methyl-2-fluorobenzamide A mixture of the substituted benzoic acid (1 equivalent) and oxalyl chloride (1 equivalent) in dry CH₂Cl₂ was treated with a catalytic amount of DMF. The reaction mixture was stirred until gas evolution ceased. To the cooled solution was added N,O-dimethylhydroxylamine hydrochloride (1.2 equivalents) in one portion. Pyridine (0.24 mL/mmol) was added dropwise and the mixture was stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo and the residue partitioned with EtOAc and 1 N HCl. The organic phase was washed with saturated aqueous NaHCO₃ and brine. The organic phase was dried (Na₂SO₄ and concentrated in vacuo to provide reasonably pure intermediate substituted-N-methoxy-N-methyl-2-fluorobenzamide.

[0126] Step B Substituted-(2-Fluoro-phenyl)-(4-methoxyphenyl)-methanone

[0127] A solution of substituted-N-Methoxy-N-methyl-2-fluorobenzamide (1 equivalent) in THF (0.5 molar) was treated with 1.2 equivalents of substituted-4-methoxyphenyl magnesium bromide (0.5M). The mixture was heated at 50° C. overnight. The reaction mixture was partitioned with EtOAc and 1N HCl. The organic phase was washed with brine and dried (Na₂SO₄). The residue obtained on concentration in vacuo was purified by flash chromatography (hexane-ethyl acetate) to give the title compound.

Intermediate 1 (2-Fluoro-3-trifluoromethylphenyl)-(4-methoxyphenyl)-methanone

[0128] Step 1: 2-fluoro-N-methoxy-N-methyl-3-(trifluoromethyl)benzamide

[0129] Prepared according to Method A step A from 2-fluoro-3-trifluoromethylbenzoic acid (5.0 g, 24 mmol), N,O-dimethylhydroxylamine hydrochloride (3.4 g, 35 mmol), oxalyl chloride (2.18 mL, 25 mmol) and 6 mL of pyridine to give the title compound (6.0 g) as an oil. Used as is in the next prep

[0130]¹H NMR (DMSO-d₆): δ 3.28 (s, 3H), 3.475 (s, 3H), 7.499 (t, 1H), 7.86 (m, 2H).

[0131] MS (EI) m/z: 251 M⁺

[0132] Step 2: (2-Fluoro-3-trifluoromethylphenyl)-(4-methoxyphenyl)-methanone

[0133] Prepared according to Method A step B from 2-fluoro-N-methoxy-N-methyl-3-(trifluoromethyl)benzamide (2.5 g, 10 mmol) and 4-methoxyphenylmagnesium bromide (20 mL, 0.5 M in THF) to give 2.1 g of the title compound as a white solid.

[0134]¹H NMR (DMSO-d₆): δ 3.86 (s, 3H), 7.10 (d, 2H), 7.56 (t, 1H), 7.76 (d, 2H), 7.87 (t, 1H) 8.008 (t, 1H).

[0135] MS (-APCI) m/z: 298 M⁻

Intermediate 2 (3-chloro-2-fluorophenyl)-(4-methoxyphenyl)-methanone

[0136] Step 1: 3-chloro-2-fluoro-N-methoxy-N-methylbenzamide

[0137] Prepared according to Method A step A from 3-chloro-2-fluorobenzoic acid (3.0 g, 17.2 mmol), N,O-dimethylhydroxylamine hydrochloride (2.34 g, 24 mmol), oxalyl chloride (1.5 mL, 17.2 mmol) and 5 mL of pyridine to give the title compound (3.3 g) as an oil. Used as is in the next prep

[0138]¹H NMR (DMSO-d₆): δ 3.3 (s, 3H), 3.45 (s, 3H), 7.3 (m, 1 H), 7.45 (m, 1 H), 7.68 (m, 1H).

[0139] Step 2: (3-chloro-2-fluorophenyl)-(4-methoxyphenyl)-methanone

[0140] Prepared according to Method A step B from 3-chloro-2-fluoro-N-methoxy-N-methylbenzamide (2.5 g, 11.5 mmol) and 4-methoxyphenylmagnesium bromide (25 mL, 0.5 M in THF) to give 0.3 g of the title compound as a white solid.

[0141]¹H NMR (DMSO-d₆): δ 3.85 (s, 3H), 7.09 (d, 2H), 7.38 (t, 1H), 7.49 (m, 1H), 7.75 (d, 2H), 7.81 (d, 1H).

[0142] MS (APCI) m/z: 264 M⁺

Intermediate 3 (2,3-difluorophenyl)-(4-methoxyphenyl)-methanone

[0143] Step 1: 2,3-difluoro-N-methoxy-N-methylbenzamide

[0144] Prepared according to Method A step A from 2,3-difluorobenzoic acid (4.0 g, 25 mmol), N,O-dimethylhydroxylamine hydrochloride (3.4 g, 35 mmol), oxalyl chloride (2.2 mL, 25 mmol) and 6 mL of pyridine to give the title compound (4.7 g) as an oil. Used as is in the next preparation.

[0145]¹H NMR (DMSO-d₆, 300 MHz): δ 3.25 (s, 3H), 3.45 (s, 3H), 7.25 (m, 2H), 7.55 (m, 2H).

[0146] Step 2: (2,3-difluorophenyl)-(4-methoxyphenyl)-methanone

[0147] Prepared according to Method A step B from 2,3-difluoro-N-methoxy-N-methylbenzamide (3.0 g, 15 mmol) and 4-methoxyphenylmagnesium bromide (35 mL, 0.5 M in THF) to give 1.44 g of the title compound as a white solid.

[0148]¹H NMR (DMSO-d₆, 300 MHz): δ 3.85 (s, 3H), 7.07 (d, 2H), 7.35 (m, 2H), 7.65 (m, 1H 7.75 (d, 2H).

Intermediate 4 (2-Fluoro-3-methylphenyl)-(4-methoxyphenyl)-methanone

[0149] Step 1: 2-fluoro-N-methoxy-N,3-dimethylbenzamide

[0150] Prepared according to Method A step A from 2-fluoro-3-methylbenzoic acid (5.0 g, 32.5 mmol), N,O-dimethylhydroxylamine hydrochloride (8.4 g, 87 mmol), oxalyl chloride (2.83 mL, 32.5 mmol) and 8 mL of pyridine to give the title compound (4.8 g) as an oil. Used as is in the next prep

[0151]¹H NMR (DMSO-d₆): δ 3.25 (s, 3H), 3.47 (s, 3H), 7.15 (t, 1H), 7.24 (m, 1H), 7.35 (m, 1H).

[0152] Step 2: (2-Fluoro-3-methylphenyl)-(4-methoxyphenyl)-methanone

[0153] Prepared according to Method A step 2-fluoro-N-methoxy-N,3-dimethylbenzamide (4.8 g, 24 mmol) and 4-methoxyphenylmagnesium bromide (50 mL, 0.5 M in THF) to give 3.7 g of the title compound as a white solid.

[0154]¹H NMR (DMSO-d₆): δ 2.28 (s, 3H), 3.84 (s, 3H), 7.07 (d, 2H), 7.22 (t, 1H), 7.29 (m, 1H), 7.49 (m,1 H), 7.72 (d, 2H).

[0155] MS (APCI) m/z: 245 (M+H)⁺

Intermediate 5 (2,3-Difluorophenyl)-(4-methoxy-3-methyl-phenyl)-methanone

[0156] Prepared according to Method A step B from 2,3-difluoro-N-methoxy-N-methyl-benzamide (2.5 g, 12.4 mmol) and 4-methoxy-3-methyl-phenylmagnesium bromide (26 mL, 0.5 M in THF) to give 0.97 g of the title compound as a white solid.

[0157]¹H NMR (DMSO-d₆): 6 2.185 (s, 3H), 3.887 (s, 3H), 7.08 (d, 1H), 7.34 (m, 2H), 7.64 (m 3H).

[0158] MS (ESI) m/z: 263 (M+H)⁺

Intermediate 6 (2,3-difluorophenyl)(4-methoxy-2-methylphenyl)methanone

[0159] Prepared according to Method A step B from 2,3-difluoro-N-methoxy-N-methyl-benzamide (3.77 g, 18.7 mmol) and 4-methoxy-2-methyl-phenylmagnesium bromide (49 mL, 0.5 M in THF) to give 1.45 g of the title compound as a white solid.

[0160]¹H NMR (DMSO-d₆): δ 2.47 (s, 3H), 3.82 (s, 3H), 6.82 (d, 1H), 6.95 (s, 1H) 7.28-7.38 (m, 3H), 7.62-7.67 (m, 1H).

[0161] MS (APCI) m/z 263 ([M+H]⁺);

[0162] Anal. calcd for C₁₅H₁₂F₂O₂: C:68.70 H:4.61 Found: C:68.83 H:4.65.

Intermediate 7 3-chloro-2-fluorophenyl)(4-methoxy-2-methylphenyl)methanone

[0163] Prepared according to Method A step B from 2- fluoro-3-chloromethyl-N-methoxy-N-methylbenzamide (2.78 g, 12.8 mmol) and 4-methoxy-2-methyl-phenylmagnesium bromide (33 mL, 0.5 M in THF) to give 1.07 g of the title compound as a white solid.

[0164]¹H NMR (DMSO-d₆): δ 2.47 (s, 3H), 3.81 (s, 3H), 6.83 (d, 1H), 6.95 (s, 1H 7.32-7.36 (m, 3H), 7.44 (t, 1H), 7.80 (t, 1H).

[0165] MS (APCI) m/z 279 ([M+H]⁺);

[0166] Anal. calcd for C₁₅H₁₂ClFO₂.0.25 H₂O: C:63.61 H:4.45.

[0167] Found: C:63.73 H:4.08.

Intermediate 8 (2-fluoro-3-methylphenyl)(4-methoxy-2-methylphenyl)methanone

[0168] Prepared according to Method A step B from 2- fluoro-3-methyl-N-methoxy-N-methyl-benzamide (3.10 g, 15.7 mmol) and 4-methoxy-2-methyl-phenylmagnesium bromide (40 mL, 0.5 M in THF) to give 1.17 g of the title compound as a white solid.

[0169]¹H NMR (DMSO-d₆): δ 2.25 (s, 3H), 3.81 (s, 3H), 6.83 (d, 1H), 6.93 (s, 1H), 7.20-7.32 (m, 3H), 7.48 (t, 1 H).

[0170] MS (APCI) m/z 259 ([M+H]⁺);

[0171] Anal. calcd for C₁₆H₁₅FO₂.0.25 H₂O: C:73.13 H:5.95. Found: C:72.88 H:5.92.

Intermediate 9 [2-fluoro-3-(trifluoromethyl)phenyl](4-methoxy-2-methylphenyl)methanone

[0172] Prepared according to Method A step B from 2- fluoro-3-trifluoromethyl-N-methoxy-N-methylbenzamide (4.05 g, 16.1 mmol) and 2-methyl-4-methoxyphenylmagnesium bromide (42 mL, 0.5 M in THF) to give 1.76 g of the title compound as a white solid.

[0173]¹H NMR (DMSO-d₆): δ 2.50 (s, 3H), 3.82 (s, 3H), 6.86 (d, 1H), 6.98 (s, 1H 7.37 (d, 1H), 7.55 (t, 1H), 7.84 (t, 1H), 7.99 (t, 1H).

[0174] MS (APCI) m/z 313 ([M+H]⁺);

Intermediate 10 (2,4-dimethoxyphenyl)(2-fluoro-3-methylphenyl)methanone

[0175] Prepared according to Method A step B from 2-fluoro-3-methyl-N-methoxy-N-methyl-benzamide (2.84 g, 14.4 mmol) and 2,4-dimethoxyphenylmagnesium bromide (26 mL, 0.5 M in THF) to give 1.13 g of the title compound as a white solid.

[0176]¹H NMR (DMSO-d₆): δ 2.27 (s, 3H), 3.53 (s, 3H), 3.63 (s, 3H), 5.85-5.89 (m, 1H), 5.98-6.00 (m, 1H), 6.11-6.16 (m, 1H), 6.52 (t, 1H), 6.65-6.73 (m, 2H).

[0177] MS (APCI) m/z 275 ([M+H]⁺);

[0178] Anal. calcd for C₁₆H₁₅FO₃: C:70.06 H:5.51 Found: C:68.61 H:5.93.

Intermediate 11

[0179] (2,4-dimethoxyphenyl)[2-fluoro-3-(trifluoromethyl)phenyl]methanone

[0180] Prepared according to Method A step B from 2-fluoro-3-trifluoromethyl-N-methoxy-N-methylbenzamide (4.42 g, 17.6 mmol) and 2,4-dimethoxyphenylmagnesium bromide (32 mL, 0.5 M in THF) to give 1.67 g of the title compound as a white solid.

[0181] mp 79-82 ° C.;

[0182]¹H NMR (DMSO-d₆): δ 3.56 (s, 3H), 3.86 (s, 3H), 6.64-6.69 (m, 2H), 7.48 (t, 1H), 7.65 (t, 1H), 7.82 (t, 1H), 7.94 (t, 1H).

[0183] MS (ESI) m/z 329.1 (M+H)⁺;

[0184] MS (ESI) m/z679.16 (2M+H)⁺;

[0185] Anal. calcd for C₁₆H₁₂F₄O₃: C:58.54 H:3.68 Found: C:58.45 H:4.05.

Intermediate 12 (3-chloro-2-fluorophenyl)(2,4-dimethoxyphenyl)methanone

[0186] Prepared according to Method A step B from 2-fluoro-3-chloro-N-methoxy-N-methyl-benzamide (2.44 g, 11.2 mmol) and 2,4-dimethoxyphenylmagnesium bromide (20 mL, 0.5 M in THF) to give 0.95 g of the title compound as a white solid.

[0187]¹H NMR (DMSO-d₆): δ 3.59 (s, 3H), 3.85 (s, 3H), 6.65 (s, 2H), 7.30 (t, 1H), 7.59 (d,1 H), 7.73 (t, 1H).

[0188] MS (APCI) m/z 295 ([M+H]⁺);

[0189] Anal. calcd for C₁₅H₁₂CIFO₃: C:61.13 H:4.10 Found: C:61.25 H:4.25.

Intermediate 13 (2,3-difluorophenyl)(2,4-dimethoxyphenyl)methanone

[0190] Prepared according to Method A step B from 2,3-difluoro-N-methoxy-N-methyl-benzamide (3.22 g, 16.0 mmol) and 2,4-dimethoxyphenylmagnesium bromide (29 mL, 0.5 M in THF) to give 1.21 g of the title compound as a white solid.

[0191]¹H NMR (DMSO-d₆): δ 3.60(s, 3H), 3.86 (s, 3H), 6.65-6.68 (m, 2H), 7.27-7.29 (m, 2H), 7.55-7.64 (m, 2H).

[0192] MS (APCI) m/z 279 ([M+H]⁺);

[0193] Anal. calcd for C₁₅H₁₂F₂O₃: C:64.75 H:4.35 Found: C:64.51 H:4.20.

Intermediate 14 (3-bromo-2-fluorophenyl)(4-methoxyphenyl)methanone

[0194] Prepared according to Method A step B from 2-fluoro-3-bromo-N-methoxy-N,3-dimethyl-benzamide (8.00 g, 30.5 mmol) and 4-methoxyphenylmagnesium bromide (65 mL, 0.5 M in THF) to give 3.12 g of the title compound as a white solid.

[0195] mp 88-90° C.;

[0196]¹H NMR (DMSO-d₆): δ 3.85 (s, 3H), 7.09 (d, 1H), 7.31 (t, 1H), 7.50-7.53 (m, 1H), 7.74 (d, 2H), 7.91-7.94 (m, 1 H).

[0197] MS (ESI) m/z 309 ([M+H]⁺);

Intermediate 15 (3-bromo-2-fluorophenyl)(4-methoxy-2-methylphenyl)methanone

[0198] Step 1: 3-bromo-2-fluoro-N-methoxy-N-methylbenzamide

[0199] Prepared according to Method A step A from 2-fluoro-3-bromomethylbenzoic acid (16.0 g, 73.0 mmol), N,O-dimethylhydroxylamine hydrochloride (3.4 g, 35 mmol), oxalyl chloride (6.69 mL, 76.7 mmol) and 25 mL of pyridine to give the title compound (8.0 g) as an oil. Used as is in the next step.

[0200]¹H NMR (DMSO-d₆, 500 MHz): δ 3.26 (s, 3H), 3.465 (s, 3H), 7.235 (t, 1H), 7.48 (t, 1H), 7.80 (t, 1 H).

[0201] Step 2: (3-bromo-2-fluorophenyl)(4-methoxy-2-methylphenyl)methanone

[0202] Prepared according to Method A step B from 3-bromo-2-fluoro-N-methoxy-N-methylbenzamide (8 g, 31 mmol) and 2-methyl-4-methoxyphenyl magnesium bromide ((70 ml, 0.5 M in THF) to give 3.58 g of the title compound.

[0203]¹H NMR (DMSO-d₆): δ 2.49 (s, 3H, obscured by DMSO), 3.82 (s, 3H), 6.83 (dd, H, J=2.59 Hz and 8.70Hz), 6.95 (s, 1H), 7.28 (t, 1H), 7.32 (d, 1H), 7.46-7.50 (m, 1H), 7.89-7.92 (m, 1H).

[0204] MS (ESI) m/z 323 ([M+H]⁺);

EXAMPLES 1-29 Method B: 4-(1-substituted-6-hydroxy -1H-indazol-3-yl)benzene-1,3-diols

[0205] A solution of the substituted hydrazine salt (1 to 2 equivalents), sodium acetate (1 to 4 equivalents) and 2,2′,4,4′-tetrahydroxybenzophenone (1 equivalent) in methanol (0.2 molar solution) was stirred at ambient temperature overnight. The reaction mixtures were concentrated in vacuo and the residues partitioned with EtOAc and H₂O. The organic phase was dried (Na₂SO₄) and concentrated in vacuo to give the intermediate hydrazone. The residues were heated at 190° C. overnight. Product residues were then purified by HPLC chromatography through silica gel columns 150×12 mm (Biotage) at 10 mL/min with methyl-t-butyl ether/hexane (1:3, v/v) to give 4-(1-substituted-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diols.

Example 1 4-(6-hydroxy-1-propyl-1H-indazol-3-yl)benzene-1,3-diol

[0206] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2 mmol) and propylhydrazine oxalate (0.164 g, 1.0 mmol) to give 0.075 g of product as a pink solid.

[0207]¹H NMR (DMSO-d₆): δ 0.846 (t, 3H, J=7.32Hz), 1.83 (q, 2H, J=7.07Hz), 4.24 (t, 2H, J=6.83 Hz), 6.36 (s, 1H), 6.41 (dd, 1H), 6.74 (dd, 1H), 6.85 (s, 1H), 7.74 (d, 1H, 7.91 (d, 1H), 9.587 (broad s, 1H), 9.857 (broad s, 1H), 10.882 (s, 1H).

[0208] MS (APCI) m/z 285 ([M+H]⁺);

Example 2 4-(1-butyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol

[0209] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2 mmol) and butylhydrazine oxalate (0.178 g, 1.0 mmol) to give 0.058 g of product as a pink solid

[0210]¹H NMR (DMSO-d₆): δ 0.88 (t, 3H), 1.25 (m, 2H), 1.77 M, 2H), 4.28 (t, 2H) 6.36 (s, 1H), 6.41 (dd, 1H), 6.73 (dd, 1H), 6.84 (s, 1H) 7.73 (d, 1H), 7.89 (d, 1H), 9.57 (broad s, 1H), 9.823 (broad s, 1H), 10.856 (s, 1H).

[0211] MS (APCI) m/z 299 ([M+H]⁺);

Example 3 4-[6-hydroxy-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0212] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2 mmol) and 2-hydroxyethylhydrazine (0.085 g, 1.0 mmol) to give 0.020 g of product as a white solid

[0213]¹H NMR (DMSO-d₆): δ 3.78 (m, 2H), 4.31 (m, 2H), 4.88 (t, 1H), 6.36 (2, 1H), 6.41 (dd, 1H), 6.73 (dd, 1H), 6.85 (s, 1H), 7.73 (d, 1H), 7.91 (d, 1H), 9.587 (broad s, 1H), 9.857 (broad s, 1H), 10.882 (s, 1H).

[0214] MS (APCI) m/z 287 ([M+H]⁺);

Example 4 4-(1-cyclohexyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol

[0215] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2 mmol) and cyclohexylhydrazine hydrochloride (0.150 g, 1.0 mmol) to give 0.040 g of product as a white solid

[0216]¹H NMR (DMSO-d₆): δ 1.25 (m, 2H), 1.49 (m, 2H), 1.7 (m, 2H), 1.82 (m, 4H), 1.96 (m, 2H), 4.42 (m, 1H), 6.36 (2, 1H), 6.41 (dd, 1H), 6.75 (dd, 1H), 6.90 (s, 1H), 7.75 (d, 1H), 7.91 (d, 1H), 9.575 (broad s, 1H), 9.85 (broad s, 1H), 11.0175 (s, 1H).

[0217] MS (APCI) m/z 325 ([M+H]⁺);

Example 5 4-[6-hydroxy-1-(2,2,2-trifluoroethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0218] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2 mmol) and 2,2,2-trifluoroethylhydrazine (0.088 mL, 1.0 mmol) to give 0.028 g of product as a yellow solid

[0219]¹H NMR (DMSO-d₆): δ 5.36 (q, 2H), 6.39 (2, 1H), 6.41 (dd, 1H), 6.79 (dd, 1H), 6.98 (s, 1H), 7.65 (d, 1H), 7.86 (d, 1H), 9.629 (s, 1H), 9.97 (s, 1H), 10.4073 (s, 1H).

[0220] MS (APCI) m/z 323 [M−H]−.

Example 6 4-[1-(3-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0221] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (2.46 g, 10 mmol), sodium acetate (0.82 g, 10 mmol) and 3-chlorophenylhydrazine hydrochloride (1.97 g, 11 mmol) to give 3.1 g of product as a tan solid Crystallized from EtOAc/hexane to give 1.4 g of an off-white solid (mp 228-230° C.).

[0222]¹H NMR (DMSO-d₆): δ 6.3995-6.4434 (m, 2H), 6.81 (dd, 1H), 7.15 (s, 1H), 7.43 (dd, 1H), 7.61 (m, 2H), 7.73 (dd, 1H), 7.80 (s, 1H), 7.86 (d, 1H), 9.648 (s, 1H), 10.00 (s, 1H), 10.1418 (s, 1H).

[0223] MS (APCI) m/z 353 ([M+H]⁺);

[0224] Anal. calcd for C₁₉H₁₃ClN₂O₃.H₂O: C:61.55H:4.08 N:7.55 Found: C:61.74H:3.57 N:7.79.

Example 7 4-[1-(4-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-di I

[0225] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (2.46 g, 10 mmol), sodium acetate (0.82 g, 10 mmol) and 4-bromophenylhydrazine hydrochloride (2.25 g, 10 mmol) to give 2.1 g of product as a tan solid. Crystallized from EtOAc/hexane to give 1.3 g of an off-white solid (mp 246° C.).

[0226]¹H NMR (DMSO-d₆): δ 6.42 (m, 2H), 6.82 (dd, 1H), 7.086 (s, 1H), 7.61 (d, 1H), 7.70 (m, 2H), 7.77 (m, 2H), 7.87 d, 1H), 9.64 (s, 1H), 10.0054 (s, 1H), 10.2061 (s, 1H.

[0227] MS (APCI) m/z 397 ([M+H]⁺);

[0228] Anal. calcd for C₁₉H₁₃BrN₂O₃.0.39 C₄H₈O₂: C:57.22H:3.76 N:6.49 Found: C:56.71 H:3.50 N:6.11.

Example 8 4-[1-(2,5-dichlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0229] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.4 g, 1.6 mmol), sodium acetate (0.27 g, 3 mmol) and 2,5-dichlorophenylhydrazine hydrochloride (0.45 g, 2.5 mmol) to give 0.127 g of product as a beige solid (mp 78-80° C.).

[0230]¹H NMR (DMSO-d₆): δ 6.42 (m, 2H), 6.53 (s, 1H), 6.81 (dd, 1H), 7.66(m, 2H 7.80 (d, 1H), 7.85 (s, 1H), 7.92 (d, 1H), 7.87 d, 1H), 9.65 (s, 1H), 9.967 (s, 1H), 10.245 (s, 1H).

[0231] MS (ESI) m/z 387 ([M+H]⁺);

[0232] Anal. calcd for C₁₉H₁₂Cl₂N₂O₃: C:58.94H:3.12 N:7.23 Found: C:58.62H:3.92 N:6.42.

Example 9 4-[1-(2,5-difluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0233] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.4 g, 1.6 mmol), sodium acetate (0.27 g, 3 mmol) and 2,5-difluorophenylhydrazine hydrochloride (0.45 g, 3 mmol) to give 0.107 g of product as an off-white colored solid.

[0234] mp 88-91° C.;

[0235]¹H NMR (DMSO-d₆): δ 6.42 (m, 2H), 6.68 (s, 1H), 6.81 (dd, 1H), 7.41 (m, 1H), 7.63 m, 3H), 7.87 (d, 1H), 9.6508 (s, 1H), 9.986 (s, 1H), 10.1486 (s, 1H).

[0236] MS (ESI) m/z 355 ([M+H]⁺);

[0237] Anal. calcd for C₁₉H₁₂F₂N₂O₃: C:64.41H:3.41 N:7.91 Found: C:63.46H:3.34 N: 6.99.

Example 10 4-[1-(5-bromo-2-methylphenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0238] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.5 g, 2 mmol), sodium acetate (0.25 g, 3 mmol) and 5-bromophenylhydrazine hydrochloride (0.440 g, 2.4 mmol) to give 0.082 g of product as an off-white solid

[0239] mp 88-91° C.

[0240]¹H NMR (DMSO-d₆): δ 2.081 (s, 3H), 6.41 (m, 2H), 6.49 (s, 1H), 6.85 (dd, 1H), 7.46 (d, 1H), 7.65 (dd, 1H), 7.69 (dd, 2H), 7.94 (d, 1H), 9.11 (s, 1H), 9.63 (s, 1H).

[0241] MS (ESI) m/z 411 ([M+H]⁺);

[0242] Anal. calcd for C₂₀H₁₅BrN₂O₃: C:58.41H:3.68 N:6.81 Found: C:58.31H:4.11 N:5.81.

Example 11 4-[6-hydroxy-1-(4-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0243] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.041 g, 0.5 mmol) and 4-methoxyphenylhydrazine hydrochloride (0.087 g, 0.5 mmol) to give 0.013 g of product as a tan solid

[0244]¹H NMR (DMSO-d₆): δ 3.835 (s, 3H), 6.4 (m, 2H), 6.93 (s, 1H), 7.14 (d, 2H), 7.61 (d, 2H), 7.93 (m, 2H), 9.61 (broad s, 1H), 9.934 (broad s, 1H), 10.460 (s, 1H).

[0245] MS (APCI) m/z 349 ([M+H]⁺);

Example 12 4-[6-hydroxy-1-(2-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0246] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.041 g, 0.5 mmol) and 2-methoxyphenylhydrazine hydrochloride (0.087 g, 0.5 mmol) to give 0.010 g of product as a tan solid.

[0247]¹H NMR (DMSO-d₆): δ 3.871 (s, 3H), 6.42 (m, 2H), 6.77 (dd, 1H), 6.799 (m, 1H), 6.93 (s, 1H), 7.14 (t, 1H), 7.32 (dd, 1H), 7.49 (m, 2H), 7.75 (d, 1H), 7.95 (d, 1H 9.824 (s, 1H), 10.63 (s, 1H).

[0248] MS (APCI) m/z 349 ([M+H]⁺);

Example 13 4-{6-hydroxy-1-[4-(trifluoromethoxy)phenyl]-1H-indazol-3-yl}benzene-1,3-diol

[0249] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.041 g, 0.5 mmol) and 4-trifluoromethoxyphenylhydrazine hydrochloride (0.114 g, 0.5 mmol) to give 0.045 g of product as a tan solid.

[0250]¹H NMR (DMSO-d₆): δ 6.43 (m, 2H), 6.82 (dd, 1H), 7.09 (s, 1H), 7.61 (m, 3H), 7.89 (m, 3H), 9.635 (s, 1H), 9.98 (s, 1H), 10.1896 (s, 1H).

[0251] MS (APCI) m/z403 ([M+H]⁺);

Example 14 4-[1-(3-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0252] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.041 g, 0.5 mmol) and 3-bromophenylhydrazine hydrochloride (0.112 g, 0.5 mmol) to give 0.016 g of product as a tan solid.

[0253]¹H NMR (DMSO-d₆): δ 6.42 (m, 2H), 6.81 (dd, 1H), 7.11 (s, 1H), 7.56 (m, 3H), 7.76 (m, 1H), 7.85 (d, 1H), 7.92 (s, 1H), 9.63 (s, 1H), 10.13 (s, 1H), 10.82 (s, 1H).

[0254] MS (APCI) m/z 397 ([M+H]⁺);

Example 15 4-[3-(2,4-dihydroxyphenyl)-6-hydroxy-1H-indazol-1-yl]benzonitrile

[0255] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.041 g, 0.5 mmol) and 4-cyanophenylhydrazine hydrochloride (0.085 g, 0.5 mmol) to give 0.012 g of product as a yellow solid MS (APCI) m/z 343 (M⁻.).

Example 16 4-[1-(2-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0256] A mixture of 2,2′,4,4′-tetrahydroxybenzophenone (0.246 g, 1.0 mmol), ammonium chloride (0.16 g, 3 mmol) and 2-chlorophenyl hydrazine hydrochloride (0.535 g, 3 mmol) in 10 mL H₂O was heated at reflux for 4 hours. The reaction mixture was cooled and the solids formed were filtered washed with H₂O and dried to give 0.296 mg of the intermediate hydrazone. The hydrazone was heated to 200° C. under argon for 2 hours. The residue was purified by flash chromatography (hexane-EtOAc, 2:1) to give 0.055 g of product as a tan solid

[0257]¹H NMR (DMSO-d₆): δ 6.42 (m, 2H), 6.48 (s, 1H), 6.80 (dd, 1H), 7.58 (m, 2H), 7.66-7.79 (m, 3H), 7.96 (d, 1H), 9.64 (s, 1H), 9.925 (s, 1H), 10.406 (s, 1H).

[0258] MS (APCI) m/z 353 ([M+H]⁺);

Example 17 4-(1-ethyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol

[0259] A mixture of 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2.0 mmol) and ethylhydrazine oxalate (0.30 g, 2.0 mmol) in 2 mL H₂O was heated at 90° C. overnight. The cooled reaction mixture was partitioned with EtOAc and 1 N HCl. The organic layer was dried (Na₂SO₄) and concentrated in vacuo to give the crude product. The residue was purified by HPLC chromatography using a silica gel column 150×12 mm (Biotage) at 10 mL/min with methyl-t-butyl ether/hexane (1:3, v/v) to give 0.025 g of product as an off-white solid.

[0260]¹H NMR (DMSO-d₆): δ 1.369 (t, 3H), 4.31 (q, 2H), 6.37 (s, 1H), 6.40 (dd, 1H) 6.74 (dd, 1H), 6.84 (s, 1H), 7.73 (d, 1H), 7.91 (d, 1H), 9.56 (s, 1H, 9.85 (s, 1H), 10.855 (s, 1H).

MS (APCI) m/z 271 ([M+H]⁺); Example 18 4-(1-benzyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol

[0261] A mixture of 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2.0 mmol) and benzylhydrazine dihydrochloride (0.39 g, 2.0 mmol) in 2 mL H₂O was heated at 90° C. overnight. The cooled reaction mixture was partitioned with EtOAc and 1 N HCl. The organic layer was dried (Na₂SO₄) and concentrated in vacuo to give the crude product. The residue was purified by HPLC chromatography using a silica gel column 150×12 mm (Biotage) at 10 mL/min with methyl-t-butyl ether/hexane (1:3, v/v) to give 0.062 g of product as an amber solid.

[0262]¹H NMR (DMSO-d₆): δ 5.54 (s, 2H), 6.36 (s, 1H), 6.41 (dd, 1H), 6.74 (dd, 1H), 6.88 (s, 1H), 7.21-7.33 (m, 5H), 7.73 (d, 1H), 7.91 (d, 1H), 9.58 (s, 1H), 9.856 (s, 1H), 10.760 (s, 1H).

[0263] MS (APCI) m/z 333 ([M+H]⁺);

Example 19 4-[6-hydroxy-1-(3-hydroxybenzyl)-1H-indazol-3-yl]benzene-1,3-diol

[0264] A mixture of 2,2′,4,4′-tetrahydroxybenzophenone (0.123 g, 0.5 mmol), sodium acetate (0.164 g, 2.0 mmol) and 3-hydroxybenzylylhydrazine dihydrochloride (0.422 g, 1.0 mmol) in 2 mL H₂O was heated at 90° C. overnight. The cooled reaction mixture was partitioned with EtOAc and 1 N HCl. The organic layer was dried (Na₂SO₄) and concentrated in vacuo to give the crude product. The residue was purified by HPLC chromatography using a silica gel column 150×12 mm (Biotage) at 10 mL/min with methyl-t-butyl ether/hexane (1:3, v/v) to give 0.042 g of product as a yellow solid.

[0265]¹H NMR (DMSO-d₆): δ 5.46 (s, 2H), 6.37 (s, 1H), 6.41 (dd, 1H), 6.55 (s, 1H), 6.66 (m, 1H), 6.74 (dd, 1H), 6.84 (s, 1H), 7.09 (t, 1H), 7.74 (d, 1H), 7.92 (d, 1H), 9.38 (s, 1H), 9.588 (s, 1H), 9.862 (s, 1H), 10.794 (s, 1H).

[0266] MS (APCI) m/z 349 ([M+H]⁺);

Example 20 4-[6-hydroxy-1-(4-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0267] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 4-methylphenylhydrazine hydrochloride (0.390 g, 2.5 mmol) to give 0.018 g of product as a pink solid,

[0268] mp 160-162° C.

[0269]¹H NMR (DMSO-d₆): δ 2.39 (s, 3H), 6.40-6.43 (m, 2H), 6.80 (dd, 1H, J=1.95 and 8.79 Hz), 7.02 (s, H), 7.39 (d, 2H), 7.59 (d, 2H), 7.69 (d, 1H), 7.91 (d, H), 9.63 (s, H), 9.95 (s,H), 10.43 (s,H).

[0270] MS (APCI) m/z 333 ([M+H]⁺);

[0271] Anal. calcd for C₂₀H₁₆N₂O₃.0.50 H₂O: C:70.37 H:5.02 N:8.21 Found: C:70.03H:5.28 N:7.69.

Example 21 4-[1-(3-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0272] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 3-fluorophenylhydrazine hydrochloride (0.400 g, 2.5 mmol) to give 0.017 g of product as a pink solid.

[0273]¹H NMR (DMSO-d₆): δ 6.40-6.44 (m, 2H), 6.82 (dd, 1H, J=1.95 and 8.79 Hz), 7.14 (s, 1H), 7.19-7.24 (m, 1H), 7.60-7.63 (m, 4H), 7.86 (d, 1H), 9.65 (s, 1H), 10.00 (s, 1H), 10.17 (s, 1H).

[0274] mp>200° C.

[0275] MS (ACPI) m/z 337 ([M+H]⁺)

[0276] Anal. calcd for C₁₉H₁₃FN₂O₃.0.50H₂O: C:66.08H:4.09 N:8.11 Found: C:66.39H:3.72 N:8.06.

Example 22 4-[1-(2-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0277] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 2-fluorophenylhydrazine hydrochloride (0.400 g, 2.5 mmol) to give 0.050 g of product as a pink solid.

[0278] mp>205° C.;

[0279]¹H NMR (DMSO-d₆): δ 6.41-6.43 (m, 2H), 6.63-6.64 (m, 1H), 6.81 (dd, 1H, J=1.95 and 8.79 Hz), 7.41-7.44 (m, 1H), 7.54-7.57 (m, 2H), 7.66-7.68 (m, 1H), 7.9 (d, 1H), 9.65 (broad s, 1H), 9.96 (broad s, 1H), 10.30 (broad s, 1H).

[0280] MS (APCI) m/z 337 ([M+H]⁺);

[0281] Anal. calcd for C₁₉H₁₃FN₂O₃.0.10 C₆H₁₄.0.10H₂O: C:67.89 H:4.24 N: 8.08 Found: C:67.71 H:3.83 N:7.87.

Example 23 4-[6-hydroxy-1-(3-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0282] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 3-methylphenylhydrazine hydrochloride (0.390 g, 2.5 mmol) to give 0.178 g of product as a tan solid.

[0283] mp>200° C.;

[0284]¹H NMR (DMSO-d₆): δ 2.42 (s, 3H), 6.41-6.43 (m, 2H), 6.80 (dd, 1H, J=1.95 and 8.79 Hz), 7.07 (s, 1H), 7.47-7.67 (m, 3H), 7.68 (d, 1H), 9.64 (broad s, 1H), 9.96 ) broad s, 1H), 10.40 (broad s, 1H).

[0285] Anal. calcd for C₂₀H₁₆N₂O₃.0.70 H₂O: C:69.64H:5.08 N:8.12 Found: C:69.90H:4.40 N:8.02.

Example 24 4-[1-(3-chloro-4-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol

[0286] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 3-chloro-4-fluorophenylhydrazine hydrochloride (0.392 g, 2.5 mmol) to give 0.027 g of product as an off-white solid.

[0287] mp decomp at 185° C.;

[0288]¹H NMR (DMSO-d₆): δ 6.39-6.43 (m, 1H), 6.81 (dd, 1H), 7.05 (s, 1H), 7.59-7.64 (m, 2H), 7.74-7.78 (m, 1H), 7.84-7.86 (d, 1H), 7.91-7.97 (m, 1H), 9.64 (broad s, 1H), 10.10 (broad s, 1H), 10.11 (broad s, 1H).

[0289] MS (APCI) m/z 371 ([M+H]⁺);

[0290] Anal. calcd for C₁₉H₁₂ClFN₂O₃.0.25 H₂O: C:60.81H:3.36 N:7.46 Found: C:59.72 H:2.59 N:7.25.

Example 25 4-[6-hydroxy-1-(3-nitrophenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0291] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 3-nitrophenylhydrazine hydrochloride (0.463 g, 2.5 mmol) to give 0.149 g of product as a yellow ochre solid.

[0292] mp>205° C.;

[0293]¹H NMR (DMSO-d₆): δ 6.41 (dd, 1H, J=2.44 and 8.30 Hz), 6.44 (s, 1H), 6.84 (dd, 1H, 1.95 and 9.03 Hz), 7.20 (s, 1H), 7.56 (d, 1H), 7.83-7.89 (m, 2H), 8.18 (d, 1H), 8.24 (d, 1H), 8.50 (s, 1H), 9.65 (broad s, 1H), 10.02 (broad s, 1H), 10.98 (broad s, 1H).

[0294] MS (APCI) m/z 364 ([M+H]⁺);

[0295] Anal. calcd for C₁₉H₁₃N₃O₅.1.25 H₂O: C:59.14H:4.05 N:10.89 Found: C:58.94H:3:66 N:10.79.

Example 26 4-{6-hydroxy-1-[3-(trifluoromethyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol

[0296] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 3-trifluoromethylphenylhydrazine hydrochloride (0.430 g, 2.5 mmol) to give 0.209 g of product as a tan solid.

[0297] mp 201-203° C.;

[0298]¹H NMR (DMSO-d₆): δ 6.40-6.45 (m, 2H), 6.82 (dd, 1H, J=1.71 and 8.79), 7.13 (s, 1H), 7.58 (d, 1H), 7.73 (m, 1H), 7.81-7.86 (m, 2H), 8.03 (s, 1H), 8.07-8.09 (m, 1H), 9.65 (broad s, 1H), 10.04-10.07 (broad s, 2H).

[0299] MS (APCI) m/z 387 ([M+H]⁺);

[0300] Anal. calcd for C₂₀H₁₃F₃N₂O₃.1.25 H₂O: C:58.76H:3.82 N:6.85 Found: C:58.71 H:3.03 N:6.89.

Example 27 4-[6-hydroxy-1-(4-isopropylphenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0301] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 4-isopropylphenylhydrazine hydrochloride (0.455 g, 2.5 mmol) to give 0.141 g of product as a tan solid.

[0302] mp 130-133° C.;

[0303]¹H NMR (DMSO-d₆): δ 1.26 (d, 6H), 2.95-3.02 (m, 1H), 6.41-6.43 (m, 2H), 6.80 (dd, 1H, J=1.95 and 9.03 Hz), 7.03 (s, 1H), 7.45 (d, 2H), 7.61 (d, 2H), 7.67 (d, 1H), 7.92 (d, 1H), 9.64 (broad s, 1H), 9.93 (broad s, 1H), 10.45 (broad s, 1H).

[0304] MS (APCI) m/z 361 ([M+H]⁺);

[0305] Anal. calcd for C₂₂H₂₀N₂O₃.0.50 H₂O: C:71.53H:5.73 N:7.58 Found: C:72.83H:5.61 N:7.50.

Example 28 4-{6-hydroxy-1-[4-(methylsulfonyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol

[0306] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and (4-methanesulfonyl)phenylhydrazine hydrochloride (0.454 g, 2.5 mmol) to give 0.378 g of product as a tan solid.

[0307] mp 94-96° C.;

[0308]¹H NMR (DMSO-d₆): δ 3.28 (s, 3H), 6.41 (dd, 1H, 2.44 and 8.54 Hz), 6.45 (s, 1H), 6.63 (d, 1H), 6.85 (dd, 1H, J=1.95 and 8.78 Hz), 7.24 (s, H), 7.48 (dd, 1H, J=1.95 and 6.83 Hz), 7.58 (d, 1H), 7.84 (d, 1H), 8.03 (dd, 1H, J=2.20 and 4.15 Hz), 8.12 (d, 1H), 9.76 (broad s, 1H), 10.09 (broad s, 2H).

[0309] MS (APCI) m/z 397 ([M+H]⁺);

[0310] Anal. calcd for C₂₀ H₁₆N₂O₅S 1.50 H₂O: C:56.73H:4.52 N:6.62 Found: C:56.75 H:4.00 N:6.73.

Example 29 4-[6-hydroxy-1-(4-nitrophenyl)-1H-indazol-3-yl]benzene-1,3-diol

[0311] Prepared according to Method B from 2,2′,4,4′-tetrahydroxybenzophenone (0.400 g, 1.60 mmol), sodium acetate (0.267 g, 3.3 mmol) and 4-nitrophenylhydrazine hydrochloride (0.463 g, 2.5 mmol) to give 0.101 g of product as a pink solid.

[0312] mp>200° C.;

[0313]¹H NMR (DMSO-d₆): δ 6.41 (d, 1H), 6.46 (s, 1H), 6.87 (dd, 1H, J=1.71 and 8.79 Hz), 7.29 (s, 1H), 7.55 (d, 1H), 7.83 (d, 1H), 8.04 (d, 2H), 8.41 (d, 2H), 9.68 (broad s, 1H), 10.01 (broad s, 1H), 10.14 (broad s, 1H).

[0314] MS (APCI) m/z 364 ([M+H]⁺);

[0315] Anal. calcd for C₁₉H₁₃N₃O₅.H₂O: C:59.84H:3.96 N:11.02 Found: C:60.33H: 3.46 N:10.86.

EXAMPLES 30-33 Method C: 4-(1,7-disubstituted-1H-indazol-3-yl)phenols

[0316] Step A: A solution of (2-fluoro-3-substituted-phenyl)(4-methoxy-2-substituted-phenyl)-methanone (1 equivalent), 1-substituted hydrazine (1 eq.) and DMAP (1 eq.) in pyridine was heated at 100° C. for hrs. The cool reaction mixture was partitioned with EtOAc and 1 N HCl. The organic phase was washed with brine and dried (Na₂SO₄). The resulting residue was purified by flash chromatography.

[0317] Step B: A solution of 3-(4-methoxyphenyl)-7-substituted-1-substituted-1H-indazole in CH₂Cl₂ containing excess equivalents of cyclohexene at −78° C. was treated with boron tribromide (4 eq.) and slowly allowed to warm to ambient temperature. The reaction was quenched by dropwise edition of CH₃OH to the cooled reaction. The solvent was removed in vacuo and the residue partitioned with EtOAc and 1 N HCl. The organic phase was washed with brine and dried (Na₂SO₄). Removal of the solvent afforded the crude product which was isolated in pure form either by crystallization or by flash chromatography through water deactivated silica gel.

Example 30 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol

[0318] Step 1: 7-chloro-1-cyclohexyl-3-(4-methoxyphenyl)-1H-indazole

[0319] Prepared according to Method C step A (3-chloro-2-fluorophenyl)-(4-methoxyphenyl)-methanone (0.55 g, 1.85 mmol), cyclohexylhydrazine hydrochloride (0.42 g, 2.7 mmol) and DMAP (0.225 g, 1.85 mmol) to give the product (0.58 g) as a yellow oil.

[0320]¹H NMR (DMSO-d₆): δ 1.2-1.3 (m, 1H), 1.465 (m, 2H), 1.71 (d, 1H), 1.875 (2H), 1.97 (m, 2H), 2.07 (m, 2H), 3.817 (s, 3H), 7.08 (d, 2H), 7.175 (t, 1H), 7.48 (dd, 1H), 7.825 (d, 2H), 7.96 (dd, 1H).

[0321] MS (APCI) m/z 341 ([M+H]⁺);

[0322] Step 2: 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol

[0323] Prepared according to Method C step B from 7-chloro-1-cyclohexyl-3-(4-methoxyphenyl)-1H-indazole (0.55 g, 1.61 mmol), boron tribromide (0.61 mL, 6.5 mmol) and 1.0 mL of cyclohexene to give the product (0.26 g) as an off-white solid.

[0324] mp 176-177° C.;

[0325]¹H NMR (DMSO-d₆): δ 1.24 (m, 1H), 1.46 (m, 2H), 1.70 (d, 1H), 1.87 (d, 2H 1.96 (m, 2H), 2.03 (d, 2H), 5.23 (m, 1H), 6.90 (dd, 2H), 7.15 (t, 1H), 7.47 (d, 1H), 7.71 (d, 2H), 7.94 (d, 1H), 9.655 (s, 1H).

[0326] MS (ESI) m/z 327 ([M+H]⁺);

[0327] Anal. calcd for C₁₉H₁₉ClN₂O: C:69.83H:5.86 N:8.57 Found: C:69.47H:5.87 N:8.36.

Example 31 4-[1-(4-bromophenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0328] Step 1:1-(4-bromophenyl)-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole

[0329] Prepared according to Method C step A from (2-fluoro-3-trifluoromethyl-phenyl)-(4-methoxyphenyl)-methanone (0.149 g, 0.5 mmol), 4-bromophenylhydrazine hydrochloride (0.134 g, 0.6 mmol) and DMAP (0.061 g, 0.5 mmol) to give the title compound.

[0330]¹H NMR (DMSO-d₆): δ 3.83 (s, 3H), 7.11 (d, 2H), 7.45 (m, 3H), 7.76 (d, 2H 7.9 (d, 2H), 8.42 (d, 1H).

[0331] MS (APCI) m/z 447 ([M+H]⁺);

[0332] Step 2: 4-[1-(4-bromophenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0333] Prepared according to Method C step B from 1-(4-bromophenyl)-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.5 mmol), boron tribromide (0.188 mL, 2.0 mmol) and 0.2 mL of cyclohexene to give the product (0.025 g) as a tan solid.

[0334] mp 176-177° C.;

[0335]¹H NMR (DMSO-d₆): δ 6.93 (dd, 2H), 7.51 (m, 3H), 7.76 (m, 4H), 7.90 (d, 1H), 8.41 (d, 1H), 9.79 (s, 1H).

[0336] MS (APCI) m/z 433 ([M+H]⁺);

Example 32 4-[1-cyclohexyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0337] Step 1: 1-cyclohexyl-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole

[0338] Prepared according to Method C step A (2-fluoro-3-trifluoromethyl-phenyl)-(4-methoxyphenyl)-methanone (0.149 g, 0.5 mmol), cyclohexylhydrazine hydrochloride (0.90 g, 0.6 mmol) and DMAP (0.061 g, 0.5 mmol) to give the title compound.

[0339]¹H NMR (DMSO-d₆): δ 1.24 (m, 1H), 1.38 (m, 2H), 1.725 (d, 1H), 1.75-2.2 (m, 6H), 3.82 (s, 3H), 4.56 (m, 1H), 7.10 (d, 2H), 7.35 (m, 1H), 7.84 (m, 3H), 8.31 (d, 1H).

[0340] MS (APCI) m/z 375 ([M+H]⁺);

[0341] Step 2: 4-[1-cyclohexyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0342] Prepared according to Method C step B from 1-cyclohexyl-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.5 mmol), boron tribromide (0.188 mL, 2.0 mmol) and 0.2 mL of cyclohexene to give the product (0.028 g) as a tan solid.

[0343]¹H NMR (DMSO-d₆): δ 1.2-1.42 (m, 4H), 1.71 (d, 1H), 1.92 (m, 3H), 2.03 (m, 2H), 4.54 (m, 1H), 6.92 (dd, 2H), 7.33 (t, 1H), 7.72 (d, 2H), 7.86 (d, 1H), 8.28 (d, 1H, 9.72 (s, 1H).

[0344] MS (APCI) m/z 361 ([M+H]⁺);

Example 33 4-(1-cyclohexyl-7-fluoro-1H-indazol-3-yl)phenol

[0345] Step 1: 1-cyclohexyl-7-fluoro-3-(4-methoxyphenyl)-1H-indazole

[0346] Prepared according to Method C step A (2,3-difluorophenyl)-(4-methoxyphenyl)-methanone (0.150 g, 0.6 mmol), cyclohexylhydrazine hydrochloride (0.90 g, 0.6 mmol) and DMAP (0.073 g, 0.6 mmol) to give 0.09 g of the title compound.

[0347]¹H NMR (DMSO-d₆): δ 1.3 (m, 1H), 1.45 (m, 2H), 1.725 (d, 1H), 1.8-2.1 (m, 6H), 3.812 (s, 3H), 4.65 (m, 1H), 7.075 (d, 2H), 7.15 (m, 1H), 7.2-7.3 (m, 2H), 7.84 (m, 3H).

[0348] MS (ESI) m/z 325 ([M+H]⁺);

[0349] Step 2: 4-[1-cyclohexyl7-(fluoro)-1H-indazol-3-yl]phenol

[0350] Prepared according to Method C step B from 1-cyclohexyl-7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.9 g, 0.5 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.5 mL of cyclohexene to give the product (0.040 g) as a tan solid.

[0351]¹H NMR (DMSO-d₆): δ 1.25 (m, 1H), 1.42 (m, 2H), 1.695 (d, 1H), 1.86 (d, 2H), 1.96 (m, 2H), 2.04 (m, 2H), 4.64 (m, 1H), 6.90 (dd, 2H), 7.13 (m, 1H), 7.23 (m, 1H), 7.73 (D, 2H), 7.79 (d, 1H), 9.657 (s, 1H).

[0352] MS (APCI) m/z 311 ([M+H]⁺);

Method D: 4-(1,7-disubstituted-1H-indazol-3-yl)phenols

[0353] Step A: A solution of (2-fluoro-3-substituted-phenyl)(4-methoxy-2-substituted-phenyl)-methanone (1 equivalent), hydrazine hydrate (10 eq.) and DMAP (1 eq.) in pyridine was heated at 100° C. for 24-48 hrs. The cooled reaction mixture was partitioned with EtOAc and 1 N HCl. The organic phase was washed with brine and dried (Na₂SO₄). The resulting residue was purified by flash chromatography to give the intermediate 3-(4-methoxyphenyl)-7-substituted-1-1H-indazole.

[0354] Step B: A solution of the intermediate 3-(4-methoxyphenyl)-7-substituted-1-1H-indazole (1 eq.) in DMF was added in one portion sodium hydride (1 eq., 60% in oil). After the gas evolution ceased, the alkyl halide was added and the reaction was stirred at ambient to 50° C. overnight. The cool reaction mixture was partitioned with EtOAc and 1 N HCl. The organic phase was washed with brine and dried (Na₂SO₄). The resulting residue was purified by flash chromatography or by HPLC chromatography through silica gel columns 150×12 mm (Biotage) at 10 mL/min with methyl-t-butyl ether/hexane (gradient elution 1:9 to 1:1) to give the intermediates 3-(4-methoxyphenyl)-7-substituted-1-substituted-1H-indazole and 3-(4-methoxyphenyl)-7-substituted-2-substituted-2H-indazole.

[0355] Step C: A solution of 3-(4-methoxyphenyl)-7-substituted-(1 or 2-substituted)-(1H or 2H)-indazole (1 eq.) in CH₂Cl₂ containing excess equivalents of cyclohexene at −78° C. was treated with boron tribromide (4 eq.) and slowly allowed to warm to ambient temperature. The reaction was quenched by dropwise edition of CH₃OH to the cooled reaction. The solvent was removed in vacuo and the residue partitioned with EtOAc and 1 N HCl. The organic phase was washed with brine and dried (Na₂SO₄). Removal of the solvent in vacuo afforded the crude product. Pure product was obtained by crystallization or flash chromatography through water deactivated silica gel. Note: HPLC retention times were obtained using the following conditions: Column: Keystone Aquasil C18 (50 × 2 mm, 5 u), Solvent System: A: 95% 10 mM NH4OAc/5% acetonitrile, B: 95% acetonitrile 5% 10 mM NH₄OAc, Gradient 0% B to 100% B over 0-15 minutes, Flow 0.8 mL/min Detection: UV. various wavelengths

INTERMEDIATES 16-27 Intermediate 16 3-(4-methoxyphenyl)-7-methyl-1H-indazole

[0356] Prepared according to Method D Step A from (2-Fluoro-3-methylphenyl)-(4-methoxyphenyl)-methanone (3.6 g, 14.7 mmol), hydrazine hydrate (4.3 mL, 140 mmol) and DMAP (1.8 g, 14.7 mmol) to give the product (1.7 g) as a yellow solid.

[0357]¹H NMR (DMSO-d₆): δ 2.52 (s, 3H), 3.81 (s, 3H), 7.06 (m, 3H), 7.13 (d, 1H), 7.81 (d, 1H), 7.89 (d, 2H), 13.132 (s, 1H).

[0358] MS (APCI) m/z 239 ([M+H]⁺);

Intermediate 17 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole

[0359] Prepared according to Method D Step A from (2-Fluoro-3-trifluoromethylphenyl)-(4-methoxyphenyl)-methanone (3.6 g, 14.7 mmol), hydrazine hydrate (4.3 mL, 140 mmol) and DMAP (1.8 g, 14.7 mmol) to give the product (1.7 g) as a yellow solid.

[0360]¹H NMR (DMSO-d₆, 300 MHz): δ 2.52 (s, 3H), 3.82 (s, 3H), 7.07 (d, 2H), 7.18 (t, 1H), 7.48 (d, 1H), 7.91 (d, 2H), 8.0 (d, 1H), 13.132 (s, 1H).

[0361] MS (APCI) m/z 239 ([M+H]⁺);

Intermediate 18 7-chloro-3-(4-methoxyphenyl)-1H-indazole

[0362] Prepared according to Method D Step A from (3-chloro-2-fluoro-phenyl)-(4-methoxyphenyl)-methanone (0.84 g, 3.2 mmol), hydrazine hydrate (1.0 mL, 32 mmol) and DMAP (0.39 g, 3.2 mmol) to give the product (0.75 g) as a white solid.

[0363]¹H NMR (DMSO-d₆): 3.81 (s, 3H), 7.06 (d, 2H), 7.13 (d, 1H), 7.81 (d, 1H), 7.89 (d, 2H), 13.52 (s, 1H).

[0364] MS (APCI) m/z 259 ([M+H]J);

Intermediate 19 7-fluoro-3-(4-methoxyphenyl)-1H-indazole

[0365] Prepared according to Method D Step A from (2,3-difluorophenyl)-(4-methoxyphenyl)-methanone (1.1 g, 4.4 mmol), hydrazine hydrate (1.37 mL, 44 mmol) and DMAP (0.54 g, 4.4 mmol) to give the product (0.85 g) as a white solid.

[0366]¹H NMR (DMSO-d₆): 3.82 (s, 3H), 7.06 (d, 3H), 7.1-7.25 (m, 2H), 7.83 (d, 1H), 7.92 (d, 2H), 13.53 (s, 1H).

[0367] MS (APCI) m/z 243 ([M+H]⁺);

Intermediate 20 7-fluoro-3-(4-methoxy-3-methylphenyl)-1H-indazole

[0368] Prepared according to Method D Step A from (2,3-difluorophenyl)-(4-methoxy-3-methyl-phenyl)-methanone (0.9 g, 3.45 mmol), hydrazine hydrate (1.06 mL, 34 mmol) and DMAP (0.42 g, 3.45 mmol) to give the product (0.80 g) as a yellow solid.

[0369]¹H NMR (DMSO-d₆): δ 2.247 (s, 3H), 3.845 (s, 3H), 7.07 (d, 1H), 7.13 (m, 1H), 7.22 (m, 1H), 7.75 (m, 2H), 7.83 (d, 1H), 13.62 (broad s, 1H).

[0370] MS (ESI) m/z 257 ([M+H]⁺);

Intermediate 21 3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole

[0371] Prepared according to Method D Step A from (2,4-dimethoxyphenyl)[2-fluoro-3-(trifluoromethyl)phenyl]methanone (1.50 g, 5.17 mmol), hydrazine hydrate (1.61 mL, 51.7 mmol) and DMAP (0.632 g, 5.17 mmol) to give the product (0.619 g) as a yellow solid.

[0372]¹H NMR (DMSO-d₆): δ 3.78 (s, 3H), 3.83 (s, 3H), 6.66 (dd, 1H, J=2.38 and 8.33 Hz), 6.75 (s, 1H), 7.24 (t, 1H), 7.43 (d, 1H), 7.72 (d, 1H), 7.89 (d, 1H).

[0373] MS (APCI) m/z 323 ([M+H]⁺);

[0374] Anal. calcd for C₁₆H₁₃F₃N₂O₂: C:59.63H:4.07 N:8.69 Found: C:59.91H:4.08 N:7.95.

Intermediate 22 3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole

[0375] Prepared according to Method D Step A from [2-fluoro-3-(trifluoromethyl)phenyl](4-methoxy-2-methylphenyl)methanone (1.34 g, 4.90 mmol), hydrazine hydrate (1.61 mL, 51.7 mmol) and DMAP (0.632 g, 5.17 mmol) to give the product (0.620 g) as a yellow solid.

[0376]¹H NMR (DMSO-d₆): δ 2.31 (s, 3H), 3.81 (s, 3H), 6.92 (d, 1H), 6.98 (s, 1H 7.29 (t, 1H), 7.41 (d, 1H), 7.70 (d, 1H), 7.90 (d, 1H).

[0377] MS (APCI) m/z 307 ([M+H]⁺);

[0378] Anal. calcd for C₁₆ H₁₃F₃N₂0: C:62.74H:4.28 N:9.15 Found: C:62.35H:4.01 N:9.34.

Intermediate 23 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole

[0379] Prepared according to Method D Step A from (2,4-dimethoxyphenyl)[2,3-difluorophenyl]-methanone (1.60 g, 5.8 mmol), hydrazine hydrate (1.79 mL, 5702 mmol) and DMAP (0.632 g, 57.5 mmol) to give the product (1.66 g) as a yellow solid.

[0380]¹H NMR (DMSO-d₆): δ 3.77 (s, 3H), 3.83 (s, 3H), 6.65 (dd, 1H, J=2.13 and 8.40 Hz), 6.72 (s, 1H), 7.02-7.05 (m, 1H), 7.13-7.17 (m, 1H), 7.41 (t, 1H), 13.54 (broad s, 1H).

[0381] MS (ESI) m/z 273 ([M+H]⁺);

Intermediate 24 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0382] Prepared according to Method D Step A from [2-fluoro-3-(trifluoromethyl)phenyl](4-methoxy-2-methylphenyl)methanone (1.34 g, 4.90 mmol), hydrazine hydrate (1.61 mL, 51.7 mmol) and DMAP (0.632 g, 5.17 mmol) to give the product (0.620 g) as a yellow solid.

[0383]¹H NMR (DMSO-d₆): δ 2.30 (s, 3H), 3.80 (s, 3H), 6.89 (dd, 1H, J=2.44 and 8.39 Hz), 6.95 (s, 1H), 7.06-7.11 (m, 1H), 7.19-7.22 (m, 1H), 7.38-7.40 (m, 2H), 13.64 (broad s, 1H).

[0384] MS (ESI) m/z 257 ([M+H]⁺);

Intermediate 25 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0385] Prepared according to Method D Step A from [2-fluoro-3-chlorophenyl](4-methoxy-2-methylphenyl)methanone (1.26 g, 4.52 mmol), hydrazine hydrate (1.61 mL, 51.7 mmol) and DMAP (0.632 g, 5.17 mmol) to give the product (0.613 g) as a yellow solid.

[0386]¹H NMR (DMSO-d₆): δ 2.31 (s, 3H), 3.81 (s, 3H), 6.89 (dd, 1H, J=2.57 and 8.53 Hz), 6.96 (s, 1H), 7.13 (t, 1H), 7.39 (d, 1H), 7.47 (d, 1H), 7.54 (d, 1H), 13.62 (broad s, 1H).

[0387] MS (ESI) m/z 273 ([M+H]⁺);

Intermediate 26 7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole

[0388] Prepared according to Method D Step A from (2,4-dimethoxyphenyl)[2-fluoro-3-chlorophenyl]methanone (1.20 g, 4.1 mmol), hydrazine hydrate (1.61 mL, 51.7 mmol) and DMAP (0.632 g, 5.17 mmol) to give the product (0.618 g) as a yellow solid.

[0389]¹H NMR (DMSO-d₆): δ 3.77 (s, 3H), 3.83 (s, 3H), 6.65 (dd, 1H, J=2.18 and 8.33 Hz), 6.73 (s, 1H), 7.07 (t, 1H), 7.41 (d, 1H), 7.55 (d, 1H), 13.52 (broad s, 1H).

[0390] MS (ESI) m/z 289 ([M+H]⁺);

Intermediate 27 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole

[0391] Prepared according to Method D Step A from (2,4-dimethoxyphenyl)[2-fluoro-3-chlorophenyl]methanone (1.20 g, 4.1 mmol), hydrazine hydrate (1.60 mL, 57.5 mmol) and DMAP (0.702 g, 5.75 mmol) to give the product (1.50 g) as a dark oil.

[0392]¹H NMR (DMSO-d₆): 3.77 (s, 3H), 3.83 (s, 3H), 6.65 (dd, 1H, J-2.13 and 8.40 Hz 6.72 (s, 1H), 7.02-7.05 (m, 1H), 7.13-7.17 (m, 1H), 7.41 (t, 1H), 13.54 (broad s, 1H).

[0393] MS (ESI) m/z 273 ([M+H]⁺);

EXAMPLES 34-123 Example 34 4-(7-methyl-1H-indazol-3-yl) phenol

[0394] Prepared according to Method D step C from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.10 g, 0.42 mmol), boron tribromide (0.159 mL, 1.68 mmol) and 0.5 mL of cyclohexene to give the product (0.070 g) as an off-white solid.

[0395] mp sinters 149, melts 190° C.;

[0396]¹H NMR (DMSO-d₆): δ 2.51 (s, 3H),), 6.88 (d, 2H). 7.05 (t, 1H), 7.13 (d, 1H), 7.78 (m, 1H), 9.57 (broad s, 1H), 13.06 (broad s, 1H).

[0397] MS (APCI) m/z 225 ([M+H]⁺);

[0398] Anal. calcd for C₁₄ H₁₂N₂O.H₂O: C:69.41H:5.82 N:11.56 Found: C:69.82H:5.08 N:11.60.

Example 35 4-(7-methyl-1-pentyl-1H-indazol-3-yl)phenol

[0399] Step 1: 3-(4-methoxyphenyl)-7-methyl-1-pentyl-1H-indazole

[0400] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.23 g, 1.0 mmol), sodium hydride (60% in oil, 0.048 g, 1.2 mmol) and 1-iodopentane (0.26 mL, 2.0 mmol) to give the title compound (0.105 g) as a white solid.

[0401]¹H NMR (DMSO-d₆): δ 0.85 (t, 3H), 1.3099 (m, 4H), 1.81 (m, 2H), 2.7158 (s, 3H), 3.810 (s, 3H), 4.567 (t, 2H), 7.06 (m, 2H), 7.15 (d, 1H), 7.82 (m, 3H).

[0402] MS (APCI) m/z 309 ([M+H]⁺);

[0403] Step 2: 4-(7-methyl-1-pentyl-1H-indazol-3-yl)phenol

[0404] Prepared according to Method D step C from 3-(4-methoxyphenyl)-7-methyl-1-pentyl-1H-indazole (0.105 g, 0.34 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.043 g) as an off-white solid.

[0405]¹H NMR (DMSO-d₆): δ 0.847 (t, 3H), 1.3038 (m, 4H), 1.798 (m, 2H), 2.704 (s, 3H), 4.548 (t, 2H), 6.88 (d, 2H), 7.03 (t, 1H), 7.13 (d, 1H), 7.70 (d, 2H), 7.78 (d, 1H), 9.58 (broad s, 1H).

[0406] MS (APCI) m/z 295 ([M+H]⁺);

Example 36 4-[7-methyl-2-pentyl-2H-indazol-3-yl]phenol

[0407] Step 1: 3-(4-methoxyphenyl)-7-methyl-2-pentyl-2H-indazole

[0408] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.23 g, 1.0 mmol), sodium hydride (60% in oil, 0.048 g, 1.2 mmol) and 1-iodopentane (0.26 mL, 2.0 mmol) to give the title compound (0.014 g). Used as is in the next step.

[0409] Step 2: 4-[7-methyl-2-pentyl-2H-indazol-3-yl]phenol

[0410] Prepared according to Method D step C from 3-(4-methoxyphenyl)-7-methyl-2-pentyl-2H-indazole (0.014 g, 0.045 mmol), boron tribromide (0.050 mL, 1.0 mmol) and 0.2 mL of cyclohexene to give the product (0.006 g).

[0411]¹H NMR (300 MHz, DMSO-d₆): δ 0.78 (t, 3H), 1.17 (m, 4H), 1.82 (m, 2H), 4.32 (t, 2H), 6.85-7.0 (m, 3H), 7.25 (d, 1H), 7.35 (d, 2H), 9.85 (broad s, 1H).

[0412] MS (ESI) m/z 295 ([M+H]⁺); RT-7.06 min

Example 37 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol

[0413] Step 1: 3-(4-methoxyphenyl)-7-methyl-1-propyl-1H-indazole

[0414] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.115 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.098 mL, 1.0 mmol) to give the title compound (0.070 g) as a white solid.

[0415]¹H NMR (DMSO-d₆): δ 0.902 (t, 3H), 1.83 (m, 2H), 2.7139 (s, 3H), 3.809 (s, 3H), 4.538 (t, 2H), 7.05 (m, 2H), 7.15 (d, 1H), 7.83 (m, 3H).

[0416] MS (APCI) m/z 281 ([M+H]⁺);

[0417] Step 2: 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol

[0418] Prepared according to Method D step C from 3-(4-methoxyphenyl)-7-methyl-1-propyl-1H-indazole (0.07 g, 0.25 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.033 g) as an off-white solid.

[0419]¹H NMR (DMSO-d₆): δ 0.894 (t, 3H), 1.82 (m, 2H), 2.704 (s, 3H), 4.52 (t, 2H), 6.88 (d, 2H), 7.03 (t, 1H), 7.12 (d, 1H), 7.70 (d, 2H), 7.78 (d, 1H). 9.57 (broad s, 1H)

[0420] MS (ESI) m/z 267 ([M+H]⁺);

[0421] Anal. calcd for C₁₇H₁₈N₂O.0.25 H₂O: C:75.39 H:6.88 N:10.34 Found: C:75.10 H:6.77 N:9.98.

Example 38 4-[7-methyl-2-propyl-2H-indazol-3-yl]phenol

[0422] Step 1: 3-(4-methoxyphenyl)-7-methyl-2-propyl-2H-indazole

[0423] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.115 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.098 mL, 1.0 mmol) to give the title compound (0.014 g). Used as is in the next step.

[0424] Step 2: 4-[7-methyl-2-propyl-2H-indazol-3-yl]phenol

[0425] Prepared according to Method D step C from 3-(4-methoxyphenyl)-7-methyl-2-propyl-2H-indazole (0.014 g, 0.05 mmol), boron tribromide (0.050 mL, 1.0 mmol) and 0.2 mL of cyclohexene to give the product (0.007 g).

[0426] MS (ESI) m/z 267 ([M+H]⁺);

[0427] RT=6.02 min

Example 39 4-(1-isopropyl-7-methyl-1H-indazol-3-yl)phenol

[0428] Step 1: 1-isopropyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole

[0429] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.115 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.057 g) as a white solid.

[0430]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 2.7328 (s, 3H), 3.8117 (s, 3H), 5.25 (m, 1H), 7.05 (m, 2H), 7.15 (d, 1H), 7.83 (m, 3H).

[0431] MS (APCI) m/z 281 ([M+H]⁺);

[0432] Step 2: 4-(1-isopropyl-7-methyl-1H-indazol-3-yl)phenol

[0433] Prepared according to Method D step C from 1-isopropyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.057 g, 0.20 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.027 g) as an off-white solid.

[0434]¹H NMR (DMSO-d₆): δ 1.51 (d, 6H), 2.723 (s, 3H), 5.235 (m, 1H), 6.89 (d, 2H), 7.03 (t, 1H), 7.12 (d, 1H), 7.71 (d, 2H), 7.77 (d, 1H), 9.58 (s, 1H).

[0435] MS (APCI) m/z 267 ([M+H]⁺);

Example 40 4-[2-isopropyl-7-methyl-2H-indazol-3-yl]phenol

[0436] Step 1: 2-isopropyl-3-(4-methoxyphenyl)-7-methyl-2H-indazole

[0437] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.115 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.01 g) as a white solid.

[0438] Step 2: 4-[2-isopropyl-7-methyl-1H-indazol-3-yl]phenol

[0439] Prepared according to Method D step C from 2-isopropyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.010 g, 0.035 mmol), boron tribromide (0.05 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.007 g).

[0440] MS (ESI) m/z 267 ([M+H]⁺);

[0441] RT=6.32 min

Example 41 4-(7-chloro-1-pentyl-1H-indazol-3-yl)phenol

[0442] Step 1: 7-chloro-3-(4-methoxyphenyl)-1-pentyl-1H-indazole

[0443] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopentane (0.130 mL, 1.0 mmol) to give the title compound (0.072 g) as a white solid.

[0444]¹H NMR (DMSO-d₆): δ 0.838 (t, 3H), 1.301 (m, 4H), 1.84 (m, 2H), 3.817 (s, 3H 4.72 (t, 2H), 7.08 (d, 2H), 7.18 (t, 1H), 7.50 (dd, 1H), 7.83 (d, 2H), 7.97 (dd, 1H).

[0445] MS (APCI) m/z 329 ([M+H]⁺);

[0446] Step 2: 4-(7-chloro-1-pentyl-1H-indazol-3-yl)phenol

[0447] Prepared according to Method D step C from 7-chloro-3-(4-methoxyphenyl)-1-pentyl-1H-indazole (0.070 g, 0.23 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.047 g) as an off-white solid.

[0448]¹H NMR (DMSO-d₆): δ 0.837 (t, 3H), 1.297 (m, 4H), 1.88 (m, 2H), 4.7087 (t, 2H), 6.90 (d, 2H), 7.15 (t, 1H), 7.48 (d, 1H), 7.71(d, 2H), 7.95 (d, 1H), 9.68 (s, 1H).

[0449] MS (APCI) m/z 315 [M+H]+.

Example 42 4-[7-chloro-2-pentyl-2H-indazol-3-yl]phenol

[0450] Step 1: 7-chloro-3-(4-methoxyphenyl)-2-pentyl-2H-indazole

[0451] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopentane (0.130 mL, 1.0 mmol) to give the title compound (0.015 g).

[0452] Step 2: 4-[7-chloro-2-pentyl-2H-indazol-3-yl]phenol

[0453] Prepared according to Method D step C from 7-chloro-3-(4-methoxyphenyl)-2-pentyl-2H-indazole (0.015 g, 0.045 mmol), boron tribromide (0.05 mL, 0.5mmol) and 0.2 mL of cyclohexene to give the product (0.007 g).

[0454] MS (ESI) m/z315 [M+H]+.

[0455] RT=7.3 min

Example 43 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol

[0456] Step 1: 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole

[0457] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.098 mL, 1.0 mmol) to give the title compound (0.081 g) as a white solid.

[0458]¹H NMR (DMSO-d₆): δ 0.8896 (t, 3H), 1.864 (m, 2H), 3.819 (s, 3H), 4.7004 (t, 2H), 7.0 (d, 2H), 7.184 (t, 1H), 7.5 (d, 1H), 7.84 (d, 2H), 7.97 (d, 1H).

[0459] MS (ESI) m/z 301 [M+H]+.

[0460] Anal. calcd for C₁₇ H₁₇ClN₂O: C:67.88 H:5.70 N:9.31 Found: C:67.78 H:5.58 N:9.06.

[0461] Step 2: 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol

[0462] Prepared according to Method D step C from 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.081 g, 0.26 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.057 g) as an off-white solid.

[0463]¹H NMR (DMSO-d₆): δ 0.880 (s, 3H), 1.85 (m, 2H), 4.68 (t, 2H), 6.90 (d, 2H), 7.16 (t, 1H), 7.49 (dd, 1H), 7.71 (d, 2H), 7.95 (dd, 1H), 9.67 (s, 1H).

[0464] MS (ESI) m/z 287 [M+H]+.

[0465] Anal. calcd for C₁₆H₁₅ClN₂O.0.15 HCl: C:65.76H:5.23 N:9.59 Found: C:65.76H:5.29 N:9.45.

Example 44 4-[7-chloro-2-propyl-2H-indazol-3-yl]phenol

[0466] Step 1: 7-chloro-3-(4-methoxyphenyl)-2-propyl-2H-indazole

[0467] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.098 mL, 1.0 mmol) to give the title compound (0.013 g).

[0468] Step 2: 4-[7-chloro-2-propyl-2H-indazol-3-yl]phenol

[0469] Prepared according to Method D step C from 7-chloro-3-(4-methoxyphenyl)-2-propyl-2H-indazole (0.013 g, 0.043 mmol), boron tribromide (0.05 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.007 g).

[0470]¹H NMR (DMSO-d₆): δ 0.764 (t, 3H), 1.86 (m, 2H), 4.34 (t, 2H), 6.98 (m, 3H), 7.37 (m, 3H), 7.43 (d, 1H).

[0471] MS (ESI) m/z 287 [M+H]+.

[0472] Anal. calcd for C₁₆H₁₅ClN₂O: C:67.02 H:5.27 N:9.77 Found: C:66.47 H:5.21 N:9.20.

Example 45 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)phenol

[0473] Step 1: 7-chloro-1-isopropyl-3-(4-methoxyphenyl)-1H-indazole

[0474] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.043 g) as a white solid.

[0475]¹H NMR (DMSO-d₆): δ 1.54 (d, 6H), 3.819 (s, 3H), 5.68 (m, 1H), 7.08 (d, 2H), 7.179 (t, 1H), 7.49 (dd, 1H), 7.83 (d, 2H), 7.96 (dd, 1H).

[0476] MS (APCI) m/z 301 [M+H]+.

[0477] Step 2: 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)phenol

[0478] Prepared according to Method D step C from 7-chloro-1-isopropyl-3-(4-methoxyphenyl)-1H-indazole (0.093 g, 0.30 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.025 g) as an off-white solid.

[0479]¹H NMR (DMSO-d₆): δ 1.54 (d, 6H), 5.66 (m, 1H), 6.90 (d, 2H), 7.15 (t, 1H), 7.47 (d, 1H), 7.715 (d, 2H), 7.94 (dd, 1H), 9.6 (broad s, 1H).

[0480] MS (APCI) m/z 287 [M+H]+.

Example 46 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)phenol

[0481] Step 1: 7-chloro-2-isopropyl-3-(4-methoxyphenyl)-2H-indazole

[0482] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.016 g).

[0483] Step 2: 4-(7-chloro-2-isopropyl-1H-indazol-3-yl)phenol

[0484] Prepared according to Method D step C from 7-chloro-2-isopropyl-3-(4-methoxyphenyl)-2H-indazole (0.016 g, 0.05 mmol), boron tribromide (0.050 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.006 g).

[0485] MS (ESI) m/z 287 [M+H]+.

[0486] RT=6.5 min

Example 47 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0487] Step 1: 3-(4-methoxyphenyl)-7-trifluoromethyl-1-pentyl-1H-indazole

[0488] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.146 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopentane (0.130 mL, 1.0 mmol) to give the title compound (0.068 g) as a white solid.

[0489]¹H NMR (DMSO-d₆): δ 0.857 (t, 3H), 1.325 (m, 4H), 1.852 (m, 2H), 3.828 (s, 3H), 4.458 (t, 2H), 7.10 (d, 2H), 7.35 (t, 1H), 7.84 (d, 2H), 7.87 (d, 1H), 8.32 (dd, 1H).

[0490] MS (APCI) m/z 363 [M+H]+.

[0491] Step 2: 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0492] Prepared according to Method D step C from 3-(4-methoxyphenyl)-1-pentyl-7-trifluoromethyl-1H-indazole (0.068 g, 0.19 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.032 g) as an off-white solid.

[0493]¹H NMR (DMSO-d₆): δ 0.8553 (t, 3H), 1.3208 (m, 4H), 1.843 (m, 2H), 4.4426 (t, 2H), 6.92 (d, 2H), 7.338 (t, 1H), 7.72 (d, 2H), 7.87 (d, 1H), 8.30 (d, 1H), 9.728.

[0494] MS (APCI) m/z 349 [M+H]+.

Example 48 4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0495] Step 1: 3-(4-methoxyphenyl)-7-trifluoromethyl-1-propyl-1H-indazole

[0496] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.146 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.098 mL, 1.0 mmol) to give the title compound (0.058 g) as a white solid.

[0497]¹H NMR (DMSO-d₆): δ 0.9138 (t, 3H), 1.868 (m, 2H), 3.828 (s, 3H), 4.43 (t, 2H), 7.10 (d, 2H), 7.36 (t, 1H), 7.85 (d, 2H), 7.89 (d, 1H), 8.32 (d, 1H).

[0498] MS (APCI) m/z 335 [M+H]+.

[0499] Step 2: 4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0500] Prepared according to Method D step C from 3-(4-methoxyphenyl)-1-propyl-7-trifluoromethyl-1H-indazole (0.058 g, 0.17 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.047 g) as an off-white solid.

[0501]¹H NMR (DMSO-d₆): δ 0.9065 (t, 3H), 1.85 (m, 2H), 4.413 (t, 2H), 6.92 (d, 2H), 7.34 (t, 1H), 7.72 (d, 2H), 7.87 (d, 1H), 8.30 (d, 1H), 9.75 (s, 1H).

[0502] MS (APCI) m/z 321 [M+H]+.

Example 49 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0503] Step 1: 3-(4-methoxyphenyl)-7-trifluoromethyl-1-isopropyl-1H-indazole

[0504] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.146 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.043 g) as a white solid.

[0505]¹H NMR (DMSO-d₆): δ 1.54 (d, 6H), 3.82 (s, 3H), 5.00 (m, 1H), 7.10 (d, 2H), 7.351 (t, 1H), 7.51 (d, 1H), 7.84 (d, 2H), 7.89 (d, 1H).

[0506] MS (APCI) m/z 335 [M+H]+.

[0507] Step 2: 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0508] Prepared according to Method D step C from 3-(4-methoxyphenyl)-1-isopropyl-7-trifluoromethyl-1H-indazole (0.043 g, 0.13 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.032 g) as an off-white solid,

[0509] mp 156-157° C.

[0510]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 4.97 (m, 1H), 6.925 (d, 2H), 7.33 (t, 1H), 7.725 (d, 2H), 7.86 (d, 1H), 8.29 (d, 1H), 9.71 (s, 1H).

[0511] MS (APCI) m/z 321 [M+H]+.

[0512] MS (ESI) m/z 319 [M−H]−.

[0513] Anal. calcd for C₁₇H₁₅F₃N₂O: C:63.75 H:4.72 N:8.75 Found: C:63.15 H:4.77 N:8.48.

Example 50 4-(1-allyl-7-fluoro-1H-indazol-3-yl)phenol

[0514] Step 1: 1-allyl-7-fluoro-3-(4-methoxyphenyl)-1H-indazole

[0515] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.108 g, 0.44 mmol), sodium hydride (60% in oil, 0.018 g, 0.45 mmol) and allylbromide (0.043 mL, 0.5 mmol) to give the title compound (0.085 g) as a white solid.

[0516]¹H NMR (DMSO-d₆): δ 3.8 (s, 3H), 4.97 (d, 1H, J=17.083 Hz), 5.17 (m, 3H), 6.08 (m, 1H), 7.08 (dd, 2H), 7.16 (m, 1H), 7.24 (m, 1H), 7.88 (m, 3H).

[0517] MS (APCI) m/z 283 [M+H]+.

[0518] Step 2: 4-(1-allyl-7-fluoro-1H-indazol-3-yl)phenol

[0519] Prepared according to Method D step C from 1-allyl-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.070 g, 0.25 mmol), boron tribromide (0.094 mL, 1.0 mmol) and 0.3 mL of cyclohexene to give the product (0.055 g) as a tan solid.

[0520]¹H NMR (DMSO-d₆): δ 4.95 (d, 1H, J=17.79 Hz), 5.13 (m, 3H), 6.08 (m, 1H), 6.90(dd, 2H), 7.15 (m, 1H), 7.28 (m, 1H), 7.75 (d, 2H), 7.81 (d, 1H).

[0521] MS (APCI) m/z 269 [M+H]+.

Example 51 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol

[0522] Step 1: 7-chloro-1-cyclopentyl-3-(4-methoxyphenyl)-1H-indazole

[0523] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and cyclopentylbromide (0.107 mL, 1.0 mmol) to give the title compound (0.080 g) as a white solid.

[0524]¹H NMR (DMSO-d₆): δ 1.70 (m, 2H), 1.88 (m, 2H), 3.817 (s, 3H), 5.821 (m, 1H), 7.08 (d, 2H), 7.17 (t, 1H), 7.49 (d, 1H), 7.83 (d, 2H), 7.97 (d, 1H).

[0525] MS (APCI) m/z 327 [M+H]+.

[0526] Step 2: 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol

[0527] Prepared according to Method D step C from 7-chloro-1-cyclopentyl-3-(4-methoxyphenyl)-methyl-1H-indazole (0.063 g, 0.19 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.048 g) as an off-white solid.

[0528]¹H NMR (DMSO-d₆): δ 1.69 (m, 2H), 1.88 (m, 2H), 2.13 (m, 4H), 5.808 (m, 1H), 6.89 (d, 2H), 7.15 (t, 1H), 7.47 (d, 1H), 7.715 (d, 2H), 7.95 (d, 1H), 9.669 (broad s, 1H).

[0529] MS (ESI) m/z 313 [M+H]+.

[0530] Anal. calcd for C₁₈H₁₇ClN₂O.0.50 H₂O: C:67.18 H:5.64 N:8.70 Found: C:67.13 H:5.28 N:8.47.

Example 52 4-(7-chloro-2-cyclopentyl-2H-indazol-3-yl)phenol

[0531] Step 1: 7-chloro-2-cyclopentyl-3-(4-methoxyphenyl)-2H-indazole

[0532] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.129 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and cyclopentylbromide (0.107 mL, 1.0 mmol) to give the title compound (0.004 g).

[0533] MS (ESI) m/z 327 ([M+H]⁺)

[0534] Step 2: 4-(7-chloro-2-cyclopentyl-2H-indazol-3-yl)phenol

[0535] Prepared according to Method D step C from 7-chloro-2-cyclopentyl-3-(4-methoxyphenyl)-methyl-2H-indazole (0.004 g, 0.012 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.004 g).

[0536] MS (ESI) m/z 313 [M+H]+.

[0537] RT=9.64 min

Example 53 4-(7-fluoro-1-propyl-1H-indazol-3-yl)phenol

[0538] Step 1: 7-fluoro-3-(4-methoxyphenyl)-1-propyl-1H-indazole

[0539] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.121 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.096 mL, 1.0 mmol) to give the title compound (0.074 g) as a white solid.

[0540]¹H NMR (DMSO-d₆): δ 0.835 (t, 3H), 1.87 (q, 2H), 3.81 (t, 3H), 4.475 (t, 2H), 7.075 (d, 2H), 7.16 (m, 1H), 7.227 (m, 1H), 7.84 (m, 3H).

[0541] MS (APCI) m/z 285 [M+H]+.

[0542] Step 2: 4-(7-fluoro-1-propyl-1H-indazol-3-yl)phenol

[0543] Prepared according to Method D step C from 1-propyl-7-fluoro-3-(4-methoxyphenyl)-methyl-1H-indazole (0.051 g, 0.197 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.051 g) as an off-white solid.

[0544]¹H NMR (DMSO-d₆): δ 0.852 (t, 3H), 1.86 (m, 2H), 4.458 (t, 2H), 6.9 (d, 2H), 7.13 (m, 1H), 7.21 (m, 1H), 7.73 (d, 2H), 7.80 (d, 1H), 9.667 (s, 1H).

[0545] MS (ESI) m/z 271 [M+H]+.

Example 54 4-(7-fluoro-2-propyl-2H-indazol-3-yl)phenol

[0546] Step 1: 7-fluoro-3-(4-methoxyphenyl)-2-propyl-2H-indazole

[0547] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.121 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 1-iodopropane (0.096 mL, 1.0 mmol) to give the title compound (0.006 g).

[0548] Step 2: 4-(7-fluoro-2-propyl-1H-indazol-3-yl)phenol

[0549] Prepared according to Method D step C from 2-propyl-7-fluoro-3-(4-methoxyphenyl)-methyl-2H-indazole (0.006 g, 0.021 mmol), boron tribromide (0.05 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.0006 g).

[0550] MS (ESI) m/z 271 [M+H]+.

Example 55 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)phenol

[0551] Step 1: 7-fluoro-1-isopropyl-3-(4-methoxyphenyl)-1H-indazole

[0552] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.121 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.088 g) as a white solid.

[0553]¹H NMR (DMSO-d₆): δ 1.54 (d, 6H), 3.81 (s, 3H), 5.085 (m, 1H), 7.075 (d, 2H), 7.159 (m, 1H), 7.222 (m, 1H), 7.845 (m, 3H).

[0554] MS (APCI) m/z 285 [M+H]+.

[0555] Step 2: 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)phenol

[0556] Prepared according to Method D step C from 7-fluoro-1-isopropyl-3-(4-methoxyphenyl)-methyl-1H-indazole (0.065 g, 0.23 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.047 g) as an off-white solid.

[0557]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 5.069 (m, 1H), 6.90 (d, 2H), 7.14 (m, 1H), 7.24 (m, 1H), 7.73 (d, 2H), 7.78 (d 1H), 9.663 (broad s, 1H).

[0558] MS (ESI) m/z 271 [M+H]+.

Example 56 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)phenol

[0559] Step 1: 7-fluoro-2-isopropyl-3-(4-methoxyphenyl)-2H-indazole

[0560] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.121 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and 2-iodopropane (0.10 mL, 1.0 mmol) to give the title compound (0.007 g).

[0561] Step 2: 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)phenol

[0562] Prepared according to Method D step C from 7-fluoro-2-isopropyl-3-(4-methoxyphenyl)-methyl-2H-indazole (0.007 g, 0.025 mmol), boron tribromide (0.05 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.006 g).

[0563] MS (ESI) m/z 271 [M+H]+.

Example 57 4-(1-allyl-7-methyl-1H-indazol-3-yl)phenol

[0564] Step 1: 1-allyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole

[0565] Prepared according to Method D step B from 7-methyl-3-(4-methoxyphenyl)-1H-indazole (0.112 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and allylbromide (0.086 mL, 1.0 mmol) to give the title compound (0.027 g) as a white solid. Used as is without further characterization.

[0566] Step 2: 4-(1-allyl-7-methyl-1H-indazol-3-yl)phenol

[0567] Prepared according to Method D step C from 1-allyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole (0.027 g, 0.23 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.020 g) as a tan solid.

[0568]¹H NMR (DMSO-d₆): δ 4.70 (dd, 1H), 5.10 (dd, 1H), 5.22 (m, 2H), 6.086 (m, 1H), 6.89 (d, 2H), 7.058 (t, 1H), 7.14 (d, 1H), 7.72 (d, 2H), 7.80 (d, 1H), 9.608 (s, 1H).

[0569] MS (ESI) m/z 265 [M+H]+.

Example 58 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0570] Step 1: 1-allyl-3-(4-methoxyphenyl)-7-methyl-1H-indazole

[0571] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.146 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and allylbromide (0.086 mL, 1.0 mmol) to give the title compound (0.027 g) as a white solid. Used as is without further characterization.

[0572] Step 2: 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0573] Prepared according to Method D step C from 1-allyl-3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.027 g, 0.08 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.024 g) as a grey solid.

[0574]¹H NMR (DMSO-d₆): δ 4.83 (dd, 1H), 5.12 (m, 3H), 6.04 (m, 1H), 6.93 (d, 2H), 7.36 (t, 1H), 7.73 (d, 2H), 7.885 (d, 1H), 8.32 (d, 1H), 9.74 (s, 1H).

[0575] MS (ESI) m/z 319 [M+H]+.

Example 59 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]phenol

[0576] Step 1: 2-allyl-3-(4-methoxyphenyl)-7-methyl-2H-indazole

[0577] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (0.146 g, 0.5 mmol), sodium hydride (60% in oil, 0.024 g, 0.6 mmol) and allylbromide (0.086 mL, 1.0 mmol) to give the title compound (0.007 g) as a white solid.

[0578] MS (ESI) m/z 333 [M+H]⁺

[0579] Step 2: 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]phenol

[0580] Prepared according to Method D step C from 2-allyl-3-(4-methoxyphenyl)-7-trifluoromethyl-2H-indazole (0.007 g, 0.02 mmol), boron tribromide (0.10 mL, 1.05 mmol) and 0.3 mL of cyclohexene to give the product (0.007 g).

[0581] MS (ESI) m/z 319 [M+H]+.

[0582] RT=9.1 min

Example 60 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol

[0583] Step 1: 1-cyclopentyl-7-fluoro--3-(4-methoxyphenyl)-1H-indazole

[0584] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.94 g, 3.8 mmol), sodium hydride (60% in oil, 0.148 g, 3.7 mmol) and cyclopentyl-bromide (0.43 mL, 4.0 mmol) to give the title compound (0.80 g) as a white solid,

[0585] mp 70-71° C.

[0586]¹H NMR (DMSO-d₆): δ 1.69 (m, 2H), 1.882 (m, 2H), 2.132 (m, 4H), 3.814 (s, 3H), 5.252 (m, 1H), 7.07 (dd, 2H), 7.15 (m, 1H), 7.23 (m, 2H), 7.80 (d, 1H), 7.85(d, 2H)

[0587] MS (ESI) m/z 311 [M+H]+.

[0588] Step 2: 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol

[0589] Prepared according to Method D step C from 1-cyclopentyl-7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.57 g, 1.83 mmol), boron tribromide (0.70 mL, 7.35 mmol) and 3 mL of cyclohexene to give the product (0.25 g) as a white solid.

[0590] mp 131° C.;

[0591]¹H NMR (DMSO-d₆, 500 MHz): δ 1.697 (m, 2H), 1.880 (m, 2H), 2.124 (m, 4H), 5.255 (m, 1H), 6.90 (d, 2H), 7.12 (m, 1H), 7.21 (m, 2H), 7.73 (d, 2H), 7.78 (d, 1H), 9.643 (s, 1H).

[0592] MS (ESI) m/z 297 [M+H]+.

[0593] Anal. calcd for C₁₈ H₁₇FN₂O: C:72.96 H:5.78 N:9.45 Found: C:73.17 H:5.73 N:9.60.

Example 61 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)phenol

[0594] Step 1: 2-cyclopentyl-7-fluoro-3-(4-methoxyphenyl)-2H-indazole

[0595] Prepared according to Method D step B from 7-fluoro-3-(4-methoxyphenyl)-1H-indazole (0.75 g, 3.1 mmol), sodium hydride (60% in oil, 0.124 g, 3.1 mmol) and cyclopentylbromide (0.36 mL, 3.3 mmol) to give the title compound (0.055 g) as a white solid.

[0596] Step 2: 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)phenol

[0597] Prepared according to Method D step C from 2-cyclopentyl-7-fluoro-3-(4-methoxyphenyl)-2H-indazole (0.055 g, 0.177 mmol), boron tribromide (0. 70 mL, 0.74 mmol) and 0.3 mL of cyclohexene to give the product (0.03 g) as an amber solid.

[0598]¹H NMR (DMSO-d₆): δ 1.63 (m, 2H), 1.94 (m, 2H), 2.118 (m, 4H), 4.96 (m, 1H), 6.98 (m, 4H), 7.25 (d 1H), 7.36 (d, 2H), 9.925 (s, 1H).

[0599] MS (ESI) m/z 297 [M+H]+.

Example 62 4-(7-fluoro-1-(3,3,3-trifluoropropyl)-1H-indazol-3-yl)phenol

[0600] Step 1: 7-chloro-3-(4-methoxyphenyl)-1-(3,3,3-trifluoropropyl)-1H-indazole

[0601] Prepared according to Method D step B from 7-chloro-3-(4-methoxyphenyl)-1H-indazole (0.108 g, 0.4 mmol), sodium hydride (60% in oil, 0.016 g, 0.4 mmol) and 3,3,3-trifluoropropyliodide (0.047 mL, 0.4 mmol) to give the title compound (0.008 g).

[0602]¹H NMR (DMSO-d₆): δ 2.95 (m, 2H), 3.82 (s, 3H), 5.03 (m, 1H), 7.09 (d, 2H), 7.22 (t, 1H), 7.55 (d, 1H), 7.84 (d, 2H), 7.99 (d, 1H).

[0603] MS (APCI) m/z 355 [M+H]+.

[0604] Step 2: 4-(7-fluoro-1-(3,3,3-trifluoropropyl)-1H-indazol-3-yl)phenol

[0605] Prepared according to Method D step C from 7-chloro-3-(4-methoxyphenyl)-1-(3,3,3-trifluoropropyl)-1H-indazole (0.008 g, 0.022 mmol), boron tribromide (0. 05 mL, 0.5 mmol) and 0.2 mL of cyclohexene to give the product (0.004 g).

[0606] MS (ESI) m/z 339 [M−H]−.

Example 63 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)-2-methylphenol

[0607] Step 1: 1-cyclopentyl-7-fluoro-3-(4-methoxy-3-methylphenyl)-1H-indazole

[0608] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-3-methylphenyl)-1H-indazole (0.76 g, 0.4 mmol), sodium hydride (60% in oil, 0.120 g, 3.0 mmol) cyclopentyl bromide (0.321 mL, 3.0 mmol) to give the title compound (0.75 g).

[0609]¹H NMR (DMSO-d₆): δ 1.70 (m, 2H), 1.88 (m, 2H), 2.13 (m, 4H), 3.842 (s, 3H), 5.26 (m, 1H), 7.06 (d, 1H), 7.14 (m, 1H), 7.23 (m, 1H), 7.69 (m, 2H), 7.81 (d, 1H)

[0610] MS (ESI) m/z 325 ([M+H]⁺).

[0611] Step 2: 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)-2-methylphenol

[0612] Prepared according to Method D step C from 1-cyclopentyl-7-fluoro-3-(4-methoxy-3-methylphenyl)-1H-indazole (0.70 g, 2.16 mmol), boron tribromide (0.82 mL, 8.6 mmol) and 1.0 mL of cyclohexene to give the product (0.15 g) as a white solid,

[0613] mp 107° C.

[0614]¹H NMR (DMSO-d₆): δ 1.68 (m, 2H), 1.88 (m, 2H), 2.124 (m, 4H), 5.24 (m, 1H), 6.90 (d, 1H), 7.12 (m, 1H), 7.22 (m, 1H), 7.55 (dd, 1H), 7.60 (s, 1H), 7.79 (d, 1H), 9.540 (s, 1H).

[0615] MS (ESI) m/z 311 [M+H]+.

[0616] Anal. calcd for C₁₉H₁₉FN₂O: C:73.53 H:6.17 N:9.03 Found: C:73.31 H:6.10 N:8.90.

Example 64 4-[l1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0617] Step 1: 1-allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole

[0618] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole 0.52 g, 1.6 mmol), sodium hydride (60% in oil, 0.065 g, 1.6 mmol) and allyl bromide (0.138 mL, 1.6 mmol) to give the title compound (0.26 g) as a white solid.

[0619]¹H NMR (DMSO-d₆): δ 3.73 (s, 3H), 3.80 (s, 3H), 4.85 (dd, 1H, J=1.5 and 14.65), 5.1 (m, 3H), 5.97-6.05 (m, 1H), 6.39 (dd, 1H, J=2.32 and 6.14), 6.64 (s, 1H), 7.25 (t, 1H), 7.35 (d, 1H), 7.85-7.87 (m, 2H),).

[0620] MS (ESI) m/z 363 [M+H]+.

[0621] Step 2: 4-[-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0622] Prepared according to Method D step C from 1-allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (0.065 g, 0.18 mmol), boron tribromide (0.136 mL, 1.4 mmol) and 1.0 mL of cyclohexene to give the product (0.066 g) as a white solid.

[0623] mp 114-115° C.;

[0624]¹H NMR (DMSO-d₆): δ 4.87 (dd, 1H, J=1.37 and 17.10 Hz), 5.31-5.08 (m, 3H), 6.01-6.08 (m, H), 6.39 (dd, 1H, J=2.44 and 8.40 Hz), 6.46 (s, 1H), 7.30 (t, 1H), 3.78 (d, 1H), 7.85-7.87 (m, 1H), 8.14-8.19 (m, 1H), 9.59 (broad s, 1H), 9.82 (broad s, 1H)

[0625] MS (ESI) m/z 335 [M+H]+.

[0626] Anal. calcd for C₁₇ H₁₃F₃N₂O₂: C:61.08 H:3.92 N:8.38 Found: C:61.02 H:3.76 N:8.28.

Example 65 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0627] Step 1: 3-(2,4-dimethoxyphenyl)-1-isopropyl-7-(trifluoromethyl)-1H-indazole

[0628] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (1.50 g, 4.65 mmol), sodium hydride (60% in oil, 0.195 g, 4.88 mmol) and 2-iodopropane (0.47 mL, 4.88 mmol) to give the title compound (0.55 g) as a white solid.

[0629] mp 128-129° C.;

[0630]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H, J=6.4 Hz), 3.77 (s, 3H), 3.84 (s, 3H), 4.99 (m, 1H), 6.67 (dd, 1H, J=8.4 and 2.2 Hz), 6.75 (d, 1H, J=2.2 Hz), 7.25 (t, 1H, 7.8 Hz) 7.39 (d, 1H, J=8.4 Hz), 7.82 (d, 1H, J=7.3 Hz), 7.88 (d, 1H, J=8.1 Hz)

[0631] MS (ESI) m/z 365 [M+H]+.

[0632] Anal. calcd for C₁₉ H₁₉F₃N₂O₂: C:62.63 H:5.26 N:7.69 Found: C:62.52 H:5.28 N:7.59.

[0633] Step 2: 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0634] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-1-isopropyl-7-(trifluoromethyl)-1H-indazole (0.442 g, 1.2 mmol), boron tribromide (0.688 mL, 7.27 mmol) and 1.0 mL of cyclohexene to give the product (0.268 g) as an off-white solid.

[0635] mp 61-63° C.;

[0636]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H, J=6.3 Hz), 4.99 (m, 1H), 6.39 (dd, 1H, J=8.3 and 2.3 Hz), 6.46 ( d, 1H, J=2.1 Hz), 7.28 (t, 1H, J=7.8 Hz), 7.40 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=7.5 Hz), 8.15 (d, 1H, J=8.1 Hz), 9.58 (s, 1H), 9.88 (s, 1H)

[0637] MS (ESI) m/z 337 [M+H]+.

[0638] Anal. calcd for C₁₇H₁₅F₃N₂O₂.0.11 C₄H₈O₂.0.10 H₂O: C:60.23 H:4.66 N:8.05 Found: C:60.14 H:4.51 N:7.65

Example 66 4-[1-cyclopentyl-7-(trifluoromethyl)-1H-indazol-3-yl] benzene-1,3-diol

[0639] Step 1: 1-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole

[0640] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (2.00 g, 6.20 mmol), sodium hydride (60% in oil, 0.297 g, 7.44 mmol) and cyclopentyl bromide (1.00 mL, 9.30 mmol) to give the title compound (0.68 g) as a white solid, mp 79-80° C.;

[0641]¹H NMR (DMSO-d₆): δ 1.67 (m, 2H), 1.92 (m, 2H), 2.11 (m, 4H), 3.77 (s, 3H), 3.84 (s, 3H), 5.17 (m, 1H) 6.67 (dd, 1H, J=8.4 and 2.3 Hz), 6.74 (d, 1H, J=2.3 Hz), 7.25 (t, 1H, 7.7 Hz) 7.38 (d, 1H, J=8.4 Hz), 7.82 (d, 1H, J=7.3 Hz), 7.88 (d, 1H, J=8.1 Hz)

[0642] MS (EI) m/z 390([M+H]⁺):;

[0643] Anal. calcd for C₂₁H₂₁F₃N₂O₂: C:64.61 H:5.42 N:7.18 Found: C:64.55 H:5.34 N:7.20.

[0644] Step 2: 4-[1-cyclopentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0645] Prepared according to Method D step C from 1-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (0.465 g, 1.2 mmol), boron tribromide (0.67 mL, 7.1 mmol) and 1.0 mL of cyclohexene to give the product (0.424 g) as an off-white solid.

[0646] mp 159-160° C.;

[0647]¹H NMR (DMSO-d₆): δ 1.70 (m, 2H), 1.92 (m, 2H), 2.07 (m, 2H), 2.13 (m, 2H), 5.18 (m 1H), 6.39 (dd, 1H, J=8.4 and 2.4 Hz), 6.46 (d, 1H, J=2.1 Hz), 7.27 (t, 1H, J=7.8 Hz), 7.39 (d, 1H, J=8.4 Hz), 7.84 (d, 1H, J=7.3 Hz), 8.14 (d, 1H, J=8.2 Hz), 9.58 (s, 1H), 9.87 (s, 1H)

[0648] MS (ESI) m/z 361 [M−H]−.

[0649] Anal. calcd for C₁₉H₁₇F₃N₂O₂: C:62.98 H:4.73 N:7.73 Found: C:62.64 H:4.57 N:7.47.

Example 67 4-[1-(cyclohexylmethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0650] Step 1: 1-Cyclohexylmethyl-3-(2,4-dimethoxyphenyl)-7-trifluoromethyl-1H-indazole

[0651] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (1.82 g, 5.64 mmol), sodium hydride (60% in oil, 0.451 g, 11.28 mmol) and (bromomethyl)cyclohexane (4.00 g, 22.5 mmol) to give the title compound (0.804 g) as a white solid.

[0652]¹H NMR (DMSO-d₆): δ 1.02 (m, 2H), 1.14 (m, 4H), 1.55 (m, 2H), 1.65 (m, 2H), 1.96 (m, 4H), 3.77 (s, 3H), 3.84 (s, 3H), 4.29 (d, 2H, J=7.0 Hz), 6.67 (dd, 1H, J=8.4 and 2.2 Hz), 6.75 (d, 1H, J=2.1 Hz), 7.26 (t, 1H, 7.7 Hz) 7.37 (d, 1H, J=8.4 Hz), 7.83 (d, 1H, J=7.3 Hz), 7.89 (d, 1H, J=7.9 Hz)

[0653] MS (ESI) m/z419 [M+H]+.

[0654] Anal. calcd for C₂₃ H₂₅F₃N₂O₂: C:66.02 H:6.02 N:6.69 Found: C:66.24 H:6.22 N:6.34.

[0655] Step 2: 4-[1-(cyclohexylmethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0656] Prepared according to Method D step C from 1-(cyclohexylmethyl)-3-(2,4-dimethoxy-phenyl)-7-(trifluoromethyl)-1H-indazole (0.841 g, 2.0 mmol), boron tribromide (1.14 mL, 12 mmol) and 0.5 mL of cyclohexene to give the product (0.567 g) as an off-white solid.

[0657] mp 117-118° C.;

[0658]¹H NMR (DMSO-d₆): δ 1.02 (m, 2H), 1.13 (m, 3H), 1.52 (m, 2H), 1.64 (m, 3H 1.97 (m, 1H), 4.29 (d, 2H J=7.2 Hz), 6.39 (dd, 1H, J=8.4 and 2.4 Hz), 6.46 (d, 1H, J=2.1 Hz), 7.28 (t, 1H, J=7.8 Hz), 7.38 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=7.3 Hz), 8.15 (d, 1H, J=8.2 Hz), 9.59 (s, 1H), 9.87 (s, 1H).

[0659] MS (ESI) m/z 389 [M−H]−.

[0660] Anal. calcd for C₂₁H₂₁F₃N₂O₂.0.05 C₆H₁₄: C:64.82 H:5.54 N:7.10 Found: C:65.14 H:5.55 N:7.18.

Example 68 4-[1-isobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0661] Step 1: 1-isobutyl-3-(2,4-dimethoxyphenyl)-7-trifluoromethyl-1H-indazole

[0662] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (2.00 g, 6.20 mmol), sodium hydride (60% in oil, 0.297 g, 7.44 mmol) and 1-Iodo-2-Methylpropane (1.07 mL, 9.30 mmol) to give the title compound (0.708 g) as a white solid.

[0663]¹H NMR (DMSO-d₆): δ 0.88 (d, 6H, J=6.72 Hz), 2.28 (m, 1H), 3.77 (s, 3H), 3.84 (s, 3H), 4.27 (d, 2H, J=7.3 Hz), 6.67 (dd, 1H, J=8.4 and 2.2 Hz), 6.75 (d, 1H, J=2.1 Hz), 7.27 (t, 1H, 7.8 Hz) 7.38 (d, 1H, J=8.4 Hz), 7.84 (d, 1H, J=7.3 Hz), 7.89 (d, 1H, J=8.0 Hz)

[0664] MS (ESI) m/z 379 [M+H]+.

[0665] Anal. calcd for C₂₀H₂₁F₃N₂O₂: C:63.48 H:5.59 N:7.40 Found: C:63.35 H:5.56 N:7.20.

[0666] Step 2: 4-[1-isobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0667] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-1-isobutyl-7-(trifluoromethyl)-1H-indazole (0.675 g, 1.2 mmol), boron tribromide (1.01 mL, 10.7 mmol) and 1.0 mL of cyclohexene to give the product (0.208 g) as an off-white solid.

[0668] mp 91-92° C.;

[0669]¹H NMR (DMSO-d₆): δ 0.88 (d, 6H, J=6.6 Hz), 2.27 (m, 1H), 4.26 (d, 2H, J=7.2 Hz) 6.39 (dd, 1H, J=8.4 and 2.4 Hz), 6.46 (d, 1H, J=2.1 Hz), 7.28 (t, 1H, J=7.38 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=7.3 Hz), 8.15 (d, 1H, J=8.2 Hz), 9.59 (s, 1H), 9.85 (s, 1H)

[0670] MS (ESI) m/z 351 [M+H]+.

[0671] Anal. calcd for C₁₈H₁₇F₃N₂O₂: C:61.71 H:4.89 N:8.00 Found: C:61.60 H:4.98 N:7.84.

Example 69 4-[1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0672] Step 1: 3-(2,4-dimethoxyphenyl)-1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazole

[0673] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (2.00 g, 6.20 mmol), sodium hydride (60% in oil, 0.496 g, 12.4 mmol) and 1-Bromo-2-Ethylbutane (3.07 g, 18.6 mmol) to give the title compound (0.748 g) as a white solid.

[0674]¹H NMR (DMSO-d₆): 8 0.82 (t, 6H, J=7.5 Hz), 1.30 (m, 4H), 2.05 (m, 1H), 3.77 (s, 3H), 3.84 (s, 3H), 4.35 (d, 2H, J=7.3 Hz), 6.67 (dd, 1H, J=8.4 and 2.4 Hz), 6.75 (d, 1H, J=2.2 Hz), 7.27 (t, 1H, 7.6 Hz) 7.36 (d, 1H, J=8.4 Hz), 7.84 (d, 1H, J=7.3 Hz), 7.89 (d, 1H, J=8.3 Hz).

[0675] MS (ESI) m/z 407 [M+H]+.

[0676] Anal. calcd for C₂₂H₂₅F₃N₂O₂: C:65.01 H:6.20 N:6.89 Found: C:65.01 H:6.15 N:6.75.

[0677] Step 2: 4-[1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1.3-diol

[0678] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazole (0.720 g, 1.77 mmol), boron tribromide (1.01 mL, 10.7 mmol) and 0.5 mL of cyclohexene to give the product (0.222 g) as an off-white solid.

[0679] mp 89-90° C.;

[0680]¹H NMR (DMSO-d₆): δ 0.82 (t, 6H, J=7.5 Hz), 1.29 (m, 4H), 2.04 (m, 1H), 4.35 (d, 2H J=7.5 Hz), 6.39 (dd, 1H, J=8.4 and 2.4 Hz), 6.46 (d, 1H, J=2.3 Hz), 7.28 (t, 1H, J=7.6 Hz), 7.38 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=7.5 Hz), 8.16 (d, 1H, J=8.1 Hz), 9.59 (s, 1H), 9.85 (s, 1H).

[0681] MS (ESI) m/z 379 [M+H]+.

[0682] Anal. calcd for C₂₀H₂₁F₃N₂O₂: C:63.48 H:5.59 N:7.40 Found: C:63.59 H:5.60 N:7.31.

Example 70 4-[1-cyclobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0683] Step 1: 1-cyclobutyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole

[0684] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (2.38 g, 7.40 mmol), sodium hydride (60% in oil, 0.592 g, 14.8 mmol) and bromocyclobutane (3.00 g, 22.2 mmol) to give the title compound (0.643 g) as a white solid.

[0685] mp 109-110° C.;

[0686]¹H NMR (DMSO-d₆): δ 1.87 (m, 2H), 2.45 (m, 2H), 2.77 (m, 2H), 3.77 (s, 3H), 3.85 (s, 3H), 5.25 (m, 1H), 6.68 (dd, 1H, J=8.4 and 2.3 Hz), 6.76 (d, 1H, J=2.1Hz) 7.27 (t, 1H, 7.8 Hz), 7.43 (d, 1H, J=8.4 Hz), 7.83 (d, 1H, J=7.3 Hz), 7.87 (d, 1H, J=8.1 Hz).

[0687] MS (ESI) m/z 377 [M+H]+.

[0688] Anal. calcd for C₂₀H₁₉F₃N₂O₂.0.10 C₆H₁₄: C:64.27 H:5.34 N:7.28 Found: C:64.38 H:5.12 N:7.38.

[0689] Step 2: 4-[1-cyclobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0690] Prepared according to Method D step C from 1-cyclobutyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (0.575 g, 1.5 mmol), boron tribromide (0.866 mL, 9.1 mmol) and 0.5 mL of cyclohexene to give the product (0.214 g) as an off-white solid.

[0691] mp 124-125° C.;

[0692]¹H NMR (DMSO-d₆): δ 1.85 (m, 2H), 2.44 (m, 2H), 2.75 (m, 2H), 5.24 (m, 1H), 6.39 (dd, 1H, J=8.4 and 2.3 Hz), 6.47 (d, 1H, J=2.3 Hz), 7.28 (t, 1H, J=7.8 Hz), 7.39 (d, 1H, J=8.4 Hz), 7.83 (d, 1H, J=7.5 Hz), 8.10 (d, 1H, J=8.1 Hz), 9.58 (s, 1H), 9.81 (s, 1H).

[0693] MS (ESI) m/z 347 [M−H]−.

[0694] Anal. calcd for C₁₈ H₁₅F₃N₂O₂: C:62.07 H:4.34 N:8.04 Found: C:61.61 H:4.25 N:7.93.

Example 71 4-[1-(1-ethylpropyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0695] Step 1: 3-(2,4-dimethoxyphenyl)-1-(1-ethylpropyl)-7-(trifluoromethyl)-1H-indazole

[0696] Prepared according to Method D step B from 3-(2,4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (2.50 g, 7.75 mmol), sodium hydride (60% in oil, 0.62 g, 15.5 mmol) and 3-Bromopentane (3.51 g, 23 mmol) to give the title compound (0.866 g) as a white solid.

[0697] mp 115-116° C.;

[0698]¹H NMR (DMSO-d₆): δ 0.68 (t, 6H, J=7.5 Hz), 1.90 (m, 2H), 2.00 (m, 2H), 3.78 (s, 3H), 3.84 (s, 3H), 4.51 (m, 1H), 6.67 (dd, 1H, J=8.4 and 2.1 Hz), 6.75 (d, 1H, J=2.1 Hz), 7.25 (t, 1H, 7.8 Hz), 7.37 (d, 1H, J=8.3 Hz), 7.82 (d, 1H, J=7.3 Hz), 7.89 (d, 1H, J=8.1 Hz).

[0699] MS (ESI) m/z 393 [M+H]+.

[0700] Anal. calcd for C₂₁H₂₃F₃N₂O₂: C:64.28 H:5.91 N:7.14 Found: C:64.21 H:5.78 N:7.10.

[0701] Step 2: 4-[1-(1-ethylpropyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1.3-diol

[0702] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-1-(1-ethylpropyl)-7-(trifluoromethyl)-1H-indazole (0.557 g, 1.42 mmol), boron tribromide (0.81 mL, 8.51 mmol) and 0.5 mL of cyclohexene to give the product (0.367 g) as an off-white solid.

[0703] mp 121-122° C.;

[0704]¹H NMR (DMSO-d₆): δ 0.67 (t, 6H, J=7.5 Hz), 1.91 (m, 2H), 1.98 (m, 2H), 4.51 (m, 1H), 6.39 (dd, 1H, J=8.4 and 2.3 Hz), 6.46 (d, 1H, J=2.3 Hz), 7.28 (t, 1H, J=7.6 Hz), 7.42 (d, 1H, J=8.4 Hz), 7.85 (d, 1H, J=7.3 Hz), 8.18 (d, 1H, J=8.1 Hz), 9.60 (s, 1H), 9.92 (s, 1H).

[0705] MS (ESI) m/z 365 [M+H]+.

[0706] Anal. calcd for C₁₉H₁₉F₃N₂O₂: C:62.63 H:5.26 N:7.69 Found: C:62.75 H:5.12 N:7.57.

Example 72 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-3-methylphenol

[0707] Step 1: 2-allyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-2H-indazole

[0708] Prepared according to Method D step B from 3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole (0.150 g, 0.49 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.74 mmol) to give the title compound (0.055 g) as a white solid.

[0709]¹H NMR (DMSO-d₆): δ 1.99 (s, 3H), 3.83 (s, 3H), 4.77-4.98 (m, 3H), 5.13 (dd, 1H, J=1.19 and 10.32 Hz), 5.88-6.01 (m, 1H), 6.95 (dd, 1H, J=2.58 and 8.53 Hz), 7.04 (s, 1H), 7.14 (t, 1H), 7.28 (d, 1H), 7.58 (d, 1H), 7.69 (d, 1H).

[0710] MS (ESI) m/z 347 [M+H]+.

[0711] Step 2: 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-3-methylphenol

[0712] Prepared according to Method D step C from 2-allyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-2H-indazole (0.043 g, 0.124 mmol), boron tribromide (0.05 mL, 0.52 mmol) and 1.0 mL of cyclohexene to give the product (0.033 g) as a white solid.

[0713]¹H NMR (DMSO-d₆): δ 1.93 (s, 3H), 4.77-4.82 (m, H), 4.88-4.96 (m, 2H), 5.12 (dd, 1H, J=1.37 and 10.38 Hz), 5.74-5.98 (m, 1H), 6.82 (s, 1H), 6.76 (dd, 1H, J=2.44 and 8.39), 7.12-7.15 (m, 1H), 7.58 (d, 1H), 7.67 (d, 1H), 9.81 (broad s, 1H).

[0714] MS (ESI) m/z 333 [M+H]+.

Example 73 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzen-1,3-diol

[0715] Step 1: 3-(2,4-dimethoxyphenyl)-1-pentyl-7-(trifluoromethyl)-1H-indazole

[0716] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (0.150 g, 0.49 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 1-iodopentane (0.07 mL, 0.7 mmol) to give the title compound (0.069 g) as a white solid.

[0717]¹H NMR (DMSO-d₆): δ 0.83-0.88 (m, 2H), 1.22-1.37 (m, 4H), 1.81-1.86 (m, 2H), 3.74 (s, 3H), 3.83 (s, 3H), 6.66 (dd, 1H, J=2.18 and 8.33 Hz), 6.75 (s, 1H), 7.26 (t, 1H), 7.38 (d, 1H), 7.85 (m, 2H).

[0718] MS (ESI) m/z 393 [M+H]+.

[0719] Step 2: 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

[0720] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-1-pentyl-7-(trifluoromethyl)-1H-indazole (0.055 g, 0.14 mmol), boron tribromide (0.136 mL, 1.4 mmol) and 1.0 mL of cyclohexene to give the product (0.048 g) as a white solid.

[0721]¹H NMR (DMSO-d₆): δ 0.82-0.89 (m, 3H), 1.28-1.35 (m, 4H), 1.81-1.85 (m, 2H), 4.44 (t, 2H), 6.38 (dd, 1H, J=2.29 and 8.40 Hz), 6.46 (s, 1H), 7.28 (t, 1H), 7.38 (d, 1H), 7.85 (d, 1H), 8.13 (d, 1H), 9.59 (broad s, 1H), 9.83 (broad s, 1H).

[0722] MS (ESI) m/z 363 [M−H]−.

Example 74 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol

[0723] Step 1: 1-allyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole

[0724] Prepared according to Method D step B from 3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole (0.150 g, 0.49 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.090 g) as a white solid.

[0725]¹H NMR (DMSO-d₆): δ 2.27 (s, 3H), 3.81 (s, 1H), 4.76 (d, 1H), 5.10-5.14 (m, 3H), 6.01-6.08 (m, 1H), 6.90 (d, 1H), 6.98 (s, 1H), 7.30-7.39 (m, 2H), 7.87-7.90 (m, 2H).

[0726] MS (ESI) m/z 347 [M+H]+.

[0727] Step 2: 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol

[0728] Prepared according to Method D step C from 1-allyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole (0.075 g, 0.22 mmol), boron tribromide (0.082 mL, 0.87 mmol) and 1.0 mL of cyclohexene to give the product (0.086 g) as a white solid.

[0729]¹H NMR (DMSO-d₆): δ 2.21 (s, 3H), 4.77 (d, 1H), 5.10-5.13 (m, 3H), 6.02-6.10 (m, 1H), 6.76 (dd, H, J=2.44 and 8.27 Hz), 6.78 (s, 1H), 7.25 (d, 1H), 7.32 (t, 1H), 7.86-7.89 (m, 2H), 9.60 (broad s1H).

[0730] MS (ESI) m/z 333 [M+H]+.

Example 75 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-1,3-benzenediol

[0731] Step 1: 2-allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-2H-indazole

[0732] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-(trifluoro-methyl)-1H-indazole (0.150 g, 0.49 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.062 g) as a white solid.

[0733]¹H NMR (DMSO-d₆): δ 3.75 (s, 3H), 3.86 (s, 3H), 4.87-4.99 (m, 3H), 5.13 (d, 1H), 5.90-5.99 (m, 1H), 6.72 (d, 1H), 6.79 (s, 1H), 7.12 (t, 1H), 7.31 (d, 1H), 7.61-7.68 (m, 2H).

[0734] MS (ESI) m/z 363 [M+H]+.

[0735] Step 2: 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-1,3-benzenediol

[0736] Prepared according to Method D step C from 2-allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-2H-indazole (0.05 g, 0.14 mmol), boron tribromide (0.104 mL, 1.1 mmol) and 1.0 mL of cyclohexene to give the product (0.019 g) as a white solid.

[0737]¹H NMR (DMSO-d₆): δ 4.80-4.82 (dd, 1H, J=1.68 and 6.87 Hz), 4.83-5.01 (m, 2H), 5.12 (d, 1H), 5.93-6.02 (m, 1H), 6.38-6.45 (m, 1H), 6.50 (s, 1H), 7.00-7.70 (m, 2H), 7.65-7.66 (m, 2H), 9.72 (broad s, 1H), 9.88 (broad s, 1H).

[0738] MS (ESI) m/z 335 [M+H]+.

[0739] Anal. calcd for C₁₇H₁₃F₃N₂O₂.0.50 C₆H₁₄: C:63.65 H:5.34 N:7.42 Found: C:63.67 H:4.96 N:7.26.

Example 76 3-methyl-4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0740] Step 1: 3-(4-methoxy-2-methylphenyl)-1-propyl-7-(trifluoromethyl)-1H-indazole

[0741] Prepared according to Method D step B from 3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole (0.150 g, 0.49 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and iodopropane (0.07 mL, 0.7 mmol) to give the title compound (0.098 g) as a white solid.

[0742]¹H NMR (DMSO-d₆): δ 0.9 (t, 3H), 1.85-1.94 (m, 2H), 2.28 (s, 3H), 3.81 (s, 3H), 4.44 (t, 2H), 6.91 (dd, 1H, J=2.60-8.40 Hz), 6.98 (s, 1H), 7.30 (t, 1H), 7.38 (d, 1H).

[0743] MS (ESI) m/z349 [M+H]+.

[0744] Step 2: 3-methyl-4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol

[0745] Prepared according to Method D step C from 3-(4-methoxy-2-methylphenyl)-1-propyl-7-(trifluoromethyl)-1H-indazole (0.087 g, 0.25 mmol), boron tribromide (0.136 mL, 1.4 mmol) and 1.0 mL of cyclohexene to give the product (0.091 g) as a white solid,

[0746]¹H NMR (DMSO-d₆): δ 0.89 (t, 3H), 1.85-1.89 (m, 2H), 2.22 (s, 3H), 4.42 (t, 2H), 6.73 (dd, 1H, J=2.29 and 8.25 Hz), 6.78 (s, 1H), 725 (d, 1H), 7.29 (t, 1H), 7.86 (m, 1H), 9.58 (broad s, 1H).

Example 77 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol

[0747] Step 1: 7-chloro-1-isopropyl-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0748] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-iodopropane (0.07 mL, 0.7 mmol) to give the title compound (0.100 g) as a white solid.

[0749]¹H NMR (DMSO-d₆): δ 1.5 (d, 6H), 1.3 (s, 3H), 3.80 (s, 3H), 5.66-5.68 (m, 1H), 7.54 (d, 1H, J=2.59 and 8.39 Hz), 6.96 (s, 1H), 7.12 (t, 1H), 7.39 (d, 1H), 7.47 (d, 1H), 7.54 (d, 1H).

[0750] MS (ESI) m/z 315 [M+H]+.

[0751] Step 2: 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol

[0752] Prepared according to Method D step C from 7-chloro-1-isopropyl-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.090 g, 0.3 mmol), boron tribromide (0.104 mL, 1.1 mmol) and 1.0 mL of cyclohexene to give the product (0.048 g) as a white solid.

[0753]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H), 2.23 (s, 3H), 5.63-5.69 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.24 Hz), 6.76 (s, 1H), 7.10 (t, 1H), 7.26 (d, 1H), 7.46 (d, 1H), 9.54 (broad s, 1H).

[0754] MS (ESI) m/z 301 [M+H]+.

Example 78 4-(2-allyl-7-chloro-2H-indazol-3-yl)-3-methylphenol

[0755] Step 1: 2-allyl-7-chloro-3-(4-methoxy-2-methylphenyl)-2H-indazole

[0756] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.068 g) as a white solid.

[0757]¹H NMR (DMSO-d₆): δ 1.99 (s, 3H), 3.82 (s, 3H), 4.75-4.79 (m, 1H), 4.90-4.93 (m, 2H), 5.13 (m, 2H, J=0.916 and 10.23 Hz), 5.92-5.99 (m, 1H), 6.93-7.02 (m, 3H), 7.25 (t, 2H), 7.38 (d, 2H).

[0758] MS (ESI) m/z 313 [M+H]+.

[0759] Step 2: 4-(2-allyl-7-chloro-2H-indazol-3-yl)-3-methylphenol

[0760] Prepared according to Method D step C from 2-allyl-7-chloro-3-(4-methoxy-2-methylphenyl)-2H-indazole (0.068 g, 0.2 mmol), boron tribromide (0.20 mL, 2.10 mmol) and 1.0 mL of cyclohexene to give the product (0.065 g) as a white solid.

[0761]¹H NMR (DMSO-d₆): δ 1.93 (s, 3H), 4.61-4.79 (m, 1H), 4.87-4.92 (m, 2H), 5.13 (dd, 1H, J=1.22 and 10.23 Hz), 5.90-5.98 (m, 1H), 6.75 (dd, 1H, J=2.44 and 8.24 Hz), 6.81 (s, 1H), 6.96-6.99 (m, H) 7.12 (d, H), 7.24 (d, H), 7.36 (d, H), 9.78 (broad s, H).

[0762] MS (ESI) m/z 299 [M+H]+.

Example 79 4-(7-chloro-2-propyl-2H-indazol-3-yl)-3-methylphenol

[0763] Step 1: 7-chloro-3-(4-methoxy-2-methylphenyl)-2-propyl-2H-indazole

[0764] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 1-propyl iodide (0.07 mL, 0.7 mmol) to give the title compound (0.056 g) as a white solid.

[0765]¹H NMR (DMSO-d₆): δ 0.71 (t, 3H), 1.79 (m, 2H), 2.00 (s, 3H), 3.83 (s, 3H), 4.04-4.09 (m, 1H), 4.20-4.25 (m, 1H), 6.94-6.98 (m, 2H), 7.00 (s, 1H), 7.22 (d, 1H), 7.27 (d, 1H), 7.35 (d, 1H).

[0766] MS (ESI) m/z 315 [M+H]+.

[0767] Step 2: 4-(7-chloro-2-propyl-2H-indazol-3-yl)-3-methylphenol 7-chloro-3-(4-methoxy-2-methylphenyl)-2-propyl-1H-indazole

[0768] Prepared according to Method D step C from 7-chloro-3-(4-methoxy-2-methylphenyl)-2-propyl-2H-indazole (0.04 g, 0.13 mmol), boron tribromide (0.20 mL, 2.10 mmol) and 1.0 mL of cyclohexene to give the product (0.023 g) as a white solid.

[0769]¹H NMR (DMSO-d₆): δ 0.71 (t, 3H), 1.76-1.81 (m, 2H), 1.93 (s, 3H), 4.03-4.08 (m, 1H), 4.19-4.24 (m, 1H), 6.77 (dd, 1H, J=2.29 and 8.24 Hz), 6.82 (s, 1H), 6.96 (t, 1H), 7.12 (d, 1H), 7.22 (d, 1H), 7.34 (d, 1H), 9.78 (broad s, 1H).

[0770] MS (ESI) m/z 301 [M+H]+.

Example 80 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol

[0771] Step 1: 7-chloro-3-(2,4-dimethoxyphenyl)-1-isopropyl-1H-indazole

[0772] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.46 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-iodopropane (0.07 mL, 0.7 mmol) to give the title compound (0.132 g) as a white solid.

[0773]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 3.76 (s, 3H), 3.83 (s, 3H), 5.62-5.68 (m, 1H), 6.65 (dd, 1H, J=2.44 and 8.39 Hz), 6.72 (s, 1H), 7.07 (t, 1H), 7.36 (d, 1H), 7.43 (d, 1H), 7.52 (d, 1H).

[0774] MS (ESI) m/z 331 [M+H]+.

[0775] Step 2: 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)benzene-1.3-diol

[0776] Prepared according to Method D step C from 7-chloro-3-(2,4-dimethoxyphenyl)-1-isopropyl-1H-indazole (0.132 g, 0.4 mmol), boron tribromide (0.377 mL, 4.0 mmol) and 1.0 mL of cyclohexene to give the product (0.090 g) as a white solid.

[0777]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 5.64-5.69 (m, 1H), 6.39 (dd, 1H, J=2.44 and 8.39 Hz), 6.43 (s, 1H), 7.13 (t, 1H), 7.47-7.50 (m, 2H), 7.89 (d, 1H), 9.58 (broad s, 1H), 10.06 (broad s, 1H).

[0778] MS (ESI) m/z 303 [M+H]+.

Example 81 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)-3-methylphenol

[0779] Step 1: 7-chloro-2-isopropyl-3-(4-methoxy-2-methylphenyl)-2H-indazole

[0780] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-iodopropane (0.07 mL, 0.7 mmol) to give the title compound (0.059 g) as a white solid.

[0781]¹H NMR (DMSO-d₆): δ 1.46 (s, 6H), 1.99 (s, 3H), 3.83 (s, 3H), 4.42-4.47 (m, 1H), 6.94-6.98 (m, 2H), 7.04 (s, 1H), 7.20 (dd, 1H, J=0.61 and 8.25 Hz), 7.26 (d, 1H), 7.35 (dd, 1H, J=0.76 and 7.17 Hz).

[0782] MS (ESI) m/z 315 [M+H]+.

[0783] Step 2: 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)-3-methylphenol

[0784] Prepared according to Method D step C from 7-chloro-2-isopropyl-3-(4-methoxy-2-methylphenyl)-2H-indazole (0.05 g, 0.16 mmol), boron tribromide (0.19 mL, 2.0 mmol) and 1.0 mL of cyclohexene to give the product (0.016 g) as a white solid.

[0785]¹H NMR (DMSO-d₆): δ 1.45 (d, 6H), 1.93 (s, 3H), 4.43-4.48 (m, 1H), 6.77 (dd, 1H, J=2.29 and 8.24 Hz), 6.83 (s, 1H), 6.96 (t, 1H), 7.12 (d, 1H), 7.20 (d, 1H), 7.34 (d, 1H), 9.78 (broad s, 1H).

[0786] MS (ESI) m/z 301 [M+H]+.

Example 82 4-(1-allyl-7-chloro-1H-indazol-3-yl)-3-methylphenol

[0787] Step 1: 1-allyl-7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0788] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.102 g) as a white solid.

[0789]¹H NMR (DMSO-d₆): δ 2.27 (s, 3H), 3.80 (s, 3H), 4.80 (dd, 1H, J=1.37 and 17.10 Hz), 5.13 (dd, 1H, J=1.37 and 10.38 Hz), 5.36 (dd, 1H, J=3.36 and 1.67 Hz), 6.07-6.13 (m, 1H), 6.90 (dd, 1H, J=2.59 and 8.39 Hz), 6.96 (s, 1H), 7.14 (t, 1H), 7.36 (d, 1H), 7.48 (d, 1H), 7.53 (d, 1H);

[0790] MS (ESI) m/z 313 [M+H]+.

[0791] Step 2: 4-(1-allyl-7-chloro-1H-indazol-3-yl)-3-methylphenol

[0792] Prepared according to Method D step C from 7-chloro-1-cyclopentyl-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.102 g, 0.33 mmol), boron tribromide (0.19 mL, 2.0 mmol) and 1.0 mL of cyclohexene to give the product (0.099 g) as a white solid.

[0793]¹H NMR (DMSO-d₆): δ 2.21 (s, 1H), 4.82 (dd, 1H, J=1.37 and 17.10 Hz), 5.12 (d, 1H), 5.36 (s, 2H), 6.06-6.13 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.24 Hz), 6.76 (s, 1H), 1H), 7.24 (d, 1H), 7.47 (d, 1H), 7.52 (d, 1H), 9.56 ( broad s, 1H).

[0794] MS (ESI) m/z 299 [M+H]+.

Example 83 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol

[0795] Step 1: 1-isopropyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole

[0796] Prepared according to Method D step B from 3-(4-methoxy-2-methylphenyl)-7-(trifluoro-methyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.072 g) as a white solid.

[0797]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H), 2.30 (s, 3H), 3.81 (s, 3H), 4.99-5.02 (m, 1H), 6.91 (dd, 1H, J=2.60 and 8.40 Hz), 6.98 (d, 1H), 7.32 (t, 1H), 7.41 (d, 1H), 7.86-7.91 (m, 2H).

[0798] MS (ESI) m/z 349 [M+H]+.

[0799] Step 2: 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol

[0800] Prepared according to Method D step C from 1-isopropyl-3-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-1H-indazole (0.062 g, 0.2 mmol), boron tribromide (0.067 mL, 0.7 mmol) and 1.0 mL of cyclohexene to give the product (0.093 g) as a white solid.

[0801]¹H NMR (DMSO-d₆): δ 1.51 (d, 6H), 2.24 (d, 3H), 4.97-5.02 (m, H), 6.73 (dd, 1H, J=2.44 and 8.24 Hz), 6.79 (s, 1H), 7.27-7.30 (m, 2H), 7.85 (d, 1H), 7.89 (d, 1H), 9.59 (broad s, 1H).

[0802] MS (ESI) m/z 335 [M+H]+.

[0803] MS (ESI) m/z 333 [M−H]−.

Example 84 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)-3-methylphenol

[0804] Step 1: 7-chloro-1-cyclopentyl-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0805] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and cyclopentyl bromide (0.075 mL, 0.7 mmol) to give the title compound (0.090 g) as a white solid.

[0806]¹H NMR (DMSO-d₆): δ 1.67-1.73 (m, 2H), 1.82-1.87 (m, 2H), 2.09-2.15 (m, 4H), 3.80 (s, 3H), 5.81-5.84 (m, 1H), 6.90 (dd, 1H, J=2.59 and 8.39 Hz), 6.96 (s, 1H), 7.10-7.14 (t, 1H), 7.39 (d, 1H), 7.47 (d, 1H), 7.55 (d, 1H).

[0807] MS (ESI) m/z 341 [M+H]+.

[0808] Step 2: 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)-3-methylphenol

[0809] Prepared according to Method D step C from 7-chloro-1-cyclopentyl-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.090 g, 0.26 mmol), boron tribromide (0.100 mL, 1.0 mmol) and 1.0 mL of cyclohexene to give the product (0.035 g) as a white solid.

[0810]¹H NMR (DMSO-d₆): δ 1.67-1.72 (m, 1H), 1.82-1.88 (m, 2H), 2.07-2.16 (m, 4H), 2.24 (s, 3H), 5.79-5.85 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.24 Hz), 6.76 (s, 1H), 7.11 (t, 1H), 7.26 (d, 1H), 7.45 (d, 1H), 7.54 (d, 1H), 9.54 (broad s, 1H).

[0811] MS (ESI) m/z 327 [M+H]+.

Example 85 4-(1-allyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol

[0812] Step 1: 1-allyl-7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole

[0813] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (0.150 g, 0.46 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and allyl bromide (0.07 mL, 0.7 mmol) to give the title compound (0.101 g) as a white solid.

[0814]¹H NMR (DMSO-d₆): δ 3.76 (s, 3H), 3.83 (s, 3H), 4.88 (dd, 1H, J=1.52 and 17.10 Hz), 5.13 (dd, 1H, J=1.52 and 10.38 Hz), 5.35 (d, 2H), 6.07-6.11 (m, 1H), 6.64 (dd, 1H, J=2.44 and 8.39 Hz), 6.73 (s, 1H), 7.09 (t, 1H), 7.37 (d, 1H), 7.44 (d, 1H), 7.54 (d, 1H).

[0815] MS (ESI) m/z 329 [M+H]+.

[0816] Step 2: 4-(1-allyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol

[0817] Prepared according to Method D step C from 1-allyl-7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole (0.101 g, 0.30 mmol), boron tribromide (0.226 mL, 2.4 mmol) and 1.0 mL of cyclohexene to give the product (0.048 g) as a white solid.

[0818]¹H NMR (DMSO-d₆): δ 4.80 (dd, 1H, J=1.37 and 17.10 Hz), 5.11 (d, 1H), 5.35 (s, 1H), 6.06-6.13 (m, 1H), 6.40 (dd, 1H, J=2.44 and 8.39 Hz), 6.43 (s, 1H), 7.13 (t, 1H),7.47-7.50 (m, 1H), 7.89 (d, 1H), 9.58 (broad s, 1H), 9.90 (broad s, 1H).

[0819] MS (ESI) m/z 301 [M+H]+.

Example 86 4-(7-chloro-1-propyl-1H-indazol-3-yl)-3-methylphenol

[0820] Step 1: 7-chloro-3-(4-methoxy-2-methylphenyl)-1-propyl-1H-indazole

[0821] Prepared according to Method D step B from 7-chloro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-iodopropane (0.07 mL, 0.7 mmol) to give the title compound (0.100 g) as a white solid.

[0822]¹H NMR (DMSO-d₆): δ 0.87 (t, 3H), 1.84-1.91 (m, 2H), 2.28 (s, 3H), 3.80 (s, 3H), 4.70 (t, 2H), 6.89 (dd, 1H, J=2.59 and 8.39 Hz), 6.95 (s, 1H), 7.12 (t, 1H), 7.35 (d, 1H), 7.48 (d, 1H), 7.52 (d, 1H).

[0823] MS (ESI) m/z 315 [M+H]+.

[0824] Step 2: 4-(7-chloro-1-propyl-1H-indazol-3-yl)-3-methylphenol

[0825] Prepared according to Method D step C from 7-chloro-3-(4-methoxy-2-methylphenyl)-1-propyl-1H-indazole (0.90 g, 0.3 mmol), boron tribromide (0.113 mL, 1.20 mmol) and 1.0 mL of cyclohexene to give the product (0.073 g) as a white solid.

[0826]¹H NMR (DMSO-d₆): δ 0.86 (t, 3H), 1.87 (m, 2H), 2.21 (s, 3H), 4.67-4.70 (m, 2H), 6.71 (dd, 1H, J=2.44 and 8.24 Hz), 6.76 (s, 1H), 7.11 (t, 1H), 7.20 (s, 1H), 7.46 (d, 1H), 7.51 (d, 1H), 9.55 (broad s, 1H).

[0827] MS (ESI) m/z 301 [M+H]+.

Example 87 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol

[0828] Step 1: 3-(2,4-dimethoxyphenyl)-7-fluoro-1-isopropyl-1H-indazole

[0829] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.300 g, 1.1 mmol), sodium hydride (60% in oil, 0.058 g, 1.44 mmol) and 2-iodopropane (0.20 mL, 2.0 mmol) to give the title compound (0.232 g) as a white solid.

[0830]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 3.77 (s, 3H), 3.82 (s, 3H), 5.03-5.08 (m, 1H), 6.63 (dd, 1H, J=2.29 and 8.39 Hz), 6.72 (s, 1H), 7.02-7.05 (m, 1H), 7.15-7.20 (m, 1H), 7.37-7.39 (m, 2H).

[0831] MS (ESI) m/z 315 [M+H]+.

[0832] Step 2: 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)benzene-13-diol

[0833] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-7-fluoro-1-isopropyl-1H-indazole (0.213 g, 0.68 mmol), boron tribromide (0.513 mL, 5.0 mmol) and 1.0 mL of cyclohexene to give the product (0.160 g) as a white solid.

[0834]¹H NMR (DMSO-d₆): δ 1.53 (s, 6H), 5.05-5.11 (m, 1H), 6.40 (dd, 1H, J=2.44 and 8.39 Hz), 6.42 (s, 1H), 7.09-7.14 (m, 1H), 7.23-7.27 (m, 1H), 7.55 (d, 1H), 7.77 (d, 1H), 9.58 (s, 1H), 10.16 (s, 1H).

[0835] MS (ESI) m/z 287 [M+H]+.

Example 88 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol

[0836] Step 1: 1-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole

[0837] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.150 g, 0.55 mmol), sodium hydride (60% in oil, 0.058 g, 0.66 mmol) and cyclopentyl bromide (0.214 mL, 2.0 mmol) to give the title compound (0.234 g) as a white solid.

[0838]¹H NMR (DMSO-d₆): δ 1.67-1.70 (m, 2H), 1.84-1.87 (m, 2H), 2.08-2.16 (m, 4H), 3.76 (s, 3H), 3.82 (s, 3H), 5.23-5.26 (m, 1H), 6.64 (dd, 1H, J=2.29 and 8.39 Hz), 6.71 (s, 1H), 7.01-7.05 (m, 1H), 7.15-7.19 (m, 1H), 7.37 (d, 2H).

[0839] MS (ESI) m/z 341 [M+H]+.

[0840] Step 2: 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol

[0841] Prepared according to Method D step C from 1-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.225 g, 0.6 mmol), boron tribromide (0.5 mL, 5 mmol) and 1.0 mL of cyclohexene to give the product (0.147 g) as a white solid.

[0842]¹H NMR (DMSO-d₆): δ 1.68-1.75 (m, 2H), 1.81-1.98 (m, 2H), 1.99-2.10 (m, 2H), 2.13-2.19 (m, 2H), 5.25-5.31 (m, H), 6.40 (dd, 1H, J=2.44 and 8.39 Hz), 6.42 (s, 1H), 7.09-7.13 (m, 1H), 7.23-7.27 (m, 1H), 7.55 (d, 1H), 7.77 (d, 1H), 9.59 (broad s, 1H), 10.16 (broad s, 1H).

[0843] MS (ESI) m/z 313 [M+H]+.

Example 89 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)benzene-1,3-diol

[0844] Step 1: 3-(2,4-dimethoxyphenyl)-7-fluoro-2-isopropyl-2H-indazole

[0845] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 2-iodopropane (0.20 mL, 2.00 mmol) to give the title compound (0.080 g) as a white solid.

[0846]¹H NMR (DMSO-d₆): δ 1.36 (d, 3H), 1.53 (d, 3H), 3.75 (s, 3H), 3.86 (s, 3H), 4.46-4.51 (m, H), 6.73 (dd, 1H, J=2.29 and 8.24 Hz), 6.78 (s, 1H), 6.89-6.93 (m, 1H), 6.98-7.01 (m, 1H), 7.10 (d, 1H), 7.28 (d, 1H).

[0847] MS (ESI) m/z 315 [M+H]+.

[0848] Step 2: 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)benzene-1,3-diol

[0849] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-7-fluoro-2-isopropyl-2H-indazole (0.07 g, 0.22 mmol), boron tribromide (0.12 mL, 1.2 mmol) and 1.0 mL of cyclohexene to give the product (0.023 g) as a white solid.

[0850] mp>160° C.;

[0851]¹H NMR (DMSO-d₆): δ 0.64 (d, 3H), 0.76 (d, 3H), 2.19-2.23 (m, 1H), 3.89-3.93 (m, 1H), 4.06-4.12 (m, 1H), 6.53 (dd, 1H, J=2.29-8.24 Hz), 6.60 (s, 1H), 6.88-6.92 (m, 1H), 6.97-7.01 (m, 1H), 7.10-7.13 (m, 2H), 9.95 (broad s, 1H).

[0852] MS (ESI) m/z 285 [M−H]−.

Example 90 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)benzene-1,3-di I

[0853] Step 1: 2-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-fluoro-2H-indazole

[0854] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 2-iodopropane (0.20 mL, 2.00 mmol) to give the title compound (0.073 g) as a white solid.

[0855]¹H NMR (DMSO-d₆): 61.55-1.65 (m, 2H), 1.88-1.98 (m, 4H), 2.09-2.19 (m, 2H), 3.74 (s, 3H), 3.86 (s, 3H), 4.654.68 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.39 Hz), 6.78 (s, 1H), 6.88-6.92 (m, 1H), 6.97-7.01 (m, 1H), 7.09 (d, 1H), 7.28 (d, 1H).

[0856] MS (ESI) m/z 341 [M+H]+.

[0857] Step 2: 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)benzene-13-diol

[0858] Prepared according to Method D step C from 2-cyclopentyl-3-(2,4-dimethoxyphenyl)-7-fluoro-2H-indazole (0.062 g, 0.18 mmol), boron tribromide (0.12 mL, 1.2 mmol) and 1.0 mL of cyclohexene to give the product (0.025 g) as a white solid.

[0859]¹H NMR (DMSO-d₆): δ 1.55-1.66 (m, 2H), 1.86-1.98 (m, 4H), 2.11-2.24 (m, 2H), 4.70-4.81 (m, 1H), 6.40 (dd, 1H, J=2.29 and 8.24 Hz), 6.50 (s, 1H), 6.86-6.91 (m, 1H), 6.95-7.00 (m, 1H), 7.05 (s, 1H), 7.09-7.14 (m, 1H), 6.70 (s, 1H), 9.97 (s, 1H).

[0860] MS (ESI) m/z 311 [M−H]−.

Example 91 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol

[0861] Step 1: 7-fluoro-1-isopropyl-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0862] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 2-iodopropane (0.075 mL, 0.7 mmol) to give the title compound (0.161) as a white solid.

[0863]¹H NMR (DMSO-d₆): δ 1.53 (d, 6H), 2.31 (s, 3H), 3.80 (s, 3H), 5.05-5.11 (m, 1H), 6.89 (dd, 1H, J=2.75 and 8.39 Hz), 6.95 (s, 1H), 7.07-7.11 (m, 1H), 7.21-7.25 (m, 1H), 7.40 (dd, 1H, J=2.29 and8.09 Hz).

[0864] MS (ESI) m/z 297 [M+H]+.

[0865] Step 2: 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol

[0866] Prepared according to Method D step C from 7-fluoro-1-isopropyl-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.151 g, 0.500 mmol), boron tribromide (0.118 mL, 1.25 mmol) and 1.0 mL of cyclohexene to give the product (0.144 g) as a white solid.

[0867]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H), 2.25 (s, 3H), 5.04-5.09 (m, 1H), 6.72 (dd, 1H, J=2.59 and 8.24 Hz), 6.76 (s, 1H), 7.06-7.10 (m, 1H), 7.19-7.23 (m, 1H), 7.27 (d, 1H), 7.39 (d, 1H).

Example 92 4-(7-fluoro-2-propyl-2H-indazol-3-yl)-3-methylphenol

[0868] Step 1: 7-fluoro-3-(4-methoxy-2-methylphenyl)-2-propyl-2H-indazole

[0869] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.150 g, 0.52 mmol), sodium hydride (60% in oil, 0.025 g, 1.04 mmol) and 1-iodopropane (0.075 mL, 0.7 mmol) to give the title compound (0.071 g) as a white solid.

[0870]¹H NMR (DMSO-d₆): δ 0.70 (t, 3H), 1.75-1.97 (m, 2H), 1.99 (s, 3H), 3.83 (s, 3H), 4.02-4.08 (m, 1H), 4.18-4.24 (m, 1H), 6.92-6.96 (m, 2H), 7.00-7.07 (m, 3H), 7.27 (d, 1H).

[0871] MS (ESI) m/z 299 [M+H]+.

[0872] Step 2: 4-(7-fluoro-2-propyl-2H-indazol-3-yl)-3-methylphenol

[0873] Prepared according to Method D step C from 7-fluoro-3-(4-methoxy-2-methylphenyl)-2-propyl-2H-indazole (0.059 g, 0.20 mmol), boron tribromide (0.05 mL, 0.5 mmol) and 1.0 mL of cyclohexene to give the product (0.052 g) as a white solid.

[0874]¹H NMR (DMSO-d₆): δ 0.71 (t, 3H), 1.77-1.81 (m, 2H), 1.93 (s, 3H), 4.03-4.07 (m, 1H), 4.17-4.23 (m, 1H), 6.76 (dd, 1H, J=2.44 and 8.24 Hz), 6.82 (s, 1H), 6.91-6.95 (m, 1H), 6.99-7.03 (m, 1H), 7.06 (d, 1H), 7.12 (d, 1H).

Example 93 4-(7-fluoro-1-propyl-1H-indazol-3-yl)-3-methylphenol

[0875] Step 1: 7-fluoro-3-(4-methoxy-2-methylphenyl)-1-propyl-1H-indazole

[0876] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 2-iodopropane (0.20 mL, 2.00 mmol) to give the title compound (0.279 g) as a white solid.

[0877]¹H NMR (DMSO-d₆): δ 0.84 (t, 3H), 1.85-1.90 (m, 2H), 2.30 (s, 3H), 3.80 (s, 3H), 6.89 (dd, 1H, J=2.59 and 8.39 Hz), 6.95 (s, 1H), 7.0-7.11 (m, 1H), 7.21-7.25 (m, 1H), 7.38 (d, 2H).

[0878] MS (ESI) m/z 297 [M−H]−. MS (ESI) m/z 299 [M+H]+.

[0879] Step 2: 4-(7-fluoro-1-propyl-¹H-indazol-3-yl)-3-methylphenol

[0880] Prepared according to Method D step C from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1-propyl-1H-indazole (0.268 g, 0.90 mmol), boron tribromide (0.275 mL, 2.90 mmol) and 1.0 mL of cyclohexene to give the product (0.252 g) as a white solid.

[0881]¹H NMR (DMSO-d₆): δ 0.84 (t, 3H), 1.85-1.89 (m, 2H), 2.23 (s, 3H), 4.46 (t, 2H), 6.70-6.72 (m, 1H), 6.76 (s, 1H), 7.07-7.09 (m, 1H), 7.20-7.24 (m, 1H), 7.25 (d, 1H), 7.37 (d, 1H), 9.53 (broad s, 1H).

Example 94 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)benzene-1,3-diol

[0882] Step 1: 3-(2,4-dimethoxyphenyl)-7-fluoro-1-isobutyl-1H-indazole

[0883] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 1-iodo-2-methylpropane (0.23 mL, 2.00 mmol) to give the title compound (0.187 g) as a white solid.

[0884] mp 92-93° C.;

[0885]¹H NMR (DMSO-d₆): δ 0.88 (d, 6H), 2.17-2.22 (m, 1H), 3.77 (s, 3H), 3.82 (s, 3H), 4.29 (d, 2H), 6.63 (dd, 1H, J=2.44 and 8.39 Hz) 6.72 (s, 1H), 7.02-7.06 (m, 1H), 7.16-7.20 (m, 1H), 7.37-7.39 (m, 2H).

[0886] MS (ESI) m/z 329 [M+H]+.

[0887] Step 2: 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)benzene-1,3-diol

[0888] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-7-fluoro-1-isobutyl-1H-indazole (0.177 g, 0.5 mmol), boron tribromide (0.275 mL, 2.90 mmol) and 1.0 mL of cyclohexene to give the product (0.085 g) as a white solid.

[0889]¹H NMR (DMSO-d₆): δ 0.87 (s, 6H), 2.19-2.21 (m, 1H), 4.31 (d, 2H), 6.39 (dd, 1H, J=2.44 and 8.39 Hz), 6.43 (s, 1H), 7.08-7.12 (m, 1H), 7.22-7.26 (m, 1H), 7.52 (d, 1H), 7.75 (d, 1H), 9.58 (s, 1H), 10.08 (s, 1H).

[0890] MS (ESI) m/z 301 [M+H]+.

Example 95 4-(7-fluoro-2-isobutyl-2H-indazol-3-yl)benzene-1,3-diol

[0891] Step 1: 3-(2,4-dimethoxyphenyl)-7-fluoro-2-isobutyl-2H-indazole

[0892] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 1-iodo-2-methylpropane (0.23 mL, 2.00 mmol) to give the title compound (0.046 g) as a white solid.

[0893]¹H NMR (DMSO-d₆): δ 0.65 (d, 3H), 0.76 (d, 3H), 2.18-2.23 (m, 1H), 3.74 (s, 3H), 3.86 (s, 3H), 3.88-3.94 (m, 1H), 4.09-4.13 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.39 Hz), 6.78 (s, 1H), 6.90-6.94 (m, 1H), 6.98-7.02 (m, 1H), 7.11 (d, 1H), 7.28 (d, 1H).

[0894] MS (ESI) m/z 329 [M+H]+.

[0895] Step 2: 4-(7-fluoro-2-isobutyl-2H-indazol-3-yl)benzene-1,3-diol

[0896] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-7-fluoro-2-isobutyl-2H-indazole (0.036 g, 0.1 mmol), boron tribromide (0.083 mL, 0.9 mmol) and 1.0 mL of cyclohexene to give the product (0.024 g) as a white solid.

[0897]¹H NMR (DMSO-d₆): δ 0.64-0.65 (m, 3H), 0.75-0.77 (m, 3H), 2.16-2.35 (m, H), 4.07-4.08 (m, 2H), 4.40 (dd, 1H, J=2.29 and 8.39 Hz), 6.49 (s, 1H), 6.88-6.92 (m, 1H), 6.96-7.01 (m, 1H), 7.04 (d, 1H), 7.10-7.15 (m, 1H), 6.96 (s, 1H), 9.80 (s, 1H).

[0898] MS (ESI) m/z 301 [M+H]+.

Example 96 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)-3-methylphenol

[0899] Step 1: 7-fluoro-1-isobutyl-3-(4-methoxy-2-methylphenyl)-1H-indazole

[0900] Prepared according to Method D step B from 7-fluoro-3-(4-methoxy-2-methylphenyl)-1H-indazole (0.300 g, 1.20 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and 1-iodo-2-methylpropane (0.23 mL, 2.00 mmol) to give the title compound (0.374 g) as a white solid.

[0901]¹H NMR (DMSO-d₆): δ 0.88 (d, 6H), 2.19-2.24 (m, H), 2.30 (s, 3H), 3.80 (s, 3H), 4.32 (d, 2H), 6.89 (dd, 1H, J=2.59 and 8.39 Hz), 6.95 (s, 1H), 7.07-7.11 (m, 1), 7.21-7.25)m, 1H), 7.38 (d, 2H).

[0902] MS (ESI) m/z313 [M+H]+.

[0903] Step 2: 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)-3-methylphenol

[0904] Prepared according to Method D step C from 7-fluoro-1-isobutyl-3-(4-methoxy-2-methyl-phenyl)-1H-indazole (0.364 g, 1.2 mmol), boron tribromide (0.450 mL, 4.6 mmol) and 1.0 mL of cyclohexene to give the product (0.344 g) as a white solid.

[0905] mp 126-128° C.;

[0906]¹H NMR (DMSO-d₆): δ 0.87 (d, 6H), 1.98-2.07(m, 1H), 2.23 (s, 1H), 4.30 (d, 2H), 6.71 (dd, 1H, J=2.59 and 8.24 Hz), 6.76 (s, 1H), 7.06-7.10 (m, 1H), 7.20-7.24 (m, 1H), 7.25 (d, 1H), 7.37 (d, 1H), 9.54 (s, 1H).

[0907] MS (ESI) m/z 299 [M+H]+.

Example 97 4-(2-allyl-7-fluoro-2H-indazol-3-yl)benzene-1,3-diol

[0908] Step 1: 2-allyl-3-(2,4-dimethoxyphenyl)-7-fluoro-2H-indazole

[0909] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and allyl bromide (0.173 mL, 2.00 mmol) to give the title compound (0.067 g) as a white solid.

[0910]¹H NMR (DMSO-d₆): δ 3.75 (s, 3H), 3.85 (s, 3H), 4.82-4.87 (m, 2H), 4.98 (d, 1H), 5.12 (dd, 1H, J=1.37 and 10.23 Hz), 5.92-6.00 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.39 Hz) 6.78 (s, 1H), 6.91-6.95 (m, 1H), 7.00-7.04 (m, 1H), 7.14 (d, 1H), 7.27 (d, 1H).

[0911] MS (ESI) m/z 313 [M+H]+.

[0912] Step 2: 4-(2-allyl-7-fluoro-2H-indazol-3-yl)benzene-1,3-diol

[0913] Prepared according to Method D step C from 2-allyl-3-(2,4-dimethoxyphenyl)-7-fluoro-2H-indazole (0.057 g, 0.2 mmol), boron tribromide (0.150 mL, 1.6 mmol) and 1.0 mL of cyclohexene to give the product (0.023 g) as a white solid.

[0914] mp 69-70° C.;

[0915]¹H NMR (DMSO-d₆): δ 4.81 (dd, 1H, J=1.68 and 6.87 Hz), 4.90-5.01 (m, 2H), 5.03-5.14 (m, 1H), 5.93-6.02 (m, 1H), 6.38-6.45 (m, 2H), 6.91-7.07 (m, 3H), 7.17 (d, 1H), 9.71 (s, 1H), 9.88 (s, 1H).

[0916] MS (ESI) m/z 285 [M+H]+.

Example 98 4-(1-allyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol

[0917] Step 1: 1-allyl-3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole

[0918] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and allyl bromide(0.173 mL, 2.00 mmol) to give the title compound (0.198 g) as a white solid.

[0919]¹H NMR (DMSO-d₆): δ 3.77 (s, 3H), 3.83 (s, 3H), 5.00 (dd, 1H, J=1.22 and 17.10 Hz), 5.12 (s, 2H), 5.15 (dd, 1H, J=1.37 and 10.23 Hz), 6.04-6.10 (m, 1H), 6.64 (dd, 1H, J=2.44 and 8.55 Hz), 6.72 (s, 1H), 7.04-7.08 (m, 1H), 7.17-7.21 (m, 1H), 7.39 (d, 2H).

[0920] MS (ESI) m/z313 [M+H]+.

[0921] Step 2: 4-(1-allyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol

[0922] Prepared according to Method D step C from 1-allyl-3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.187 g, 0.6 mmol), boron tribromide (0.362 mL, 3.80 mmol) and 1.0 mL of cyclohexene to give the product (0.157 g) as a white solid.

[0923]¹H NMR (DMSO-d₆): δ 4.99 (dd, 1H, J=1.37 and 17.1), 5.12 (d, 2H), 5.16 (dd, 1H, J=1.37 and 10.23 Hz), 6.04-6.12 (m, 1H), 6.39 (dd, 1H, J=2.44 and 8.39 Hz), 6.43 (s, 1H), 7.09-7.13 (m, 1H), 7.23-7.27 (ml H), 7.51 (d, 1H), 7.75 (d, 1H), 9.59 (broad s, 1H), 10.03 (broad s, 1H);

[0924] MS (ESI) m/z 285 [M+H]+.

Example 99 4-(7-fluoro-1-propyl-1H-indazol-3-yl)benzene-1,3-diol

[0925] Step 1: 3-(2,4-dimethoxyphenyl)-7-fluoro-1-propyl-1H-indazole

[0926] Prepared according to Method D step B from 3-(2,4-dimethoxyphenyl)-7-fluoro-1H-indazole (0.300 g, 1.10 mmol), sodium hydride (60% in oil, 0.058 g, 1.50 mmol) and iodopropane (0.195 mL, 2.00 mmol) to give the title compound (0.343 g) as a white solid.

[0927]¹H NMR (DMSO-d₆): δ 0.72 (t, 3H), 1.78-1.85 (m, 2H), 3.75 (s, 3H), 3.86 (s, 3H), 4.08-4.12 (m, 1H), 4.16-4.19 (m, 1H), 6.72 (dd, 1H, J=2.44 and 8.39 Hz), 6.78 (s, 1H), 6.90-6.94 (m, 1H), 6.98-7.02 (m, 1H), 7.11 (d, 1H), 7.28 (d, 1H).

[0928] MS (ESI) m/z315 [M+H]+.

[0929] Step 2: 4-(7-fluoro-1-propyl-1H-indazol-3-yl)benzene-13-diol

[0930] Prepared according to Method D step C from 3-(2,4-dimethoxyphenyl)-7-fluoro-1-propyl-1H-indazole (0.332 g, 1.1 mmol), boron tribromide (0.830 mL, 8.8 mmol) and 1.0 mL of cyclohexene to give the product (0.303 g) as a white solid.

[0931]¹H NMR (DMSO-d₆): δ 0.85 (t, 3H), 1.84-1.89 (m, 2H), 4.47 (t, 2H), 6.39 (dd, 1H, J=2.44 and 8.39 Hz), 6.43 (s, 1H), 7.08-7.12 (m, 1H), 7.23-7.27(m, 1H), 7.52 (d, 1H), 7.75 (d, 1H), 9.59 (broad s, 1H), 10.07 (broad s, 1H).

[0932] MS (ESI) m/z 285 [M−H]−.

Example 100 7-chloro-3-(4-methoxyphenyl)-1-thien-3-yl-1H-indazole

[0933] A mixture of -chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (1.0 g, 3.93 mmol), 3-thienylboronic acid (1.0 g, 7.8 mmol), anhydrous copper(II)acetate (0.71 g, 3.9 mmol) and diisopropylethylamine (1.36 mL, 7.8 mmol) in 50 mL CH₂Cl₂ was stirred at ambient temperature overnight. The reaction mixture was preabsorbed on silica gel and the absorbed solid purified by flash chromatography (hexane, EtOAc: 3:1) to give the product (0.15 g) as a white solid,

[0934] mp 111° C.

[0935]¹H NMR (DMSO-d₆): δ 3.83 (s, 3H), 7.11 (d, 2H), 7.29 (t, 1H), 7.37 (m, 1H), 7.55 (d, 1H), 7.68 (m, 1H), 7.90 (d, 2H), 8.08 (d, 1H).

[0936] MS (ESI) m/z 341 [M+H]+.

[0937] Anal. calcd for C₁₈H₁₃ClN₂OS: C:63.43 H:3.84 N:8.22 Found: C:63.29 H:3.85 N:7.88.

Example 101 4-(7-chloro-1-thien-3-yl-1H-indazol-3-yl)phenol

[0938] Prepared according to Method D step C from -chloro-3-(4-methoxyphenyl)-1-thien-3-yl-1H-indazole (0.19 g, 0.56 mmol), boron tribromide (0.021 mL, 2.25 mmol) and 1.0 mL of cyclohexene to give the product (0.045 g) as a white solid.

[0939]¹H NMR (DMSO-d₆): δ 6.93 (d 2H), 7.27 (t, 1H), 7.365 (dd, 1H), 7.54 (d, 1H), 7.67 (dd, 1H), 7.78 (d, 2H), 7.86 (dd, 1H), 8.06 (d, 1H), 9.75 (s, 1H).

[0940] MS (ESI) m/z 325 [M−H]−.

Example 102 methyl 3-(4-hydroxyphenyl)-2-isopropyl-2H-indazol-7-carboxylate

[0941] Step 1: 2-isopropyl 3-(4-methoxyphenyl)-7-trifluoromethyl-2H-indazole

[0942] Prepared according to Method D step B from 3-(4-methoxyphenyl)-7-trifluoromethyl-1H-indazole (1.0 g, 3.4 mmol), sodium hydride (60% in oil, 0.136 g, 3.4 mmol) and 2-iodopropane (0.34 mL, 3.4 mmol) to give the title compound (0.27 g) as a white solid.

[0943]¹H NMR (DMSO-d₆): δ 1.48 (d, 6H), 3.82 (s, 3H), 4.81 (m, 1H), 7.14 (m, 3H), 7.48 (t, 1H), 2H), 7.63 (dd, 2H).

[0944] Step 2: methyl 3-(4-hydroxyphenyl)-2-isopropyl-2H-indazole-7-carboxylate

[0945] Prepared according to Method D step C from 2-isopropyl-3-(4-methoxyphenyl)-7-trifluoromethyl-2H-indazole (0.27 g, 0.81 mmol), boron tribromide (0.31 mL, 3.2 mmol) and 1.0 mL of cyclohexene. The reaction mixture was quenched with methanol and allowed to stand at ambient temperature overnight. The reaction mixture was preabsorbed on silica gel and purified by flash chromatography (hexane-EtOAc, 2:1) to give the product (0.13 g) as an buff colored solid.

[0946] mp 195-196° C.;

[0947]¹H NMR (DMSO-d₆): δ 1.52 (d, 6H), 3.89 (s, 3H), 4.84 (m, 1H), 6.99 (d, 2H), 7.10 (t, 1H), 7.36 (d, 2H), 7.71 (d, 1H), 7.93 (d, 1H), 9.93 (s, 1H).

[0948] MS (APCI) m/z 311 [M+H]+.

Example 103 4-[3-(4-hydroxyphenyl)-1-propyl-1H-indazol-7-yl]phenol

[0949] Step 1: 7-(4-methoxyphenyl)-3-(4-methoxyphenyl)-1-propyl-1H-indazole To a stirred solution of 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.10 g, 0.33 mmol) in anhydrous dioxane (3 mL) was added tris(dibenzylideneacetone)dipalladium(0) (0.004 g, 0.0043 mmol) and 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene HCl (0.0035 g, 0.0099 mmol). 4-Methoxyphenylmagnesium bromide (1.2 mL, 0.5M in diethyl ether) was added and the reaction mixture degassed. The reaction was heated to 80° C. for 18 hours. The reaction mixture was partitoned with 1N HCl and ethyl acetate. The organic layer was washed with water and brine. After drying (Na₂SO₄), the organic phase was concentrated in vacuo to yield crude title compound. The oil was purified by flash chromatography (silica gel, hexane/ethyl acetate, 5:1) to provide the title compound as a white solid (0.028 g).

[0950]¹H NMR (DMSO-d₆): δ 0.487 (t, 3H), 1.43(m, 2H), 3.82 (s, 6H), 3.89 (m, 2H), 7.08 (m, 4H), 7.17 (m, 1H), 7.25 (m, 2H), 7.40 (d, 2H), 7.86 (d, 2H), 7.99 (d, 1H).

[0951] MS (ESI) m/z 373 [M+H]+.

[0952] Step 2: 4-[3-(4-hydroxyphenyl)-1-propyl-1H-indazol-7-yl]phenol

[0953] Prepared according to Method D step C from 7-(4-methoxyphenyl)-3-(4-methoxy-phenyl)-1-propyl-1H-indazole (0.04 g, 0.11 mmol), boron tribromide (0.04 mL, 0.43 mmol) and 0.1 mL of cyclohexene to give the product (0.029 g) as an light yellow solid.

[0954]¹H NMR (DMSO-d₆): δ 0.492 (t, 3H), 1.42 (m, 2H), 3.89 (m, 2H), 6.89 (m, 4H), 7.14 ( )m, 1H), 7.19 (m, 1H), 7.25 (d, 2H), 7.73 (d, 2H), 7.93 (d, 1H), 9.60 (s, 1H) 9.634 (s, 1H).

[0955] MS (ESI) m/z 343 [M−H]−.

Example 104

[0956] 4-[7-(4-Fluorophenyl)-1-propyl-1H-indazol-3-yl]phenol

[0957] Step 1: 7-(4-Fluorophenyl)-3-(4-methoxyphenyl)-1-propyl-1H-indazole To a stirred solution of 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.247 g, 0.82 mmol) in anhydrous dioxane (6 mL) was added tris(dibenzylideneacetone)-dipalladium(0) (0.015 g, 0.016 mmol) and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene HCl (0.014 g, 0.033 mmol). 4-Fluorophenylmagnesium bromide (0.74 mL, 1.48 mmol, 2M in diethyl ether) was added and the reaction heated to 80° C. for 18 hours. After this time an additional 50% of reagents were added and the reaction heated for an additional 18 hours. The reaction mixture was treated with 1N aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer washed with water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (5/1) to provide the title compound as a white solid (0.139 g, 0.39 mmol, 47%).

[0958] Mp 110-111° C.;

[0959]¹H NMR (500 MHz, DMSO-d₆) δ 0.49 (t, 3H, J=7.3 Hz), 1.42 (q, 2H, J=14.6, 7.4 Hz), 3.82 (s, 3H), 3.86 (t, 3H, J=7.3 Hz), 7.08 (d, 2H, J=8.2 Hz), 7.20-7.27 (m, 2H), 7.55 (d, 2H, J=6.0 Hz), 7.36 (t, 2H, J=8.5 Hz), 7.86 (d, 2H, J=8.4 Hz), 8.02 (d, 1H, J=8.4 Hz).

[0960] MS (ESI) m/z 361 [M+H]+.

[0961] Anal. calcd for C₂₃ H₂₁FN₂O: C:76.65 H:5.87 N:7.77 Found: C:76.37 H:5.82 N:7.90.

[0962] Step 2: 4-[7-(4-Fluorophenyl)-1-propyl-1H-indazol-3-yl]phenol

[0963] Prepared according to Method D step C from 7-(4-Fluorophenyl)-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.125 g, 0.35 mmol), BBr₃ (0.066 mL, 0.7 mmol) to give the title compound as a white solid (0.087 g, 0.25 mmol, 72%).

[0964] mp 201-202° C.;

[0965]¹H NMR (DMSO-d₆): δ 0.49 (t, 3H, J=7.4 Hz), 1.42 (m, 2H, J=14.9, 7.4 Hz), 3.85 (t, 3H, J=7.5 Hz), 6.90 (d, 2H, J=8.6 Hz), 7.18-7.25 (m, 2H), 7.34 (t, 2H, J=8.4 Hz), 7.53-7.56 (m, 2H), 7.86 (d, 2H, J=8.6 Hz), 8.00 (q, 1H, J=8.0, 1.0 Hz).

[0966] MS (ESI) m/z 347 [M+H]+.

[0967] Anal. calcd for C₂₂ H₁₉FN₂O.0.15 H₂O: C:75.69 H:5.57 N:8.02 Found: C:75.49 H:5.41 N:8.02.

Example 105 4-(7-Morpholin-4-yl-1-propyl-1H-indazol-3-yl)phenol

[0968] Step 1: 3-(4-Methoxyphenyl)-7-morpholin-4-yl-1-propyl-1H-indazole To a stirred solution of 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.218 g, 0.73 mmol) in anhydrous degassed dimethoxyethane (3 mL) was added morpholine (0.076 mL, 0.84 mmol) and sodium t-butoxide (0.098 g, 1.02 mmol). Tris(dibenzylidene-acetone)dipalladium(0) (0.010 g, 0.011 mmol) and 2-dicyclohexyl phosphino-2′-(N,N-dimethylamino)biphenyl (0.09 g, 0.23 mmol) were added and the reaction refluxed for 90 minutes. The reaction was cooled to room temperature and water added. The mixture was extracted with ethyl acetate and the organic layer washed with water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (5/1 to 3/1) to provide the title compound as a white solid (0.157 g, 0.45 mmol, 63%). An analytical sample was crystallized from hexane.

[0969] mp 86-87° C.;

[0970]¹H NMR (DMSO-d₆): δ 0.86 (t, 3H, J=7.3 Hz), 1.82 (m, 2H, J=14.5, 7.2 Hz), 2.93-3.03 (m, 4H), 3.70-3.74 (m, 2H), 3.81 (s, 3H), 3.91-3.93 (m, 2H), 4.63 (t, 2H, J=7.1 Hz), 7.06 (d, 2H, J=8.1 Hz), 7.18-7.25 (m, 2H), 7.72 (d, 1H, J=8.1 Hz), 7.82 (t, 2H, J=8.1 Hz),

[0971] MS (ESI) m/z 352 [M+H]+.

[0972] Anal. calcd for C₂₁H₂₅N₃O₂: C:71.77 H:7.17 N:11.96 Found: C:71.43 H:7.31 N:11.95.

[0973] Step 2: 4-(7-Morpholin-4-yl-1-propyl-1H-indazol-3-yl)phenol

[0974] Prepared according to Method D step C from 3-(4-Methoxyphenyl)-7-morpholin-4-yl-1-propyl-1H-indazole (0.140 g, 0.4 mmol), BBr₃ (0.076 mL, 0.8 mmol) to give title compound as a white solid which was recrystallized from ethyl acetate and hexane (0.05 g, 0.15 mmol, 37%).

[0975] mp 187-188° C.;

[0976]¹H NMR (DMSO-d₆): δ 0.86 (t, 3H, J=7.4 Hz), 1.78-1.85 (m, 2H), 2.92-3.02 (m, 4H), 3.72 (t, 2H, J=10.6 Hz), 3.91 (d, 2H, J=10.7 Hz), 4.61 (t, 2H, J=7.3 Hz), 6.88 (d, 2H), J=8.7 Hz), 7.12 (t, 1H, J=7.7 Hz), 7.17 (t, 1H, J=6.9 Hz), 7.70 (m, 3H), 9.60 (bd, 1H).

[0977] MS (ESI) m/z 336 [M−H]−.

[0978] Anal. calcd for C₂₀H₂₃N₃O₂.0.25 H₂O: C:70.26 H:6.93 N:12.29 Found: C:70.37 H:6.67 N:12.25.

Example 106 2-Chloro-4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol

[0979] Step 1 (3-Chloro-2-fluororhenyl)(3-chloro-4-methoxyphenyl)methanone

[0980] Prepared according to Method A step B from 3-chloro-2-fluoro-N-methoxy-N-methyl-benzamide (3.7 g, 17.0 mmol) and bromo(3-chloro-4-methoxyphenyl)magnesium (100 mL, 2M in diethyl ether). The title compound was obtained as a white solid (2.3 g, 7.69 mmol, 45%).

[0981] mp 130-131° C.;

[0982]¹H NMR (DMSO-d₆): δ 3.97 (s, 3H), 7.30 (d, 1H, J=8.7 Hz), 7.86 (t, 1H, J=7.9 Hz), 7.53 (m, 1H), 7.72 (q, 1H, J=8.7, 0.9 Hz), 7.84 (m, 2H).

[0983] Anal. calcd for C₁₄ H₉Cl₂FO₂: C:56.21 H:3.03 N:0.00 Found: C:55.99 H:2.81 N:0.01.

[0984] Step 2: 7-Chloro-3-(3-chloro-4-methoxyphenyl)-1H-indazole

[0985] Prepared according to Method D, Step A from (3-chloro-2-fluorophenyl)(3-chloro-4-methoxyphenyl)methanone (2.04 g, 6.82 mmol), hydrazine hydrate (2.5 mL), dimethylaminopyridine (0.97 g) and pyridine (12.5 mL). The title compound was obtained as a white solid and recrystallized from ethyl acetate/hexane (1.74 g, 5.94 mmol, 87%).

[0986] mp 198-199° C.;

[0987]¹H NMR (DMSO-d₆): δ 3.93 (s, 3H), 7.21 (t, 1H, J=7.8 Hz), 7.30 (d, 1H, J=8.6Hz), 7.50 (d, 1H, J=7.3 Hz), 7.92 (dd, 1H, J=8.6, 2.1 Hz), 7.96 (d, 1H, J=1.7Hz), 8.00 (d, 1H, J=8.2).

[0988] MS (ESI) m/z 293 [M+H]+.

[0989] Anal. calcd for C₁₄H₁₀Cl₂N₂O: C:57.36 H:3.44 N:9.56 Found: C:57.06 H:3.49 N:9.96.

[0990] Step 3: 7-chloro-3-(3-chloro-4-methoxyphenyl)-1-propyl-1H-indazole

[0991] Prepared according to Method D Step B from 7-chloro-3-(3-chloro-4-methoxyphenyl)-1H-indazole (1.0 g, 3.4 mmol), sodium hydride (0.15 g, 60% in oil) in DMF followed by propyl bromide (0.4 mL). The title compound was obtained as an oil (0.94 g, 2.8 mmol, 82%).

[0992]¹H NMR (DMSO-d₆): δ 0.89 (t, 3H, J=7.4 Hz), 1.87 (m, 2H), 4.71 (t, 2H, J=7.2 Hz), 7.21 (t, 1H, J=7.8 Hz), 7.29 (d, 1H, J=8.6 Hz), 7.50 (d, 1H, J=7.3 Hz), J=8.6,2.1 Hz), 7.90 (t, 1H, J=1.0 Hz), 7.99 (d, 1H, J=8.2);

[0993] MS (ESI) m/z 335 [M+H]+.

[0994] Anal. calcd for C₁₇H₁₆Cl2N₂O: C:60.91 H:4.81 N:8.36 Found: C:60.97 H:4.78 N:8.38.

[0995] Step 4: 2-Chloro-4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol

[0996] Prepared according to Method D step C from 7-Chloro-3-(3-chloro-4-methoxyphenyl)-1-propyl-1H-indazole (0.39 g, 1.18mmol), BBr₃ (0.11 mL, 1.17 mmol) to give the title compound as a white solid (0.24 g, 0.75 mmol, 64%).

[0997] mp 145-146° C.;

[0998]¹H NMR (DMSO-d₆): δ 0.88 (t, 3H, J=7.4 Hz), 1.88 (m, 2H), 4.70 (t, 2H, J=7.3Hz), 7.11 (d, 1H, J=8.4 Hz), 7.19 (dd, 1H, J=8.2,7.5 Hz), 7.51 (dd, 1H, J=7.3 Hz and 0.9 Hz), 7.71 (dd, 1H, J=8.4 Hz and 2.1 Hz), 7.81 (t, 1H, J=1.1 Hz), 7.96 (dd, 1H, J=8.1 Hz and 0.8 Hz), 10.48 (bd, 1H).

[0999] MS (ESI) m/z 321 [M+H]+.

[1000] Anal. calcd for C₁₆H₁₄Cl₂N₂O: C:59.83 H:4.39 N:8.72 Found: C:59.93 H:4.21 N:8.

Example 107 4-(7-Chloro-1-propyl-1H-indazol-3-yl)-2-fluorophenyl 3,3-dimethylbutanoate

[1001] Step 1: (3-chloro-2-fluorophenyl)(3-fluoro-4-methoxyphenyl)methanone

[1002] Prepared according to Method A step B from 3-chloro-2-fluoro-N-methoxy-N-methylbenzamide (4.0 g, 18.4 mmol) and bromo(3-fluoro-4-methoxyphenyl)magnesium (100 mL, 2M in diethyl ether). The title compound was obtained as a white solid (1.65 g, 5.85 mmol, 32%).

[1003] mp 103-104° C.;

[1004]¹H NMR (DMSO-d₆): δ 3.94 (s, 3H), 7.31 (t, 1H, J=8.4 Hz), 7.39 (t, 1H, J=7.8 Hz), 7.51 (t, 1H, J=6.9 Hz), 7.56 (d, 1H, J=8.6 Hz), 7.65 (d, 1H, J=11.9 Hz), 7.83 (t, 1H, J=7.6 Hz).

[1005] MS (EI) m/z 282;

[1006] Anal. calcd for C₁₄ H₉ClF₂O₂: C:59.49 H:3.21 N:0.00 Found: C:59.12 H:2.93 N:0.04.

[1007] Step 2: 7-Chloro-3-(3-fluoro-4-methoxyphenyl)-1H-indazole

[1008] Prepared according to Method D, Step A from (3-chloro-2-fluorophenyl)(3-fluoro-4-methoxyphenyl)methanone (0.80 g, 2.83 mmol), hydrazine hydrate (1 mL), dimethyl-aminopyridine (0.390 g) and pyridine (5 mL). The reaction mixture was combined with a previous batch at this stage and the title compound was obtained as a white solid and recrystallized from ethyl acetate/hexane (1.30 g, 4.79 mmol, 83%).

[1009] mp 195-196° C.;

[1010]¹H NMR (DMSO-d₆): δ 3.91 (s, 3H), 7.20 (t, 1H, J=7.9 Hz), 7.31 (t, 1H, J=8.9 Hz), 7.50 (d, 1H, J=7.3 Hz), 7.75 (m, 2H), 8.00 (d, 1H, J=8.1 Hz), 13.71 (s, 1H).

[1011] MS (ESI) m/z 275 [M−H]−.

[1012] Anal. calcd for C₁₄ H₁₀ClFN₂O: C:60.77 H:3.64 N:10.12 Found: C:60.42 H:3.56 N:10.12.

[1013] Step 3: 7-Chloro-3-(3-fluoro-4-methoxyyhenyl)-1-propyl-1H-indazole

[1014] Prepared according to Method D Step B from 7-Chloro-3-(3-fluoro-4-methoxyphenyl)-1H-indazole (1.0 g, 3.6 mmol), sodium hydride (0.16 g, 60% in oil) in DMF followed by propyl bromide (0.42 mL). The title compound was obtained as an oil (0.86 g, 2.7 mmol, 75%).

[1015] mp 58-59° C.;

[1016]¹H NMR (DMSO-d₆): δ 0.89 (t, 3H, J=7.9 Hz), 1.88 (m, 2H), 3.90 (s, 3H), 4.71 (t, 2H, J=7.2 Hz), 7.20 (t, 1H, J=7.8 Hz), 7.31 (t, 1H, J=8.9 Hz), 7.52 (d, 1H, J=7.5 Hz), 7.70 (m, 2H), 8.01 (d, 1H, J=8.1 Hz).

[1017] MS (ESI) m/z 319 [M+H]+.

[1018] Anal. calcd for C₁₇ H₁₆ClFN₂O: C:64.05 H:5.06 N:8.79 Found: C:63.85 H:4.75 N:8.84.

[1019] Step 4: 4-(7-Chloro-1-propyl-1H-indazol-3-yl)-2-fluorophenol

[1020] Prepared according to Method D step C from 7-Chloro-3-(3-fluoro-4-methoxyphenyl)-1-propyl-1H-indazole (0.26 g, 0.82 mmol), BBr₃ (0.15 mL, 1.63 mmol) to give the title compound as a white solid (0.12 g, 0.39 mmol, 48%).

[1021] mp 134-135° C.;

[1022]¹H NMR (DMSO-d₆): δ 0.88 (t, 3H, J=7.4 Hz), 1.86 (m, 2H), 4.70 (t, 2H, J=7.3 Hz), 7.09 (t, 1H, J=8.8 Hz), 7.18 (t, 1H, J=7.9 Hz), 7.50 (d, 1H, J=7.2 Hz), 7.56 (d, 1H, J=8.4 Hz), 7.61 (dd, 1H, J=12.4, 2.0 Hz), 8.01 (d, 1H, J=8.2 Hz), 10.17 (bd, 1H.

[1023] MS (ESI) m/z 305 [M+H]+.

[1024] Anal. calcd for C₁₆H₁₄ClFN₂O: C:63.06 H:4.63 N:9.19 Found: C:62.76 H:4.42 N:9.22.

[1025] Step 5:-4-(7-Chloro-1-propyl-1H-indazol-3-yl)-2-fluorophenyl 3,3-dimethylbutanoate To a solution of 4-(7-chloro-1-propyl-1H-indazol-3-yl)-2-fluorophenol (0.10 g, 0.33 mmol) in dichloromethane (20 mL) at −78° C. was added diisopropylethylamine (0.70 mL, 0.41 mmol), 3,3-dimethylbutanoyl chloride (0.05 mL, 0.35 mmol) and catalytic amount of 4-(dimethylamino)pyridine. The reaction was stirred at this temperature for 30 minutes. The mixture was diluted with dichloromethane and the organic layer washed with 1n hydrochloric acid solution, water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (5/1) to provide the title compound as a white solid (0.11 g, 0.27 mmol, 83%).

[1026] mp 58-59° C.;

[1027]¹H NMR (DMSO-d₆): δ 1.10 (s, 9H), 4.74 (t, 2H, J=7.2 Hz), 7.23 (t, 1H, J=7.9Hz), 7.42 (t, 1H, J=8.2 Hz), 7.55 (d, 1H, J=7.5 Hz), 7.80 (d, 1H, J=8.4 Hz), 7.85 (dd, 1H, J=11.4, 1.8 Hz), 8.07 (d, 1H, J=8.1 Hz).

[1028] MS (ESI) m/z 403 [M+H]+.

[1029] Anal. calcd for C₂₂ H₂₄ClFN₂O₂: C:65.59 H:6.00 N:6.95 Found: C:65.36 H:6.14 N:6.91.

Example 108 (7-Chloro-1-cyclopentyl-1H-indazol-3-yl)-2-fluorophenol

[1030] Step 1: 7-Chloro-1-cyclopentyl-3-(3-fluoro-4-methoxyphenyl)-1H-indazole

[1031] Prepared according to Method D Step B from 7-chloro-3-(3-fluoro-4-methoxyphenyl)-1H-indazole (0.17 g, 0.61 mmol), sodium hydride (0.03 g, 60% in oil) in DMF followed by cyclopropyl bromide (0.07 mL). The title compound was obtained as a white solid (0.13 g, 0.38 mmol, 63%). The material was used directly in Step 2.

[1032] Step 2: (7-Chloro-1-cyclopentyl-1H-indazol-3-yl)-2-fluorophenol

[1033] Prepared according to Method D step C from 7-Chloro-1-cyclopentyl-3-(3-fluoro-4-methoxyphenyl)-1H-indazole (0.13 g, 0.38 mmol) and BBr₃ (0.07 mL, 0.76 mmol) to give the title compound as a white solid (0.072 g, 0.22 mmol, 58%).

[1034] mp 150-151° C.;

[1035]¹H NMR (DMSO-d₆): δ 1.70 (m, 2H), 1.90 (m, 2H), 2.13 (m, 4H), 5.82 (dd, 1H, J=13.7, 6.8 Hz), 7.10 (m, 1H), 7.18 (t, 1H, J=7.9 Hz), 7.49 (dd, 1H, J=7.4, 0.7 Hz), 7.56 (dd, 1H, J=8.3, 1.3 Hz), 7.61 (dd, 1H, J=12.3, 1.9 Hz), 7.99 (d, 1H, J=7.8 Hz), 10.11 (s, 1H).

[1036] MS (ESI) m/z 329 [M−H]−.

[1037] Anal. calcd for C₁₈H₁₆ClFN₂O: C:65.36 H:4.88 N:8.47 Found: C:65.19 H:4.66 N:8.12.

Example 109 2-Fluoro-4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol

[1038] Step 1: 3-(3-Fluoro-4-methoxyphenyl)-7-phenyl-1-propyl-1H-indazole To a stirred solution of 7-chloro-3-(3-fluoro-4-methoxyphenyl)-1-propyl-1H-indazole (0.38 g, 1.18 mmol) in anhydrous dioxane (6 mL) was added tris(dibenzylideneacetone)-dipalladium(0) (0.022 g, 0.024 mmol) and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene HCl (0.02 g, 0.047 mmol). Phenylmagnesium bromide (0.71 mL, 1.40 mmol, 2M in diethyl ether) was added and the reaction heated to 80° C. for 18 hours. The reaction mixture was treated with 1 N hydrochloric acid solution and extracted with ethyl acetate. The organic layer washed with water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (3/1) to provide the title compound as a white solid (0.28 g, 0.78 mmol, 66%). This material was used directly in step 2.

[1039] Step 2: 2-Fluoro-4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol

[1040] Prepared according to Method D step C from 3-(3-Fluoro-4-methoxyphenyl)-7-phenyl-1-propyl-1H-indazole (0.28 g, 0.78 mmol), BBr₃ (0.073 mL, 0.78 mmol) gave title compound as a white solid (0.156 g, 0.45 mmol, 58%).

[1041] mp 177-178° C.;

[1042]¹H NMR (DMSO-d₆): δ 0.45 (t, 3H, J=7.4 Hz), 1.41 (m, 2H), 3.85 (t, 2H, J=7.5Hz), 7.10 (t, 1H, J=8.9 Hz), 7.18 (t, 1H, J=7.9 Hz), 7.48-7.52 (m, 5H), 7.54-7.65 (m, 2H), 8.02 (dd, 1H, J=7.9, 0.9 Hz), 10.05 (bd, 1H).

[1043] MS (ESI) m/z 347 [M+H]+.

[1044] Anal. calcd for C₂₂H₁₉FN₂O.0.15 CHCl₃: C:73.03 H:5.30 N:7.69 Found: C:73.16 H:4.99 N:7.89.

Example 110 4-(7-phenyl-2-propyl-2H-indazol-3-yl)phenol

[1045] Step 1: 3-(4-methoxyphenyl)-7-phenyl-2-propyl-2H-indazole

[1046] To a stirred solution of 7-Chloro-3-(4-methoxyphenyl)-2-propyl-2H-indazole (0.200 g, 0.66 mmol) in anhydrous dioxane (6 mL) was added tris(dibenzylideneacetone)-dipalladium(0) (0.0128 g, 0.013 mmol) and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene.HCl (0.011 g, 0.07 mmol). Phenylmagnesium bromide (0.4 mL, 1.20 mmol, 3M in diethyl ether) was added and the reaction heated to 80° C. for 3 hours. After this time an additional equivalent of reagents was added and the reaction heated for an additional 18 hours. The reaction mixture was treated with 1N aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer washed with water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (5/1) to provide the title compound as a white solid (0.178 g, 0.52 mmol, 78%).

[1047] mp 128-129° C.;

[1048]¹H NMR (DMSO-d₆): δ ¹H NMR (DMSO-d₆): δ0.77 (t, 3H, J=7.4 Hz), 1.86 (q, 2H, J=7.3 Hz), 3.86 (s, 3H), 4.36 (t, 2H, J=7.6 Hz), 7.13 (t, 1H, J=6.9 Hz), 7.17 (d, 2H, J=6.8 Hz), 7.37 (t, 1H, J=7.3 Hz), 7.50 (m, 6H), 8.09 (d, 2H, J=7.8 Hz).

[1049] MS (ESI) m/z 343 [M+H]+.

[1050] Anal. calcd for C₂₃H₂₂N₂O: C:80.67 H:6.48 N:8.18 Found: C:80.99 H:6.33 N:8.28.

[1051] Step 2: 4-(7-phenyl-2-propyl-2H-indazol-3-yl)phenol To a solution of 3-(4-methoxyphenyl)-7-phenyl-2-propyl-2H-indazole (0.140 g, 0.43 mmol) in CH₂Cl₂ (5 mL) was added BBr₃ (0.081 mL, 0.865 mmol) at −78° C. The solution was stirred for 15 minutes and allowed to stand overnight in the refrigerator. The reaction was quenched with NH₄OH (10 mL) and extracted with CH₂Cl₂. The organic layer was washed with water and dried (MgSO₄). The reaction was purified by flash chromatography (5/1 hexane/ethyl Acetate) to give the title compound as a white solid (0.066 g, 0.15 mmol, 34%).

[1052] mp 207-208° C.;

[1053]¹H NMR (DMSO-d₆): δ 0.78 (t, 3H, J=7.3 Hz), 1.86 (q, 2H, J=7.3 Hz), 4.35 (t, 2H, J=7.2 Hz), 6.99 (d, 2H, J=8.7 Hz), 7.12 (t, 1H, 7.6 Hz), 7.45 (m, 7H), 8.09 (d, 2H, J=7.9 Hz), 9.90 (s, 1H).

[1054] MS (ESI) m/z 329 [M+H]+.

[1055] Anal. calcd for C₂₂H₂₀N₂O.0.10 H₂O: C:80.02 H:6.17 N:8.48 Found: C:79.73 H:6.08 N:8.62.

Example 111 4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol

[1056] Step 1: 3-(4-methoxyphenyl)-7-phenyl-1-propyl-1H-indazole

[1057] To a stirred solution of 7-chloro-3-(4-methoxyphenyl)-1-propyl-1H-indazole (0.600 g, 0.1.98 mmol) in anhydrous dioxane (8 mL) was added tris(dibenzylideneacetone)-dipalladium(0) (0.036 g, 0.04 mmol) and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene HCl (0.036 g, 0.08 mmol). Phenylmagnesium bromide (1.18 mL, 3.56 mmol, 3M in diethyl ether) was added and the reaction heated to 80° C. for 3 hours. After this time an additional equivalent of reagents was added and the reaction heated for an additional 18 hours. The reaction mixture was treated with 1N aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer washed with water and saturated aqueous sodium chloride solution. After drying over anhydrous magnesium sulfate, the organic phase was filtered and the filtrate evaporated in vacuo to yield crude title compound. The oil was purified by silica gel column chromatography eluting with hexane/ethyl acetate (5/1) to provide the title compound as a white solid (0.405 g, 1.18 mmol, 59%).

[1058] mp 58-59° C.;

[1059]¹H NMR (DMSO-d₆): δ 0.45 (t, 3H, J=7.3 Hz), 1.40 (q, 2H, J=7.3 Hz), 3.82 (m, 5H) 7.09 (d, 2H, J=8.8 Hz), 7.22 (m, 2H), 7.51 (m, 5H), 7.86 (d, 2H, J=8.7 Hz), 8.01 (d, 1H, J=7.5 Hz).

[1060] MS (ESI) m/z 343 [M+H]+.

[1061] Anal. calcd for C₂₃H₂₂N₂O.0.15 H₂O: C:80.04 H:6.51 N:8.12 Found: C:79.75 H:6.32 N:8.16.

[1062] Step 2: 4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol To a solution of 3-(4-methoxyphenyl)-7-phenyl-1-propyl-1H-indazole (0.375 g, 1.09 mmol) in CH₂Cl₂ (15 mL) was added BBr₃ (0.207 mL, 2.19 mmol) at −78° C. The solution was stirred for 15 minutes and allowed to stand overnight in the refrigerator. The reaction was quenched with NH₄OH (20 mL) and extracted with CH₂Cl₂. The organic layer was washed with water and dried (MgSO₄). The reaction was purified by flash chromatography (5/1 hexane/ethyl acetate) to give the title compound as a white solid (0.147 g, 0.45 mmol, 41%).

[1063] mp 171-172° C.;

[1064]¹H NMR (DMSO-d₆): 0.45 (t, 3H, J=7.3 Hz), 1.40 (q, 2H, J=7.3 Hz), 3.83 (t, 2H, J=7.5 Hz), 6.91 (d, 2H, J=8.7 Hz), 7.20 (m, 2H), 7.51 (m, 5H), 7.74 (d, 2H, J=8.7 Hz, 7.99 (d, 1H, J=7.5 Hz), 9.63 (s, 1H).

[1065] MS (ESI) m/z 329 [M+H]+.

[1066] Anal. calcd for C₂₂H₂₀N₂O.0.05 H₂O: C:80.24 H:6.15 N:8.51 Found: C:79.89 H:6.11 N:8.42.

General Method E 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenolic ester

[1067] To a stirred solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (1 equivalent) and diisopropylethyl amine (1 equivalent) in CH₂Cl₂ (0.2 molar) was added 1 equivalent of an acid chloride. The reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was diluted with additional CH₂Cl₂ and washed with 1 N HCl. The organic phase was filtered through a plug of silica gel and concentrated to an oil. The crystalline ester was obtained with the appropriate solvent

Example 112 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl pivalate

[1068] Prepared according to Method E from 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), pivaloyl chloride (0.148 mL, 1.2 mmol) and N,N-diisopropylethyl-amine (0.21 mL, 1.2 mmol) to give 0.31 g of the title compound as a white solid,

[1069] mp 105° C.

[1070]¹H NMR (DMSO-d₆): δ 1.328 (s, 9H), 1.715 (m, 2H), 1.895 (m, 2H), 2.15 (m, 4H), 5.299 (m, 1H), 7.19 (m, 1H), 7.25 (d, 2H), 7.28 (m, 1H), 7.86 (d, 1H), 7.96 (d, 2H).

[1071] MS (ESI) m/z 381 [M+H]+.

Example 113 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl 3,3-dimethylbutanoate

[1072] Prepared according to Method E from 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), 3,3-dimethylbutanoyl chloride (0.167 mL, 1.2 mmol) and N,N-diisopropylethylamine (0.21 mL, 1.2 mmol) to give 0.347 g of the title compound as a white solid, mp 74-75° C.;

[1073]¹H NMR (DMSO-d₆): δ 1.103 (s, 9H), 1.718 (m, 2H), 1.897 (m, 2H), 2.157 (m, 4H), 2.5(s, 2H), 5.30 (m, 1H), 7.19 (m, 1H), 7.25 (d, 2H), 7.28 (m, 1H), 7.86 (d, 1H), 7.97 (d, 2H.

[1074] MS (ESI) m/z 395 [M+H]+.

Example 114 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl acetate

[1075] Prepared according to Method E from 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), acetyl chloride (0.086 mL, 1.2 mmol) and N,N-diisopropylethylamine (0.21 mL, 1.2 mmol) to give 0.31 g to the title compound as a white solid,

[1076] mp 90-91° C.;

[1077]¹H NMR (DMSO-d₆): δ 1.714 (m, 2H), 1.89 (m, 2H), 2.15 (m, 4H), 2.30 (s, 3H), 5.297 (m, 1H), 7.188 (m, 1H), 7.28 (m, 3H), 7.86 (d, 1H), 7.97 (d, 2H).

[1078] MS (ESI) m/z 339 [M+H]+.

Example 115 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl propionate

[1079] Prepared according to Method E from 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), propanoyl chloride (0.105 mL, 1.2 mmol) and N,N-diisopropylethylamine (0.21 mL, 1.2 mmol) to give 0.284 g to the title compound as a white solid, mp 60-61° C.;

[1080]¹H NMR (DMSO-d₆): δ 1.154 (t, 3H), 1.712 (m, 2H), 1.892 (m, 2H), 2.15 (m, 4H), 2.63 (q, 2H), 5.298 (m, 1H), 7.19 (m, 1H), 7.27 (m, 3H), 7.86 (d, 1H), 7.96 (d, 2H

[1081] MS (ESI) m/z 353 [M+H]+.

Example 116 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl N-(tert-butoxycarbonyl)glycylglycinate

[1082] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), N-(tert-butoxycarbonyl) glycylglycine (0.232 g, 1.0 mmol), N,N-dicylohexylcarbodiimide (0.206 g, 1.0 mmol) and DMAP (0.122 g, 1.0 mmol) in 10 mL of CH₂Cl₂ was stirred overnight at ambient temperature. The reaction mixture was diluted with CH₂Cl₂ and filtered through a plug of silica gel. The gel was rinsed with additional CH₂Cl₂. The combined filtrates were concentrated in vacuo to give 0.35 g to the title compound as a white solid, mp 103-104° C.;

[1083]¹H NMR (DMSO-d₆): δ 1.368 (s, 9H), 1.716 (m, 2H), 1.895 (m, 2H), 2.14 (m, 4H), 3.62 (d, 2H), 4.15 (d, 2H), 5.30 (m, 1H), 7.06 (m, 1H), 7.19 (m, 1H), 7.27 (m, 3H) 7.86 (d, 1H), 7.98 (d, 2H), 8.38 (m, 1H).

[1084] MS (ESI) m/z 511 [M+H]+.

[1085] Anal. calcd for C₂₇H₃₁FN₄O₅: C:63.52 H:6.12 N:10.97 Found: C:63.37 H:6.29 N:11.01.

Example 117 1-tert-butyl 5-[4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl] N-(tert-butoxycarbonyl)-L-glutamate

[1086] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), 1-t-butyl-N-(tert-butoxycarbonyl)-L-glutamate (0.303 g, 1.0 mmol), N,N-dicylohexylcarbodiimide (0.206 g, 1.0 mmol) and DMAP (0.122 g, 1.0 mmol) in 10 mL of CH₂Cl₂ was stirred overnight at ambient temperature. The reaction mixture was diluted with CH₂Cl₂ and filtered through a plug of silica gel. The gel was rinsed with additional CH₂Cl₂. The combined filtrates were concentrated in vacuo to give 0.39 g to the title compound as a white solid.

[1087] mp 92-93° C.;

[1088]¹H NMR (DMSO-d₆): δ 1.40 (d, 18H), 1.717 (m, 2H), 1.90 (m, 2H), 2.05 (m, 1H), 2.15 (m, 4H), 2.69 (m, 2H), 3.93 ( m, 1H), 5.30 (m, 1H), 7.19 (m, 1H), 7.28 (m, 3H), 7.87 (d, 1H), 7.97 (d, 2H).

[1089] MS (ESI) m/z 582 [M+H]+.

[1090] Anal. calcd for C₃₂H₄₀FN₃O₆: C:66.08 H:6.93 N:7.22 Found: C:65.98 H:7.02 N:7.34.

Example 118 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl ethylcarbamate

[1091] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol) and ethyl isocyanate (0.080 mL, 1.0 mmol) in 10 mL of dioxane was heated at 80° C. for 48 hours. The reaction mixture was concentrated in vacuo. The residue was crystallized from EtOAc/hexane to give 0.275 g of the title compound as a white solid.

[1092] mp 159-160° C.

[1093]¹H NMR (DMSO-d₆): δ 1.09 (dt, 3H), 1.713 (m, 2H), 1.892 (m, 2H), 2.15 (m, 4H), 3.112 (m, 2H), 5.294 (m, 1H), 7.17 (m, 1H), 7.25 (m, 3H), 7.79 (m, 1H), 7.84 (d, 1H 7.91 (m, 2H).

[1094] MS (ESI) m/z 368 [M+H]+.

[1095] Anal. calcd for C₂₁H₂₂FN₃O₂: C:68.65 H:6.04 N:11.44 Found: C:68.40 H:5.87 N:11.37.

Example 119 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl tert-butylcarbamate

[1096] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol) and t-butyl isocyanate (0.114 mL, 1.0 mmol) in 10 mL of dioxane was heated at 80° C. for 48 hours. The reaction mixture was concentrated in vacuo. The residue was crystallized from EtOAc/hexane to give 0.195 g of the title compound as a white solid.

[1097] mp 157° C.;

[1098]¹H NMR (DMSO-d₆): δ 1.295 (s, 9H), 1.712 (m, 2H), 1.898 (m, 2H), 2.15 (m, 4H), 4.15 (d, 2H), 5.294 (m, 1H), 7.06 (m, 1H), 7.18 (m, 1H), 7.22 (d, 2H), 7.28 (m, 1H), 7.62 (s, 1H), 7.84 (d, 1H), 7.91 (d, 2H).

[1099] MS (ESI) m/z 396 [M+H]+.

[1100] Anal. calcd for C₂₃H₂₆FN₃O₂: C:69.85 H:6.63 N:10.63 Found: C:70.21 H:6.82 N:10.63.

Example 120 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl ethyl hydrogen phosphate

[1101] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), ethyl dichlorophosphate (0.13 mL, 1.1 mmol), and lithiumhexamethyldisilazide (0.183 g, 1.1 mmol) in 10 mL of THF was stirred for 1 hour at ambient temperature. The reaction mixture was quenched with H₂O and concentrated in vacuo. The residues were purified by reversed phase HPLC (Column:HS Hyperprep C18 8 u ID 22 mm; solvent gradient 40% to 100% acetonitrile (0.1% TFA) in H₂O; flowrate 10 mL/min) to give 0.065 g of the title compound as a white solid.

[1102]¹H NMR (DMSO-d₆): δ 1.12 (m, 3H), 1.706 (m, 2H), 1.893 (m, 2H), 2.14 (m, 4H), 3.38 (m, 2H), 5.27 (m, 1H), 7.14 (m, 1H), 7.28 (m, 3H), 7.82 (m, 3H).

[1103] MS (ESI) m/z 403 [M−H]−.

Example 121 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl phenyl hydrogen phosphate

[1104] A solution of 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol (0.30 g, 1.0 mmol), phenyl dichlorophosphate (0.211 mL, 1.1 mmol), and lithiumhexamethyidisilazide (0.183 g, 1.1 mmol) in 10 mL of THF was stirred for 1 hour at ambient temperature. The reaction mixture was quenched with H₂O and concentrated in vacuo. The residues were purified by reversed phase HPLC (Column:HS Hyperprep C18 8 u ID 22 mm; solvent gradient 40% to 100% acetonitrile (0.1% TFA) in H₂O; flowrate 10 mUmin) to give 0.120 g of the title compound as an oil.

[1105]¹H NMR (DMSO-d₆): δ 1.16 (m, 3H), 1.70 (m, 2H), 1.89 (m, 2H), 2.14 (m, 4H), 5.28 (m, 1H), 7.06 (m, 1H), 7.18 (m, 3H), 7.23-7.34 (m, 5H), 7.84 (m, 3H).

[1106] MS (ESI) m/z 453 [M+H]+.

[1107]

Example 122 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl 3,3-dimethylbutanoate

[1108] To a solution of 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol (0.100 g, 0.35 mmol) and 30 N,N-diisopropylethyl amine (0.5 g, 0.38 mmol) in CH₂Cl₂ (5 mL) was added dropwise tert-butylacetyl chloride (0.051 g, 0.38 mmol). The solution was allowed to stir overnight at room temperature. Water was added and the solution was extracted with CH₂Cl₂. The organic layer was washed with brine and dried (MgSO₄). The product was purified by flash chromatography (5/1 hexane/ethyl acetate) to yield a white solid (0.098 g, 72%).

[1109] mp 71-72° C.;

[1110]¹H NMR (DMSO-d₆): δ 0.89 (t, 3H, J=7.3 Hz), 1.09 (s, 9H), 1.88 (q, 2H, J=7.3 Hz), 4.72 (t, 2H, J=7.3 Hz), 7.22 (t, 1H, J=7.5 Hz), 7.26 (d, 2H, J=8.7 Hz), 7.53 (d, 1H, J−7.5 Hz), 7.95 (d, 2H, J=8.8 Hz), 8.02 (d, 1H, J=8.3 Hz).

[1111] MS (ESI) m/z 385 [M+H]+.

[1112] Anal. calcd for C₂₂H₂₅ClN₂O₂: C:68.65 H:6.55 N:7.28 Found: C:68.78 H:6.42 N:7.29.

Example 123 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl propionate

[1113] To a solution of 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol (0.100 g, 0.35 mmol) and N,N-diisopropylethyl amine (0.5 g, 0.38 mmol) in CH₂Cl₂ (5 mL) was added dropwise propionyl chloride (0.035 g, 0.38 mmol). The solution was allowed to stir overnight at room temperature. Water was added and the solution was extracted with CH₂Cl₂. The organic layer was washed with brine and dried (MgSO₄). The product was purified by flash chromatography (5/1 hexane/ethyl acetate) to yield a white solid (0.106 g, 88%).

[1114] mp 66-67° C.;

[1115]¹H NMR (DMSO-d₆): δ 0.89 (t, 3H, J=7.3 Hz), 1.15 (t, 3H, J=7.5 Hz), 1.88 (q, 2H, J=7.3 Hz), 2.64 (q, 2H, J=7.5 Hz), 4.72 (t, 2H, J=7.3 Hz), 7.21 (t, 1H, J=7.5 Hz), 7.28 (d, 2H, J=8.7 Hz), 7.53 (d, 1H, J=7.5 Hz), 7.94 (d, 2H, J=8.8 Hz), 8.03 (d, 1H, J=8.3 Hz).

[1116] MS (ESI) m/z 343 [M+H]+.

[1117] Anal. calcd for C₁₉H₁₉ClN₂O₂: C:66.57 H:5.59 N:8.17 Found: C:66.57 H:5.64 N:8.11.

Examples 124 to 224 Library synthesis of 4-(substituted-indazol-3-yl)-phenols

[1118] To the (substituted-2-fluorobenzyl-)4-methoxyphenyl)methanone (p0.075 mmol) was added a solution of a substituted-hydrazine (0.60 mL, 0.25mmol, 3 eq) in pyridine (6 hydrazines: methyl, butyl, benzyl, 2-hydroxyethyl, and hydrazine). The vials were heated for 6 days at 80° C. The pyridine was evaporated in vacuo and the residue partitioned with 1 mL EtOAc and H₂O. The EtOAc layer was concentrated in vacuo to provide the intermediate substituted-3-(4-methoxyphenyl)-indazoles.

[1119] The 4-(substituted-indazol-3-yl)-phenols were obtained by treatment of a solution of substituted 3-(4-methoxyphenyl)-indazoles in 0.7 mL of CH₂Cl₂/cyclohexene, (6:1, v/v) at −30° C. with boron tribromide (0.8 mL). Allowed to warm to ambient temperature over 5 hours. Quenched with 0.2 mL methanol and diluted with 2 mL CH₂Cl₂. The organic phases were washed with saturated aqueous NaHCO₃ and concentrated in vacuo. The residues were purified by HPLC and plated as a solution in 0.8 mL of DMSO.

[1120] Table 2 is a summary of the examples prepared. Example # Chemical Name 124 4-(1-methyl-1H-indazol-3-yl)phenol 125 4-(6-chloro-5-fluoro-1-methyl-1H-indazol-3-yl)phenol 126 4-(7-chloro-1-methyl-1H-indazol-3-yl)phenol 127 4-[1-methyl-6-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 128 4-(6-chloro-1-methyl-1H-indazol-3-yl)phenol 129 4-[1-methyl-6-(trifluoromethyl)-1H-indazol-3-yl]phenol 130 4-(H-indazol-3-yl)phenol 131 4-(6-chloro-5-fluoro-1H-indazol-3-yl)phenol 132 4-(7-chloro-1H-indazol-3-yl)phenol 133 4-(5-fluoro-1H-indazol-3-yl)phenol 134 4-(6-chloro-1H-indazol-3-yl)phenol 135 4-[7-(trifluoromethyl)-1H-indazol-3-yl]phenol 136 4-[6-(trifluoromethyl)-1H-indazol-3-yl]phenol 137 4-[5-(trifluoromethyl)-1H-indazol-3-yl]phenol 138 4-[6-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 139 4-(1-butyl-1H-indazol-3-yl)phenol 140 4-(1-benzyl-1H-indazol-3-yl)phenol 141 4-(1-benzyl-6-chloro-5-fluoro-1H-indazol-3-yl)phenol 142 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol 143 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 144 4-[1-benzyl-6-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 145 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)phenol 146 4-(1-benzyl-6-chloro-1H-indazol-3-yl)phenol 147 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol 148 4-[1-benzyl-6-(trifluoromethyl)-1H-indazol-3-yl]phenol 149 4-(1-benzyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol 150 4-[1-benzyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol 151 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol 152 4-(1-benzyl-6-chloro-1H-indazol-3-yl)benzene-1,3-diol 153 4-(1-benzyl-6-chloro-5-fluoro-1H-indazol-3-yl)benzene-1,2-diol 154 4-(1-benzyl-7-chloro-1H-indazol-3-yl)benzene-1,2-diol 155 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)benzene-1,2-diol 156 4-(1-benzyl-6-chloro-1H-indazol-3-yl)benzene-1,2-diol 157 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 158 4-[1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 159 4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 160 4-[7-chloro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 161 4-[6-chloro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 162 4-[1-(2-hydroxyethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol 163 4-[1-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-indazol-3-yl]phenol 164 4-[1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol 165 4-[1-(2-hydroxyethyl)-5-(trifluoromethyl)-1H-indazol-3-yl]phenol 166 4-[1-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-indazol-3-yl]-benzene-1,2-diol 167 4-[1-methyl-7-(trifluoromethyl )-1H-indazol-3-yl]benzene-1,3-diol 168 4-(5-fluoro-1-methyl-1H-indazol-3-yl)phenol 169 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol 170 4-(7-chloro-1-methyl-1H-indazol-3-yl)benzene-1,3-diol 171 4-[1-methyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol 172 4-(5-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,3-di 173 4-(7-chloro-1-methyl-1H-indazol-3-yl)benzene-1,2-diol 174 4-(7-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,2-diol 175 4-(5-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,2-diol 176 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 177 4-(1,5-dimethyl-1H-indazol-3-yl)benzene-1,2-diol 178 4-[1-methyl-5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 179 4-(H-indazol-3-yl)benzene-1,3-diol 180 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol 181 4-(1-butyl-7-chloro-1H-indazol-3-yl)benzene-1,2-diol 182 4-[1-benzyl-5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 183 4-(1-benzyl-1H-indazol-3-yl)benzene-1,3-diol 184 4-(1-benzyl-5-methyl-1H-indazol-3-yl)phenol 185 4-(1-benzyl-1H-indazol-3-yl)benzene-1,2-diol 186 4-(1-benzyl-5-fluoro-1H-indazol-3-yl)benzene-1,2-diol 187 4-[1-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-indazol-3-yl]-benzene-1,3-diol 188 4-[7-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 189 4-[5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 190 4-[1-(2-hydroxyethyl)-5-methyl-1H-indazol-3-yl]benzene-1,3-diol 191 4-[7-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol 192 4-[5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol 193 4-[6-chloro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol 194 4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,2-diol 195 4-[6-chloro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,2-diol 196 4-[1-(2-hydroxyethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]-benzene-1,2-diol 197 4-[1-(2-hydroxyethyl)-5-(trifluoromethy)-1H-indazol-3-yl]-benzene-1,2-diol 198 4-[1-butyl-6-(trifluoromethyl)-1H-indazol-3-yl]phenol 199 4-(1-butyl-6-chloro-1H-indazol-3-yl)phenol 200 4-(7-fluoro-1-methyl-1H-indazol-3-yl)phenol 201 4-[7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 202 4-(1H-indazol-3-yl)benzene-1,2-diol 203 4-(7-fluoro-1H-indazol-3-yl)phenol 204 4-(7-chloro-1H-indazol-3-yl)benzene-1,2-diol 205 4-[1-butyl-6-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 206 4-[1-butyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol 207 4-[1-methyl-6-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 208 4-(5-chloro-6-fluoro-1-methyl-1H-indazol-3-yl)phenol 209 4-(5-chloro-6-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,2-diol 210 4-[5-chloro-6-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol 211 4-[5-chloro-6-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,2-diol 212 4-[5-chloro-6-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,2-diol 213 4-(5-chloro-6-fluoro-1H-indazol-3-yl)benzene-1,2-diol 214 4-[5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 215 4-(6-chloro-1H-indazol-3-yl)benzene-1,2-diol 216 4-(1-butyl-7-fluoro-1H-indazol-3-yl)benzene-1,2-diol 217 4-(1-butyl-5-chloro-6-fluoro-1H-indazol-3-yl)phenol 218 4-(1-butyl-5-chloro-6-fluoro-1H-indazol-3-yl)benzene-1,2-diol 219 4-[1-butyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol 220 4-(1-butyl-7-fluoro-1H-indazol-3-yl)phenol 221 4-[1-butyl-5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol 222 4-(1-butyl-6-chloro-1H-indazol-3-yl)benzene-1,2-diol 223 4-(1-benzyl-5-chloro-6-fluoro-1H-indazol-3-yl)phenol 224 4-(1-benzyl-5-chloro-6-fluoro-1H-indazol-3-yl)benzene-1,2-diol

[1121] Table 2 is a summary of structure elucidation via exact mass (ESI_FT) Exact m/z Exptl. m/z Error Example # [M + H]¹⁺ [M + H]¹⁺ (mmu) 124 225.10224 225.10233 0.09 125 277.05385 277.05385 0 126 259.06327 259.06327 0 127 309.08454 309.08466 0.12 128 259.06327 259.0633 0.03 129 293.08963 293.08954 −0.09 130 211.08659 211.08665 0.06 131 263.0382 263.03826 0.06 132 245.04762 245.04767 0.05 133 229.07717 229.0773 0.13 134 245.04762 245.04767 0.05 135 279.07398 279.07396 −0.02 136 279.07398 279.07399 0.01 137 279.07398 279.07393 −0.05 138 295.06889 295.06901 0.12 139 267.14919 267.14917 −0.02 140 301.13354 301.13353 −0.01 141 353.08515 353.08525 0.1 142 335.09457 335.09438 −0.19 143 385.11584 385.11551 −0.33 144 385.11584 385.11551 −0.33 145 319.12412 319.12405 −0.07 146 335.09457 335.09443 −0.14 147 369.12093 369.12078 −0.15 148 369.12093 369.12068 −0.25 149 351.08949 351.08953 0.04 150 369.12093 369.1208 −0.13 151 335.11904 335.11887 −0.17 152 351.08949 351.08962 0.13 153 369.08006 369.07998 −0.08 154 351.08949 351.08951 0.02 155 335.11904 335.11894 −0.1 156 351.08949 351.08967 0.18 157 385.11584 385.11553 −0.31 158 255.11281 255.11256 −0.25 159 307.06441 307.06443 0.02 160 289.07384 289.07383 −0.01 161 289.07384 289.07383 −0.01 162 323.10019 323.10011 −0.08 163 323.10019 323.10005 −0.14 164 271.10772 271.10774 0.02 165 323.10019 323.10012 −0.07 166 339.09511 339.09496 −0.15 167 309.08454 309.08475 0.21 168 243.09282 243.09295 0.13 169 293.08963 293.08973 0.1 170 275.05819 275.05851 0.32 171 293.08963 293.08973 0.1 172 259.08774 259.08791 0.17 173 275.05819 275.05852 0.33 174 259.08774 259.08792 0.18 175 259.08774 259.08794 0.2 176 309.08454 309.08462 0.08 177 255.11281 255.11298 0.17 178 309.08454 309.08468 0.14 179 227.08151 227.08172 0.21 180 301.11022 301.11036 0.14 181 317.10514 317.10528 0.14 182 385.11584 385.11582 −0.02 183 317.12846 317.12883 0.37 184 315.14919 315.14935 0.16 185 317.12846 317.12864 0.18 186 335.11904 335.11914 0.1 187 339.09511 339.09539 0.28 188 273.10339 273.10348 0.09 189 273.10339 273.10355 0.16 190 285.12337 285.1236 0.23 191 289.0983 289.09838 0.08 192 289.0983 289.09856 0.26 193 305.06875 305.06891 0.16 194 323.05933 323.05956 0.23 195 305.06875 305.06899 0.24 196 339.09511 339.0951 −0.01 197 339.09511 339.09531 0.2 198 335.13658 335.13639 −0.19 199 301.11022 301.1101 −0.12 200 243.09282 243.0928 −0.02 201 295.06889 295.06881 −0.08 202 227.08151 227.08147 −0.04 203 229.07717 229.07713 −0.04 204 261.04254 261.04254 0 205 351.13149 351.13146 −0.03 206 335.13658 335.13644 −0.14 207 309.08454 309.08445 −0.09 208 277.05385 277.05382 −0.03 209 293.04876 293.0487 −0.06 210 307.06441 307.0644 −0.01 211 323.05933 323.05923 −0.1 212 245.07209 245.07209 0 213 279.03311 279.03311 0 214 295.06889 295.06882 −0.07 215 261.04254 261.04252 −0.02 216 301.13469 301.13463 −0.06 217 319.1008 319.10068 −0.12 218 335.09571 335.09564 −0.07 219 335.13658 335.13655 −0.03 220 285.13977 285.13964 −0.13 221 351.13149 351.13147 −0.02 222 317.10514 317.10509 −0.15 223 353.08515 353.08514 −0.01 224 369.0801 369.0802 0.14

Examples 225 to 267 Library synthesis of 4-(7-substituted-indazol-3-yl)-phenols

[1122] Under an atmosphere of argon, a series of 2 dram vials were charged with 1-substituted-7-bromo-3-(4-methoxyphenyl)-indazole (0.05 mL of 2M solution in dioxane, 0.10 mmol), substituted boronic acid ( 0.15 mL of 1.0 M sol'n in dioxane, 0.15 mmol), sodium carbonate (0.1 mL aqueous solution) and tetrakis(triphenylphosphine) palladium (0) (0.025 mL of 0.1 M solution in dioxane). The vials were heated at 85° C. for 6 hours. The reaction mixtures were partitioned with 3 mL EtOAc and 2 mL of 0.5N NaOH. The EtOAc layer was concentrated in vacuo to provide the indazole intermediate 1,7-disubstituted-3-(4-methoxyphenyl)-indazoles.

[1123] The 4-(1,7-disubstituted-indazol-3-yl)-phenols were obtained by treatment of a solution of 4-(1,7-disubstituted-indazol-3-yl)-phenols in 0.7 mL of CH₂Cl₂/cyclohexene, (6:1, v/v) at −30° C. with boron tribromide (0.8 mL). Allowed to warm to ambient temperature over 5 hours. Quenched with 0.2 mL methanol and diluted with 2 mL CH₂Cl₂. The organic phases were washed with saturated aqueous NaHCO₃ and concentrated in vacuo. The residues were purified by HPLC and plated as a solution in 0.8 mL of DMSO.

[1124] Table 4 is a summary of the examples prepared. Example # Chemical Name 225 4-{1-isopropyl-7-[4-(trifluoromethyl)phenyl]-1H-indazol-3-yl}- phenol 226 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)phenol 227 4-(1-isopropyl-7-thien-2-yl-1H-indazol-3-yl)phenol 228 4-{1-isopropyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}phenol 229 4-{7-[(E)-hept-1-enyl]-1-isopropyl-1H-indazol-3-yl}phenol 230 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}-phenol 231 4-[3-(4-hydroxyphenyl)-1-isopropyl-1H-indazol-7-yl]benzene-1,2-diol 232 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]phenol 233 4-[7-(1,1′-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]phenol 234 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]phenol 235 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol 236 4-(1-isopropyl-7-phenyl-1H-indazol-3-yl)phenol 237 4-{1-cyclopentyl-7-[4-(trifluoromethyl)phenyl]-1H-indazol-3-yl}-phenol 238 4-(1-cyclopentyl-7-thien-2-yl-1H-indazol-3-yl)phenol 239 4-{1-cyclopentyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}phenol 240 4-[1-cyclopentyl-3-(4-hydroxyphenyl)-1H-indazol-7-yl]benzene-1,2-diol 241 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]phenol 242 4-[7-(1,1′-biphenyl-4-yl)-1-cyclopentyl-1H-indazol-3-yl]phenol 243 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]phenol 244 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]phenol 245 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol 246 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)phenol 247 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)-3-methylphenol 248 4-{7-[(E)-hept-1-enyl]-1-isopropyl-1H-indazol-3-yl}-3-methyl-phenol 249 4-{7-[14-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}-3-methylphenol 250 4-[3-(4-hydroxy-2-methylphenyl)-1-isopropyl-1H-indazol-7-yl]-benzene-1,2-diol 251 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol 252 4-[7-(1,1′-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]-3-methyl-phenol 253 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]-3-methyl-phenol 254 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol 255 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methyl-phenol 256 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methyl-phenol 257 4-{1-cyclopentyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}-3-methylphenol 258 4-{1-cyclopentyl-7-[(E)-hept-1-enyl]-1H-indazol-3-yl}-3-methyl-phenol 259 4-[1-cyclopentyl-3-(4-hydroxy-2-methylphenyl)-1H-indazol-7-yl]benzene-1,2-diol 260 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]-3-methyl-phenol 261 4-[7-(1,1′-biphenyl-4-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methyl-phenol 262 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]-3-methyl-phenol 263 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl)-3-methylphenol 264 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methyl-phenol 265 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)-3-methylphenol 266 4-[7-(1-benzothien-2-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol 267 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]phenol

[1125] Table 5 is a summary of structure elucidation via exact mass (ESI_FT) Exact m/z Exptl. m/z Error Example # [M + H]¹⁺ [M + H]¹⁺ (mmu) 225 397.1522 397.1521 −0.1 226 335.1213 335.1212 −0.03 227 335.1213 335.1212 −0.04 228 375.1526 375.1525 −0.04 229 349.2274 349.2276 0.11 230 359.1754 359.1754 −0.02 231 361.1547 361.1547 0.06 232 357.1961 357.1962 0.04 233 405.1961 405.1961 −0.04 234 363.1259 363.1259 0.06 235 343.1805 343.1806 0.08 236 329.1648 329.1649 0.03 237 423.1679 423.1678 −0.12 238 361.1369 361.137 0.05 239 401.1682 401.1681 −0.09 240 387.1703 387.1703 −0.05 241 383.2118 383.2118 −0.02 242 431.2118 431.2117 −0.07 243 389.1415 389.1415 −0.05 244 345.1598 345.1598 0.07 245 369.1961 369.1961 −0.06 246 355.1805 355.1805 0 247 349.1369 349.137 0.08 248 363.2431 363.2432 0.08 249 373.1911 373.1911 0.01 250 375.1703 375.1704 0.06 251 371.2118 371.2118 0.02 252 419.2118 419.2117 −0.06 253 377.1415 377.1416 0.11 254 333.1598 333.1599 0.09 255 357.1961 357.1962 0.06 256 343.1805 343.1806 0.12 257 415.1839 415.1838 −0.02 258 389.2587 389.2587 −0.04 259 401.186 401.186 0 260 397.2274 397.2274 −0.05 261 445.2274 445.2274 0 262 403.1572 403.1572 −0.01 263 359.1754 359.1754 0.02 264 383.2118 383.2117 −0.11 265 369.1961 369.196 −0.16 266 425.1682 425.168 −0.18 267 319.1441 319.1441 −0.05 

What is claimed is:
 1. A compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof
 2. The compound according to claim 1, wherein R₁ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, or halogen; R₇ and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, hydroxy, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; or a pharmaceutical acceptable salt thereof.
 3. The compound according to claim 2, wherein R₁ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkenyl of 4-8 carbon atoms; R₂ is hydrogen, alkyl of 1-6 carbon atoms, halogen, or hydroxy; R₉ is alkyl of 1-6 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₁₀ is hydrogen; or a pharmaceutically acceptable salt thereof.
 4. The compound according to claim 3, wherein R₁ is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms; R₉ is alkyl of 1-6 carbon atoms, halogen, or trifluoromethyl; or a pharmaceutically acceptable salt thereof.
 5. The compound according to claim 1, which is a) 4-(6-chloro-5-fluoro-1-methyl-1H-indazol-3-yl)phenol; b) 4-(7-chloro-1-methyl-1H-indazol-3-yl)phenol; c) 4-(1H-indazol-3-yl)phenol; d) 4-(6-chloro-5-fluoro-1H-indazol-3-yl)phenol; e) 4-(6-chloro-1H-indazol-3-yl)phenol; f) 4-(1-butyl-1H-indazol-3-yl)phenol; g) 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol; h) 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; i) 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)phenol; j) 4-[1-benzyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; k) 4-(1-benzyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol; l) 4-(1-benzyl-7-fluoro-1H-indazol-3-yl)-1,3-benzenediol; m) 4-[l-(2-hydroxyethyl)-1H-indazol-3-yl]phenol; n) 4-[1-(2-hydroxyethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; o) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; p) 4-(5-fluoro-1-methyl-1H-indazol-3-yl)phenol; q) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; r) 4-(7-chloro-1-methyl-1H-indazol-3-yl)benzene-1,3-diol; s) 4-[1-methyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol; t) 4-(5-fluoro-1-methyl-1H-indazol-3-yl)benzene-1,3-diol; u) 4-[1-methyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,2-diol; v) 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol; w) 4-[1-benzyl-5-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; x) 4-(1-benzyl-1H-indazol-3-yl)benzene-1,3-diol; y) 4-[7-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol; z) 4-[5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]benzene-1,3-diol; aa) 4-[1-(2-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; bb) 4-[6-hydroxy-1-(4-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol; cc) 4-[6-hydroxy-1-(2-methoxyphenyl)-1H-indazol-3-yl]benzene-1,3-diol; dd) 4-{6-hydroxy-1-[4-(trifluoromethoxy)phenyl]-1H-indazol-3-yl}benzene-1,3-diol; ee) 4-[1-(3-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; ff) 4-[1-(4-bromophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; gg) 4-[3-(2,4-dihydroxyphenyl)-6-hydroxy-1H-indazol-1-yl]benzonitrile; hh) 4-[1-(3-chlorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; ii) 4-(1- ethyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol; ii) 4-(6-hydroxy-1-propyl-1H-indazol-3-yl)benzene-1,3-diol; kk) 4-(1-butyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol; ll) 4-(1-cyclohexyl-6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol; mm) 4-[6-hydroxy-1-(2,2,2-trifluoroethyl)-1H-indazol-3-yl]benzene-1,3-diol; nn) 4-[1-(3-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; oo) 4-[6-hydroxy-1-(4-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol; pp) 4-[1-(2-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; qq) 4-[6-hydroxy-1-(3-methylphenyl)-1H-indazol-3-yl]benzene-1,3-diol; rr) 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol; ss) 4-[1-(4-bromophenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; tt) 4-[1-cyclohexyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; uu) 4-(7-methyl-1H-indazol-3-yl)phenol; vv) 4-[1-(3-chloro-4-fluorophenyl)-6-hydroxy-1H-indazol-3-yl]benzene-1,3-diol; ww) 4-{6-hydroxy-1-[3-(trifluoromethyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol; xx) 4-[6-hydroxy-1-(3-nitrophenyl)-1H-indazol-3-yl]benzene-1,3-diol; yy) 4-[6-hydroxy-1-(4-isopropylphenyl)-1H-indazol-3-yl]benzene-1,3-diol; zz) 4-{6-hydroxy-1-[4-(methylsulfonyl)phenyl]-1H-indazol-3-yl}benzene-1,3-diol; aaa) 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol; bbb) 4-(1-isopropyl-7-methyl-1H-indazol-3-yl)phenol; ccc) 4-(7-chloro-1-pentyl-1H-indazol-3-yl)phenol; ddd) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol; eee) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)phenol; fff) 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; ggg) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; hhh) 4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; iii) 4-(7-methyl-2-propyl-2H-indazol-3-yl)phenol; jjj) 4-[2-isopropyl-7-methyl-2H-indazol-3-yl]phenol; kkk) 4-(7-chloro-2-pentyl-2H-indazol-3-yl)phenol; lll) 4-(7-chloro-2-propyl-2H-indazol-3-yl)phenol; mmm) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)phenol; nnn) 4-[1-butyl-6-(trifluoromethyl)-1H-indazol-3-yl]phenol; ooo) 4-(1-butyl-6-chloro-1H-indazol-3-yl)phenol; ppp) 4-(7-fluoro-1-methyl-1H-indazol-3-yl)phenol; qqq) 4-(1H-indazol-3-yl)benzene-1,2-diol; rrr) 4-(7-fluoro-1H-indazol-3-yl)phenol; sss) 4-[1-butyl-5-(trifluoromethyl)-1H-indazol-3-yl]phenol; ttt) 4-(1-cyclohexyl-7-fluoro-1H-indazol-3-yl)phenol; uuu) 4-(1-allyl-7-fluoro-1H-indazol-3-yl)phenol; vvv) 4-(1-allyl-7-methyl-1H-indazol-3-yl)phenol; www) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; xxx) 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol; yyy) 4-(7-fluoro-1-propyl-1H-indazol-3-yl)phenol; zzz) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)phenol; aaaa) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol; bbbb) 4-[1-butyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; cccc) 4-(1-butyl-7-fluoro-1H-indazol-3-yl)phenol; dddd) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]phenol; eeee) 4-(7-chloro-2-cyclopentyl-2H-indazol-3-yl)phenol; ffff) 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)phenol; gggg) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)phenol; hhhh) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)phenol; iiii) 4-[7-fluoro-1-(3,3,3-trifluoropropyl)-1H-indazol-3-yl]phenol; jjjj) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol; kkkk) 3-methyl-4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol; llll) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; mmmm) 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; nnnn) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-3-methylphenol; oooo) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-1,3-benzenediol; pppp) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol; qqqq) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)-3-methylphenol; rrrr) 4-(7-chloro-1-propyl-1H-indazol-3-yl)-3-methylphenol; ssss) 4-(7-chloro-2-propyl-2H-indazol-3-yl)-3-methylphenol; tttt) 4-(1-allyl-7-chloro-1H-indazol-3-yl)-3-methylphenol; uuuu) 4-(2-allyl-7-chloro-2H-indazol-3-yl)-3-methylphenol; vvvv) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)-2-methylphenol; wwww) 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)-3-methylphenol; xxxx) 4-(7-chloro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol; yyyy) 4-(1-allyl-7-chloro-1H-indazol-3-yl)benzene-1,3-diol; zzzz) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol; aaaaa) 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)phenol; bbbbb) 4-(1-isopropyl-7-thien-2-yl-1H-indazol-3-yl)phenol; ccccc) 4-{1-isopropyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}phenol; ddddd) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}phenol; eeeee) 4-[3-(4-hydroxyphenyl)-1-isopropyl-1H-indazol-7-yl]benzene-1,2-diol; fffff) 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]phenol; ggggg) 4-[7-(1,1 ′-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]phenol; hhhhh) 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]phenol; iiiii) 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol; jjjjj) 4-(1-isopropyl-7-phenyl-1H-indazol-3-yl)phenol; kkkkk) 4-{1-cyclopentyl-7-[4-(trifluoromethyl)phenyl]-1H-indazol-3-yl}phenol; lllll) 4-(1-cyclopentyl-7-thien-2-yl-1H-indazol-3-yl)phenol; mmmmm) 4-[1-cyclopentyl-3-(4-hydroxyphenyl)-1H-indazol-7-yl]benzene-1,2-diol; nnnnn) 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]phenol; ooooo) 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]phenol; ppppp) 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]phenol; qqqqq) 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]phenol; rrrrr) 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)phenol; sssss) 4-(1-isopropyl-7-thien-3-yl-1H-indazol-3-yl)-3-methylphenol; ttttt) 4-{7-[(1 E)-hept-1-enyl]-1-isopropyl-1H-indazol-3-yl}-3-methylphenol; uuuuu) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1H-indazol-3-yl}-3-methylphenol; vvvvv) 4-[3-(4-hydroxy-2-methylphenyl)-1-isopropyl-1H-indazol-7-yl]benzene-1,2-diol; wwwww) 4-[7-(4-ethylphenyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol; xxxxx) 4-[7-(1,1′-biphenyl-4-yl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol; yyyyy) 4-[7-(2-chlorophenyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol; zzzzz) 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]-3-methylphenol; aaaaaa) 4-[1-isopropyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methylphenol; bbbbbb) 4-(1-isopropyl-7-phenyl-1H-indazol-3-yl)-3-methylphenol; cccccc) 4-{1-cyclopentyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}-3-methylphenol; dddddd) 4-{1-cyclopentyl-7-[(1E)-hept-1-enyl]-1H-indazol-3-yl}-3-methylphenol; eeeeee) 4-[1-cyclopentyl-3-(4-hydroxy-2-methylphenyl)-1H-indazol-7-yl]benzene-1,2-diol; ffffff) 4-[1-cyclopentyl-7-(4-ethylphenyl)-1H-indazol-3-yl]-3-methylphenol; gggggg) 4-[7-(1,1 ′-biphenyl-4-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol; hhhhhh) 4-[7-(2-chlorophenyl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol; iiiiii) 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]-3-methylphenol; jjjjjj) 4-[1-cyclopentyl-7-(2-methylphenyl)-1H-indazol-3-yl]-3-methylphenol; kkkkkk) 4-(1-cyclopentyl-7-phenyl-1H-indazol-3-yl)-3-methylphenol; llllll) 4-[7-(1-benzothien-2-yl)-1-cyclopentyl-1H-indazol-3-yl]-3-methylphenol; mmmmmm) 4-[7-(2-furyl)-1-isopropyl-1H-indazol-3-yl]phenol; nnnnnn) 4-(7-fluoro-1-propyl-1H-indazol-3-yl)-3-methylphenol; oooooo) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)-3-methylphenol; pppppp) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)-3-methylphenol; qqqqqq) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)benzene-1,3-diol; rrrrrr) 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)-3-methylphenol; ssssss) 4-(7-fluoro-1-isopropyl-1H-indazol-3-yl)benzene-1,3-diol; tttttt) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)benzene-1,3-diol; uuuuuu) 4-(7-fluoro-1-isobutyl-1H-indazol-3-yl)benzene-1,3-diol; vvvvv) 4-[3-(4-hydroxyphenyl)-1-propyl-1H-indazol-7-yl]phenol; wwwwww) 4-[7-(4-fluorophenyl)-1-propyl-1H-indazol-3-yl]phenol; xxxxxx) 4-(7-morpholin-4-yl-1-propyl-1H-indazol-3-yl)phenol; yyyyyy) 4-(7-phenyl-2-propyl-2H-indazol-3-yl)phenol; zzzzzz) 4-(7-phenyl-1-propyl-1H-indazol-3-yl)phenol; aaaaaaa) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl pivalate; bbbbbbb) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl 3,3-dimethylbutanoate; ccccccc) 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenyl propionate; ddddddd) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl acetate; eeeeeee) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl propionate; fffffff) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl N-(tert-butoxycarbonyl)glycylglycinate; ggggggg) 1-tert-butyl 5-[4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl] N-(tert-butoxycarbonyl)-L-glutamate; hhhhhhh) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl ethylcarbamate; iiiiiii) 4-(7-chloro-1-thien-3-yl-1H-indazol-3-yl)phenol; jjjjjjj) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; kkkkkkk) methyl 3-(4-hydoroxyphenyl)-2-isopropyl-2H-indazole-7-carboxylate; lllllll) 4-[1-cyclopentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; mmmmmmm) 4-[1-(cyclohexylmethyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; nnnnnnn) 4-[1-isobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; ooooooo) 4-[1-cyclobutyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; ppppppp) 4-[1-(2-ethylbutyl)-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol, or a pharmaceutically acceptable salt thereof.
 6. A pharmaceutical composition, which comprises a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 7. A method of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 8. A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 9. A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 10. A method of treating or inhibiting psoriasis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R8, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 11. A method of treating or inhibiting asthma or chronic obstructive pulmonary disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 12. A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 13. A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 14. A method of treating or inhibiting Alzheimer's disease, cognitive decline, or senile dementia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 15. A method of treating or inhibiting type ll diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof.
 16. A method of treating or inhibiting sepsis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure

wherein R₁ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S; R₂, R₃, R₄, and R₅, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CN, —NO₂, —CHO, or —CO₂R₁₁; R₆, R₇, R₈, and R₉, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, —CO₂R₁₁, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized; R₁₀ is hydrogen, —COR₁₁, —CONHR₁₁, —P(═O)(OH)OR₁₁, or —CO(CH₂)_(n)CH(NHR₁₂)CO₂R₁₁; R₁₁ is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R₁₂ is hydrogen or —CO₂R₁₁; n=0-3, or a pharmaceutically acceptable salt thereof. 